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ABSTRACT 
The neurodevelopmental disorder Hirschsprung’s disease (HSCR) represents the most common cause 
for congenital obstruction and is characterized by a lack of enteric neurons (aganglionosis) in distinct 
segments of the colon. This aganglionosis is caused by dysfunctions in the neural crest cell (NCC) 
population which is responsible for enteric nervous system (ENS) generation during embryogenesis. 
Specifically, either proliferation, migration, differentiation or cell survival of NCC-derived progenitor cells 
is impaired. The main symptom of this disorder is represented by a megacolon formation. Patients are 
routinely treated by surgical resections of the aganglionic segment, but gastrointestinal impairments 
may persist in a fraction of patients even life-long. HSCR is classified as rare and multifactorial disorder. 
Up to now more than 20 genes are classified as validated disease-causing loci, including the major 
susceptibility locus RET, but many more genetic factors have been implicated in the pathoaetiology. 
However, in the majority of patients the genetic disease causes are still unknown. Next-generation 
sequencing technologies provide the possibility to rapidly uncover the individual’s genetic architecture. 
Nevertheless, dissecting the genetic findings of importance and correlating them with the 
pathomechanisms is a major challenge especially in complex diseases as HSCR. This study aimed to 
establish a complementary research approach for identification and characterization of novel HSCR 
candidate genes. By taking genetic, bioinformatics, molecular and functional data into account, better 
insights into the molecular pathogenesis of HSCR should be gained. 
In this project, two sporadic long-segment HSCR cases were analysed by whole exome sequencing in 
a trio-based setup and by genotyping of non-coding risk single nucleotide polymorphisms. In both 
patients, bioinformatic analyses of exome-wide sequencing data led to the identification of rare structural 
(copy number variations (CNVs)) and single nucleotide variants (SNVs). To narrow down the list of 
HSCR candidate genes, rare SNVs were further filtered. Finally, four candidate genes (ATP7A, 
SREBF1, ABCD1 and PIAS2) which were so far not reported in the context of HSCR, were selected for 
detailed investigations. Extensive mRNA and protein expression analyses confirmed the expression of 
these candidates in relevant murine gastrointestinal tissues of different developmental stages and 
thereby validated their putative relevance for the HSCR aetiology. Moreover, additional HSCR patients 
carrying rare variants in SREBF1 and PIAS2 were identified. To further assess functionally the neuronal 
specific role of the candidates, the CRISPR/Cas9 technology was applied in a human neuroblastoma 
cell line. Gene-specific knockout (KO) cell clones were generated for three candidate genes and the 
major HSCR susceptibility locus RET, while genome editing was not successful for PIAS2. KO clones 
were investigated on morphological and functional level by a comparison to a mock control clone. 
Comparative analyses revealed variable differences for the individual gene-specific KO clones in the 
differentiation behaviour, proliferation and migration capacity as well as in cell survival during neuronal 
differentiation. To evaluate all findings of this complementary project, a HSCR risk scoring system was 
applied. According to the gained risk scores, all four selected HSCR candidates could be classified as 
relevant for the development of HSCR. Like this, the suitability of the presented research approach for 
identification and characterization of novel HSCR candidates was validated. It is envisioned to apply the 
established study pipeline to primary ENS-like model systems to confirm the findings of this project. 
Moreover, these analyses could help to dissect the candidate gene’s relevance for HSCR in detail and 
gain insights into affected molecular pathways. 
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ZUSAMMENFASSUNG 
Die neurobiologische Entwicklungsstörung Morbus Hirschsprung (MH) repräsentiert die häufigste 
Ursache für angeborene Darmobstruktion und ist durch das Fehlen von enterischen Neuronen 
(Aganglionose) in spezifischen Abschnitten des Kolons charakterisiert. Diese Aganglionose resultiert 
aus Dysfunktionen in den Neuralleistenzellen (NLZ), welche für die Bildung des enterischen 
Nervensystems (ENS) im Rahmen der Embryogenese verantwortlich sind. Im Speziellen sind die NLZ-
abgeleiteten Vorläuferzellen entweder in ihrer Proliferation, der Migration, der Differenzierung oder dem 
Zellüberleben gestört. Das Hauptsymptom von MH ist die Bildung eines Megakolons. Die 
standardmäßige Behandlung von MH-Patienten liegt in der operativen Entfernung des aganglionären 
Darmsegmentes, wobei funktionelle Darmbeschwerden in einem Teil der Patienten auch lebenslang 
persistieren. Auf genetischer Ebene wird MH als seltene und multifaktorielle Erkrankung klassifiziert. 
Bis heute sind mehr als 20 Gene, inklusive des bisher beschriebenen Hauptrisikolocus RET, als 
krankheitsauslösend beschrieben und viele weitere Gene wurden mit der Pathogenese in Verbindung 
gebracht. Dennoch ist die genetische Ursache in der Mehrheit der MH-Patienten bisher ungeklärt. Next-
generation-sequencing Verfahren ermöglichen die schnelle Entschlüsselung der genetischen 
Architektur von Individuen. Die Auswahl der relevantesten genetischen Informationen und deren 
Korrelation mit den Pathomechanismen ist jedoch insbesondere im Zusammenhang mit komplexen 
Erkrankungen, wie MH, eine große Herausforderung. Zielsetzung dieses Projektes war die Etablierung 
einer komplementären Studienpipeline zur Identifizierung und Charakterisierung neuer MH-
Kandidatengene. Die Betrachtung von genetischen, bioinformatischen, molekularen und funktionellen 
Daten soll zu einem besseren Verständnis der molekularen MH-Pathomechanismen beitragen. 
Im Rahmen dieser Studie wurden zwei sporadische, langstreckige MH-Patienten mittels Trio-basierter 
Exom-weiter Sequenzierung analysiert und für nicht-codierende Risiko-Polymorphismen genotypisiert. 
Die bioinformatische Analyse der Exom-weiten Sequenzdaten führte zur Identifizierung von seltenen 
strukturellen (Kopienzahlvariationen) und Einzelnukleotid-Varianten in beiden Patienten. Weitere 
Filterschritte wurden genutzt, um aus der Liste an seltenen Einzelnukleotid-Varianten die 
vielversprechendsten Genloci auszuwählen. Schlussendlich konnten somit vier Kandidatengene 
(ATP7A, SREBF1, ABCD1 und PIAS2), die bisher nicht mit MH beschrieben worden waren, für weitere 
Analysen bestimmt werden. Detaillierte Expressionsanalysen auf mRNA und Proteinebene zeigten, 
dass alle Kandidaten in murinem gastrointestinalem Gewebe zu relevanten Entwicklungsstadien 
exprimiert werden. Somit bestätigte sich eine putative Relevanz dieser Gene für die MH-Pathogenese. 
Zusätzlich konnten weitere MH-Patienten als Träger von seltenen Varianten in SREBF1 oder PIAS2 
identifiziert werden. Um die neuronale Rolle der Kandidatengene experimentell zu untersuchen, wurde 
die CRISPR/Cas9 Methode in einer humanen Neuroblastomzelllinie angewandt. Gen-spezifische 
Knockout (KO) Zellklone konnten für drei Kandidaten und den bisher beschriebenen MH-
Hauptrisikolocus RET generiert werden, wobei die Genomeditierung für PIAS2 nicht erfolgreich war. Die 
Gen-spezifischen KO Klone wurden für morphologische und funktionelle Analysen verwendet und 
hierbei mit einem Mock Kontrollklon verglichen. Diese vergleichenden Analysen zeigten variable 
Unterschiede in den individuellen KO Klonen im Differenzierungs-, Proliferations-, Migrations- und 
Zellapoptose-Verhalten. Um alle Ergebnisse dieser Studie abschließend bewerten zu können, wurde 
ein Risiko-Klassifizierungssystem genutzt. Die entsprechenden Risikowerte belegten eine MH-
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Relevanz für alle vier Kandidaten. Auf diese Weise konnte die Eignung der komplementären 
Studienpipeline zur Identifizierung und Charakterisierung neuer MH-Kandidatengene validiert werden. 
Um die Daten dieser Arbeit zu bestätigen, ist anvisiert, die etablierte Studienpipeline zukünftig auch in 
einem primären ENS-ähnlichen Zellkulturmodellsystem anzuwenden. Die entsprechenden Analysen 
könnten dazu beitragen, die Relevanz der Kandidatengene detailliert zu analysieren und somit Einblick 
in die betroffenen molekularen Signalwege zu erhalten. 
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1 INTRODUCTION 
1.1 The enteric nervous system 
The enteric nervous system (ENS) resides within the gut wall and is the largest unit of the peripheral 
nervous system. Its main function is the intrinsic innervation of the gastrointestinal (GI) tract, which 
regulates the blood flow, gut motility and peristalsis, ion and fluid homeostasis as well as secretion of 
signalling mediators (Rao and Gershon, 2018). The ENS shares basic concepts with the central nervous 
system (CNS) such as the composition of signalling molecules and neurotransmitters, but can operate 
autonomously from its input. Therefore, it has been coined the “second brain” (Furness and Stebbing, 
2018; Sasselli et al., 2012). The bidirectional communication between the ENS and the CNS is 
designated as gut-brain axis (Mayer and Tillisch, 2011).  
 Structure and function  
The basic structure of the ENS includes enteric ganglia organized in two major plexuses: corresponding 
to their location, these are referred to as the outer myenteric (Auerbach’s) plexus situated between the 
circular and the longitudinal muscle layer, and the inner submucosal (Meissner’s) plexus residing within 
the submucosa (Rao and Gershon, 2018) (fig. 1 A). During embryonic development the myenteric plexus 
is generated first and can be found throughout the GI tract, whereas the submucosal plexus derived by 
a second radial migration front, is present in the small and large intestine only (Heanue and Pachnis, 
2007). Enteric ganglia in both plexus are interconnected and are composed of various neuronal 
subtypes and glia. Besides the complex network of enteric ganglia, various other cell types are required 
for neuronal circuit integration (Belkind-Gerson et al., 2006). Consequently, tight communication 
between enteric ganglia and epithelial, endocrine, immune cells as well as with interstitial cells of Cajal 
and smooth muscle cells is crucial for proper GI function (Heanue and Pachnis, 2007; Rao and Gershon, 
2018). 
Neuronal subtypes organized in enteric ganglia can be differentiated based on their neurochemical 
coding and their electrophysiological properties. In principle, neurons are classified as intrinsic primary 
afferent neurons (IPANs), inter- and motorneurons (Rao and Gershon, 2018). Projections of IPANs 
spread into intestinal villi and respond to chemical and mechanical stimuli (fig. 1 B). Therefore, IPANs 
are crucial for the regulation of ENS autonomous functions. The coordinated action of these in concert 
with afferent and efferent neurons innervating the circular muscle layer orchestrate the movement of the 
digestive tract. Gap junctions between smooth muscle cells transmit the electrical signal and thus ensure 
propulsion and mixing of the ingested food via peristalsis. Secretomotor and vasomotor neurons of the 
submucosal plexus innervate effector cells as enteroendocrine cells and blood vessels, respectively 
(Benarroch, 2007; Rao and Gershon, 2018). Consequently, secretion of hormones and digestive 
enzymes by the mucosa and fluid exchange through vasodilation are integrated as GI functions (Belkind-
Gerson et al., 2006).  
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In addition to the electrophysiological characteristics of enteric neurons, neuronal diversity is based on 
cell type specific neurotransmitter based chemical coding (Heanue and Pachnis, 2007). While most of 
the myenteric neurons are cholinergic, neuronal NITRIC OXIDE SYNTHASE (nNOS) is classically found 
in motor- and interneurons. Serotonin serves as neurotransmitter in interneurons as well, while GAMMA 
AMINOBUTYRIC ACID (GABA) and dopamine are further neuroactive molecules found in the ENS. 
Secretomotorneurons and IPANs of the submucosal plexus express VASOACTIVE INTESTINAL 
PEPTIDE (VIP) and ACETYLCHOLINE (ACh). The complex diversity in the neurotransmitter profile of 
enteric neurons is not fully understood so far (Hao and Young, 2009; Rao and Gershon, 2018; Sasselli 
et al., 2012).  
 Development 
The ENS has its origin in early embryonic development, since it arises from neural crest cells (NCCs). 
This highly proliferative and migratory cell population is specified during neurulation, as illustrated 
schematically in figure 2 A. The late gastrula stage embryo contains three regions of ectodermal origin: 
the non-neural ectoderm, the neural plate border and the neural plate (neural ectoderm). Formation of 
the neural tube is initiated when the neural plate borders rise and form the neural folds. The neural tube 
is the embryonic precursor of the CNS. Fusion of the neural folds at the midline causes the involution of 
the neural tube into the embryo. The non-neuronal epidermis develops into the epidermis covering the 
neural tube. At the dorsal fusion sites of the neural folds, the neural crest is specified (Bhatt et al., 2013; 
Gammill and Bronner-Fraser, 2003; Gilbert, 2014). After epithelium-to-mesenchyme transition (EMT), 
NCCs delaminate from this transient structure and migrate to different regions throughout the body, 
Figure 1: Schematic of the human ENS organization 
A: Crosssection of the postnatal gut displaying the organization of the ENS in two major plexus (SMP: submucosal 
plexus, MP: myenteric plexus). The MP is embedded between the longitudinal and circular muscle layer (LM and 
CM). The inset region is shown as a blow up in B: Enteric ganglia are interconnected and consist of different cell 
types (blue: neuron, green: glia, red: clonally related neurons and glia). IPANs (purple) project to the intestinal villi. 
(modified from Rao and Gershon, 2018).  
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where they give rise to various cell types and lineages (Bhatt et al., 2013; Mayor and Theveneau, 2013) 
(fig. 2 A). Amongst others, neuronal and glial cells, melanocytes and endocrine cells as well as cartilage 
and bone are generated. Corresponding to early phases of neurulation, where BONE 
MORPHOGENETIC PROTEIN (BMP), WINGLESS (WNT) and FIBROBLAST GROWTH FACTOR 
(FGF) signalling molecules play central roles in neural plate induction, these signalling pathways are as 
well involved in NCC specification (Bhatt et al., 2013; Mayor and Theveneau, 2013; Simões-Costa and 
Bronner, 2015).  
NCCs are classified into specific groups according to their position along the anterior/posterior body axis 
and corresponding to their progenitor potential: in general, cranial, vagal, trunk and sacral NCCs can be 
differentiated (Simões-Costa and Bronner, 2015). While sacral NCCs (originating posterior to somite 
28) contribute only minimally to the later ENS cell population, most enteric ganglia are derived from 
vagal NCCs. These progenitor cells are specified at the level of the first to seventh somite. Additionally, 
a small proportion of the most anterior specific trunk NCCs contribute minimally to ENS formation in the 
foregut. Delamination of the vagal NCC subpopulation is initiated between E8.5-9 in mouse and prior to 
week 4 gestation in a human embryo (Gilbert, 2014; Goldstein et al., 2013; Heanue and Pachnis, 2007; 
Lake and Heuckeroth, 2013) (fig. 2 B).  
Figure 2: Different phases of ENS development 
A: Delamination of NCCs (green) from the neural tube (blue) in the context of neurulation (modified from Simões-
Costa and Bronner, 2015). B: Different NCC subpopulations (trunk (blue), vagal (red) and sacral (yellow)) invade 
and colonize the gut (modified from Heanue and Pachnis, 2007). C: Gut colonization by trunk (blue) and vagal 
ENCDCs (red) in rostral to caudal direction (modified from(Heuckeroth, 2015). 
 Heuckeroth, 2015).  
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After delamination, these multipotent progenitor cells migrate ventrally through the somatic 
mesenchyme to reach the presumptive gut. After invasion of the developing bowel, ENS progenitor 
cells, which are termed enteric neural crest derived cells (ENCDCs), start to colonize the embryonic gut. 
At E9.5, vagal derived ENCDCs migrate in rostro-caudal direction within the developing mid- and 
hindgut. In contrast, sacral derived ENS precursor cells do not enter the gut before E13.5 and migrate 
orally (fig 2 B and C) (Heanue and Pachnis, 2007; Rao and Gershon, 2018). Gut colonization by vagal 
ENCDCs is completed around E14 in mouse and after 7 weeks gestation in human embryos. To 
generate the two interconnected ganglia layers, referred to as myenteric and submucosal plexus, a 
second radial directed migration wavefront follows the first linear migration wavefront (Lake and 
Heuckeroth, 2013). Except for gut invasion and colonization, ENCDCs cells are responsible for the 
generation of the ENS-specific neuronal and glial subtype diversity, which is achieved by respective cell 
fate commitment. Molecular mechanisms that regulate all these processes are presented in 1.1.3. 
Even after ENS formation is completed, stem and progenitor cells persist in both ganglionated plexus 
and the outer muscle layer. These postnatal enteric progenitor cells retain some characteristics of 
embryonic ENCDCs, but are more restricted in their self-renewal potential and their lineage commitment 
(Kruger et al., 2002). Nevertheless, this fact makes the ENS attractive to be used as stem cell source. 
Respective cells are suitable to mimic disease origin and progression in vitro or for disease treatment in 
future (Burns et al., 2016; Metzger et al., 2009; Obermayr and Seitz, 2018; Rollo et al., 2016).  
 Signalling pathways 
Generation of a functional ENS depends on complex interactions between different cell types and cell 
functions, which need to be tightly controlled. Responsible signalling pathways are highly coordinated 
in temporal and spatial manner. Key functions that need to be orchestrated during ENS development 
are cell migration, proliferation, survival and differentiation: While vagal derived ENCDCs migrate 
caudally and thereby colonize the entire length of the bowel, progenitor cells start to differentiate into 
neurons and glial cells. To prevent depletion of the progenitor pool and to ensure adequate colonization 
of the most distal gut, part of the ENCDCs need to maintain their proliferative capacity (survival) and at 
the same time they have to increase in number (proliferation) (Heanue and Pachnis, 2007; Obermayr 
et al., 2013; Sasselli et al., 2012).  
Except for intrinsic cell signals, secreted factors of the surrounding tissue as guiding molecules and 
differentiation factors, contribute to the regulation of cell functions impaired in HSCR (Heanue and 
Pachnis, 2007; Rao and Gershon, 2018). Central mediators involved can be grouped into three main 
signalling pathways, as outlined in the following (Lake and Heuckeroth, 2013). 
Ret signalling pathway 
The tyrosine kinase receptor Rearranged during transfection (Ret) plays a crucial role in ENS 
development. As a transmembrane receptor of the cadherin superfamily it binds ligands of the 
neurotrophic factor family, e.g. Glial-derived neurotrophic factor (Gdnf), Neurturin (Nrtn), Artemin (Artn), 
Persephin (Pspn). Upon ligand binding, Ret assembly with its co-receptor Gdnf family receptor alpha 1 
(Gfrα1) of the glycosylphosphatidylinositol (GPI)-anchored co-receptor family is initiated. Ret signalling 
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plays multiple roles in ENS development (Taraviras et al., 1999). During early phases of ENS formation 
(mouse: E9.5), Ret expression is involved in the migratory behaviour of pre-enteric NCCs. The 
surrounding gut mesoderm secretes Gdnf and its specific co-receptor Gfrα1, that serve as 
chemoattractants for Ret+ cells. Receptor expression is maintained during gut colonization, where Ret 
signalling regulates proliferation and cell survival of progenitor cells. At stage E10.5 when neuronal 
lineage commitment is initiated, Ret is expressed in prospective enteric neurons (Hao and Young, 2009; 
Sasselli et al., 2012). Even postnatally, a subset of enteric neurons maintains respective gene 
expression although detailed understanding about its role within these cells is missing so far (Rao and 
Gershon, 2018).   
Ednrb signalling pathway 
Another key mediator in ENS development is Endothelin receptor type B (Ednrb). It encodes a G-
coupled receptor specific for small peptides as Endothelin 1, 2 and 3 (Edn1, Edn2, Edn3) (Bondurand 
et al., 2018). In mouse, Ednrb starts to be expressed in ENCDCs at stage E10.5. Edn3 secretion by the 
surrounding gut mesenchyme is crucial for targeted migration of Ednrb+ cells and for colonization of the 
mid- and hindgut. Highest Edn3 levels are detectable in the caecum (Heanue and Pachnis, 2007; 
Sasselli et al., 2012). In contrast to Ret+ cells, Ednrb+ cells remain in an uncommitted state even during 
later phases of ENS development. Consequently, the pool of progenitor cells is maintained. Despite this 
antagonistic effect to the Gdnf-Ret signalling pathway, Edn3 can have a synergistic effect with regard 
to increased proliferation levels in Ret+ ENCDCs (Sasselli et al., 2012).  
Further mediators and cell type markers 
Factors modulating the activity of the Ret and Ednrb signalling pathways represent the third group of 
molecular mediators crucial for ENS development.  
The transcriptional regulator Sex determining region Y (SRY) Box 10 (Sox10) is another major player in 
ENS development. Its expression in NCC-derived progenitor cells is detectable subsequently to NCC 
delamination in mouse at stage E8.5. Sox10 is crucial for the maintenance of multipotency and cell 
survival through inhibition of apoptosis in the respective cell population. While Sox10 expression is 
downregulated in future neurons, prospective glial cells maintain the expression (Sasselli et al., 2012). 
Expression levels of this transcriptional regulator are associated to gliogenesis in general and neuronal 
subtype generation in the small intestine (Rao and Gershon, 2018). Transcriptional regulation of Ednrb 
and Ret is mediated through binding of Sox10 to respective enhancer binding sites (Heanue and 
Pachnis, 2007). 
Another transcriptional regulator involved in ENS development is Paired-like homeobox 2b (Phox2b). 
Comparable to Ret and Sox10, Phox2b is as well expressed in early bipotent pre-enteric NCCs (Lake 
and Heuckeroth, 2013). Phox2b itself is involved in the regulation of Ret and Sox10 expression levels 
and therefore contributes to progenitor cell survival and multipotency maintenance during early phases 
of ENS development (Goldstein et al., 2013; Rao and Gershon, 2018). At later stages, Phox2b is 
involved in cell differentiation, as its expression is maintained in all enteric neurons and some enteric 
glial cells (Sasselli et al., 2012).  
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The Low-affinity neutrophin receptor p75 (p75) is another important mediator for ENS formation. As a 
member of the Tumour necrosis factor (TNF)-superfamily, it binds neutrophins as Nerve growth factor 
(Ngf), Brain-derived growth factor (Bdnf), Neutrophin 3 and 4 (Nt3, Nt4) (Heanue and Pachnis, 2007; 
Underwood and Coulson, 2008). Comparable to Sox10, it is as well expressed in early pre-enteric NCCs 
after delamination from the neural tube. Moreover, p75 expression is as well decreased in cells 
committed to the neuronal lineage, while it is maintained in glial cells (Heanue and Pachnis, 2007).  
Co-expression of Phox2b, Sox10, Ret and p75 is detectable for cells at the caudal end of the migrating 
wavefront and keeps these cells in an uncommitted state. More cranially to this wavefront, cells are at 
different neuronal maturation states. In general, neuronal cell fate commitment in mouse is initiated at 
stage E10.5 and is associated to increased expression levels of pan-neuronal markers, such as 
Achaete-Scute Family BHLH (Basic Helix Loop Helix) Transcription Factor 1 (Mash1), Ubiquitin C-
Terminal Hydrolase L1 (Pgp9.5), Beta III-Tubulin (Tubb3) and Hu-Antigen C/D (HuC/D). These 
immature neuronal cells remain mitotically active and project their outgrowing neurites to the wavefront 
(Goldstein et al., 2013; Sasselli et al., 2012). Compared to immature neurons which transiently express 
combinations of different neurotransmitters, distinct neuronal subtypes exit the cell cycle and are then 
immunoreactive to specific markers only. Subtype specific markers, indicating the presence of 
serotonergic and nitridergic neurons within the enteric ganglia, are first detectable between E11.5-
E12.5. ACh, Vip, Neuropeptide Y (Npy) and Substance P (Tac1) positive neurons are generated 
subsequently between E14-E18. In general, neuronal subtype generation occurs heterogenous- and 
asynchronously and continues postembryonically (Hao and Young, 2009; Sasselli et al., 2012). Cell 
commitment to the glial lineage is connected with increased expression levels of the glial specific 
markers S100 Calcium binding Protein b (S100b), Glial fibrillary acidic protein (Gfap) and Fatty-acid-
binding protein (Fabp) (Goldstein et al., 2013). Glial cell differentiation is initiated at E11.5, but mature 
Gfap+ cells are not detectable before E16.5 (Rothman et al., 1986). 
Disturbances in the presented molecular networks controlling ENS development can cause 
neurocristopathies, as for example Hirschsprung’s disease (HSCR). 
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1.2 Hirschsprung’s disease 
 Clinical characteristics 
The neurocristopathy Hirschsprung’s disease (HSCR) has been first described by the Dutch physician 
Harald Hirschsprung in 1888 (Hirschsprung, 1888). HSCR represents the main cause for neonatal 
intestinal obstruction and is also referred to as congenital aganglionic megacolon. It is a developmental 
disorder of the ENS characterized by the complete absence of enteric ganglia in distinct segments of 
the distal bowel (Amiel et al., 2008). Depending on the length of the affected segment, the severity 
ranges between the most prevalent short segment form (S-HSCR: 80%), which is limited to the rectum 
and the sigmoid colon, a long segment form (L-HSCR: up to 20%), which extends further to the more 
proximal colon, and a total colonic aganglionosis (TCA: up to 5 %) (Heanue and Pachnis, 2007; Parisi, 
2015). In the majority of infants, the disease manifests within the first days after birth, as the ability to 
pass stool (meconium) is perturbed. Only in a minority of patients the diagnosis is made in later 
childhood (Parisi, 2015). On clinical level, the aganglionosis causes a tonic contraction of the affected 
region while the more proximal part extends massively. Consequently, a megacolon is formed, and 
patients suffer from enterocolitis, constipation, abdominal pain and emesis (Amiel et al., 2008; Heanue 
and Pachnis, 2007). On histological level, HSCR is diagnosed by the lack of enteric ganglia in biopsies 
of the gut wall. Surgical resection of the aganglionic segment via “pull-through” technique and the 
reconnection of the non-affected bowel to the anus represents the only treatment option for all patients 
(Parisi, 2015). Functional outcomes vary among patient groups (depending on the severity degree) and 
among the pull-through procedure that has been applied. Even though detailed understanding about 
postoperative impairments is still missing, a significant number of patients continues to suffer from GI 
impairments as enterocolitis (25-45%) and constipation (3-22%) (Calkins, 2018; Faure, 2017).   
 Genetics and research 
HSCR is defined as a rare genetic disease with an incidence of 1:5000 live births and shows a male sex 
predominance with a ratio of 4:1. In about 80% of patients, HSCR occurs as an isolated form. Only in a 
minority of patients, HSCR is associated to other syndromes as trisomy 21, Mowat-Wilson and Multiple 
endocrine neoplasia type 2A (MEN2A) and Waardenburg-Shah being the most frequent ones. 
Additionally, HSCR can be associated to other congenital abnormalities as heart or genitourinary 
malformations. These abnormalities might be caused by defects in other NC derivatives and occur most 
frequently in familial cases of HSCR. The mode of inheritance for most of the HSCR risk genes is 
autosomal dominant in familial cases. However, in case of the syndromic form the inheritance pattern is 
highly variable ranging from autosomal dominant or recessive to X-linked recessive (Amiel et al., 2008; 
Goldstein et al., 2013; Parisi, 2015). 
So far, about 25 risk genes have been replicated to be causative for HSCR, but many more genetic loci 
were shown to be involved in shaping the phenotypic variability. More recently, gene-environment 
interactions were as well demonstrated to have an impact on ENS development and hence to contribute 
to the aetiology of enteric neuropathies. Therefore, HSCR is classified as multifactorial trait. Moreover, 
it shows reduced penetrance and variable expressivity. However, mutations in the so far identified HSCR 
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risk loci only account for about 30% of all patients (Bahrami et al., 2017; Heuckeroth and Schäfer, 2016; 
Luzón-Toro et al., 2015b; Tilghman et al., 2019). 
Risk genes can be mainly assigned to signalling cascades that are of importance in early ENS 
development. Consequently, the major susceptibility locus so far described for HSCR is RET. Rare and 
common variants in the coding, and as well in the non-coding region of the gene, have already been 
described in the context of HSCR. Rare coding variants are more frequently found in patients affected 
by the long-segment form while common variants often occur in short-segment phenotypes. In general, 
mutations in the RET gene account for about 50% of the familial and 15-35% of the sporadic cases. On 
functional level, the majority of genetic variants result in a loss-of-function of this tyrosine 
transmembrane kinase receptor (Heanue and Pachnis, 2007; Lake and Heuckeroth, 2013; So et al., 
2011). Gain-of-function mutations within this gene are implicated in the thyroid cancer syndrome MEN2A 
(Parisi and Kapur, 2000). In about 5 % of HSCR cases, mutations in other genes than RET have been 
identified. These are: GDNF, NRTN, PSPN, GFRα1, EDNRB, EDN3, (ENDOTHELIN CONVERTING 
ENZYME 1) ECE1, SOX10, PHOX2B, ZINC FINGER E-BOX BINDING HOMOEOBOX (ZFHX1B), L1 
CELL ADHESION MOLECULE (L1CAM), KIF1 BINDING PROTEIN (KIAA1279), TRANSCRIPTION 
FACTOR 4 (TCF4), PROKINETICIN 1 (PROK1), PROKINETICIN RECEPTOR 1 and 2 (PROKR1, 
PROKR2), NEUTROPHIN 3 (NTF3), NEUROTROPHIC RECEPTOR TYROSINE KINASE 3 (NTRK3), 
NEUREGULIN 1 and 3 (NRG1, NRG3), CLASS 3 SEMAPHORINs (SEMA3A, SEMA3C and SEMA3D) 
and DNA METHYLTRANSFERASE 3 BETA (DNMT3B) (Luzón-Toro et al., 2015b).   
In total, approximately 500 rare coding variants residing in the major HSCR susceptibility loci have been 
already described. Except for these rare coding variants, a number of common non-coding single 
nucleotide polymorphisms (SNPs) were associated with increased HSCR risks. It was shown that the 
risk alleles synergistically affect key ENS signalling pathways. Among them, the transcription-enhancer 
variant rs2435357 in the first intron of RET was described to significantly increase the HSCR risk 
(Chatterjee et al., 2016; Emison et al., 2010; Emison et al., 2005; Tilghman et al., 2019). Another layer 
of genetic complexity is added by the fact that not only syndromic cases (e.g. HSCR patients with Down 
Syndrome) but as well non-syndromic HSCR subjects frequently present with structural genetic 
variations. Therefore, the presence of rare copy number variations (CNVs) might very likely as well 
contribute to the phenotype (Tang et al., 2012; Tilghman et al., 2019). 
The relevance of the previously listed HSCR risk genes were so far mainly assessed in animal models, 
as described in the following: A multitude of different Ret mutant mouse strains was generated to study 
the role of this gene for HSCR in more detail. Targeted gene knockout (KO) of Ret in mice causes total 
intestinal aganglionosis accompanied by kidney defects. Ret-/- mice die at birth. Less severe phenotypes 
ranging from hypoaganglionosis and colonic aganglionosis are caused either by mono-isoformic mutant 
alleles or mutated phosphorylation sites (Bondurand and Southard-Smith, 2016). Investigations in the 
zebrafish confirmed ret as major HSCR susceptibility locus, since morpholino mediated knockdown in 
embryos lead to the absence of enteric neurons within the distal gut (Heanue and Pachnis, 2007). 
Targeted gene KOs of the Ret ligand Gdnf or its co-receptor Gfrα1 in mice cause almost identical 
phenotypes as observable for Ret mutant strains. This is in line with different missense mutations in the 
GDNF gene that were identified in HSCR patients (Angrist et al., 1996). Less severe phenotypes are 
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observable when other Ret signalling components are targeted by gene-specific deletions. 
Consequently, Nrtn deficient mice show a reduced enteric innervation and impairments in GI motility but 
are viable and fertile (Bondurand and Southard-Smith, 2016; Heuckeroth et al., 1999). Doray et al. 
identified a heterozygous mutation in the NRTN gene, which was not disease-causing on its own but 
segregated with a RET mutation. Therefore, they concluded an oligogenic inheritance pattern, as 
mutations in further RET-associated signalling factors might act in concert with an additional RET variant 
(Doray et al., 1998).  
Corresponding to its role in early ENS development, EDNRB is another validated HSCR risk gene as 
the deletion of the receptor or point mutations within its ligand Edn3 cause an aganglionosis in the distal 
colon in mice. Moreover, such mutant strains display pigmentation defects due to dysfunctions in NCC-
derived melanocytes. In this manner, the syndromic Waardenburg-HSCR phenotype in humans is 
reflected. Mutations within EDNRB or its associated signalling factors EDN3 and ECE1 account for up 
to 5% of all HSCR cases (Bondurand and Southard-Smith, 2016; Heanue and Pachnis, 2007). 
A HSCR resembling phenotype in mice is also observable in the case of targeted mutations and gene 
KOs of Sox10, Phox2b or Zfhx1b. For example, specific Phox2b and Sox10 homozygous mutants 
display a complete intestinal aganglionosis (Bondurand and Southard-Smith, 2016; Heanue and 
Pachnis, 2007).The relevance of these two genes was also confirmed in an additional in vivo system as 
respective zebrafish mutants lack the ENS as well (Shepherd and Eisen, 2011). In humans, genetic 
variations within SOX10, PHOX2B and ZFHX1B were almost exclusively identified in syndromic HSCR 
subjects. Corresponding to this, haploinsufficiency of SOX10 in HSCR patients is associated with 
Waardenburg syndrome, as it was initially reported by Pingault et al. in 1998 (Amiel et al., 2008; Heanue 
and Pachnis, 2007; Pingault et al., 1998).  
Except for single gene contributions in HSCR, animal models as well reflect the multifactorial disease 
background. With regard to this, e.g. epistatic interactions between the major signalling pathways Ret 
and Ednrb or Ednrb and Sox10 were already described to affect the phenotypic HSCR severity in the 
corresponding in vivo model (Cantrell et al., 2004; McCallion et al., 2003; Touré et al., 2019).  
Although animal models can mimic certain human HSCR traits, there are limitations on geno- and 
phenotype level. Most mouse strains display a HSCR phenotype only in the homozygous mutation state, 
while patients usually harbour only heterozygous variants in the respective genes. Next, many animal 
models display various other phenotypic alterations besides the ENS-specific impairment. These 
additional phenotypes are not always present in patients. Moreover, a sex predominance is mostly not 
displayed by any in vivo model (Bondurand and Southard-Smith, 2016; Burns et al., 2016; Heanue and 
Pachnis, 2007; McCallion et al., 2003). To circumvent these limitations, more recent studies made use 
either of patient-specific primary ENS progenitor cells or induced pluripotent stem cells (iPSCs) for 
general functional in vitro cell characterization and to analyse HSCR risk variants (Fattahi et al., 2016; 
Lai et al., 2017; Rollo et al., 2016). The use of suitable in vitro approaches is very promising with regard 
to the examination of underlying mechanisms and the development of cell-based treatment strategies 
for enteric neuropathies in future. However, more detailed investigations and further validation 
procedures are necessary to overcome current challenges e.g. concerning cell isolation, propagation 
and characterization (Burns et al., 2016; Obermayr and Seitz, 2018; Schmitteckert et al., 2019). 
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Besides the functional characterization of HSCR risk loci and variants, dissection of the genetic 
heterogeneity of this enteric neuropathy is another aim targeted in current research projects. Recent 
studies focused on the identification of additional disease-causing variants or novel HSCR susceptibility 
loci by next-generation sequencing analyses. These investigations were combined with various 
bioinformatic filtering strategies suitable for gene and variant prioritization (Gui et al., 2017; Wu et al., 
2018; Zhang et al., 2017). To unravel the genetic architecture in familial HSCR cases, DNA sequencing 
analyses were coupled with segregation and linkage analysis (Luzón-Toro et al., 2015b). However, only 
in a minority of studies, novel genetic findings were confirmed for their HSCR relevance on experimental 
level using e.g. the zebrafish as in vivo model system (Gui et al., 2017; Tilghman et al., 2019).  
1.3 Background of the project and preliminary work 
As outlined previously, HSCR is classified by a vast heterogeneity on genotype and phenotype level, 
which can only partially be addressed in in vivo model systems. Unknown genetic causes in the majority 
of HSCR individuals, together with limited therapy options and lifelong persisting postoperative GI 
impairments in many patients request for a better understanding about the molecular mechanisms 
underlying this neurodevelopmental disorder. Although dissection of the individual’s genetic background 
might help to get further insights in the genetic heterogeneity of HSCR, validation of genetic findings on 
functional level remains a major challenge which is still often neglected in current studies.  
This PhD thesis is based on preliminary work of two previous Master Thesis projects, which aimed to 
establish a complementary study pipeline, based on two major parts (A and B), in an initial pilot study 
setup.  
(A) Identification and selection of novel HSCR candidate genes was performed, as described in a 
previous project (Master Thesis Volz, 2014).   
In brief, whole exome sequencing (WES) was performed on the DNA of two sporadic L-HSCR cases 
and their non-affected family members. Unaffected relatives served as controls for bioinformatics 
filtering of sequencing data. After variant calling, synonymous as well as variants with a minor allele 
frequency (MAF) >1% in the 1000 Genomes Project or in Exome Aggregation Consortium (ExAC) 
database were removed. Next, variants were filtered for the disease model by prioritizing de novo, 
homozygous, hemizygous and compound heterozygous variants for follow up analyses; 19 and 20 novel 
HSCR candidate genes were identified for family I and II, respectively. None of these genes was already 
reported in the context of HSCR or ENS development. To nail down the lists of putative candidates, a 
network analysis using the Ingenuity pathway analysis (IPA) software was performed. Thereby, a 
minority of candidates was identified to display multiple indirect interactions to already known HSCR risk 
genes. Based on these findings, two candidate genes per family were selected for further validation: 
ATP7A (ATPase COPPER TRANSPORTING ALPHA) and SREBF1 (STEROL REGULATORY 
ELEMENT BINDING TRANSCRIPTION FACTOR 1) represented most promising candidate genes for 
family I, while ABCD1 (ABC SUBFAMILY MEMBER 1) and PIAS2 (PROTEIN INHIBITOR OF 
ACTIVATED STAT 2) were the most promising genes for family II. ATP7A, SREBF1, ABCD1 and PIAS2 
were further investigated for their potential contribution to ENS development and HSCR-causing 
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pathomechanisms by a web-based literature search. In this manner, further evidence for a putative 
relevance of these genes in HSCR accumulated. Next, gene-specific variants in all four candidate genes 
detected by WES were validated by Sanger sequencing. Additionally, PCR based analyses in murine 
tissues containing pre-migratory vagal and sacral NCCs at stages E8.5, E9.5 and E10.5 confirmed 
respective candidate gene expression in prospective ENS tissue (Master Thesis Volz, 2014).  
(B) Detailed functional characterization of selected novel HSCR candidate genes was initiated in a 
previous project (Master Thesis Mederer, 2015). 
For the experimental validation of ATP7A, SREBF1, ABCD1 and PIAS2 as promising candidate genes 
for HSCR, protein expression analyses in murine tissues of different embryonic developmental stages 
were carried out. Srebf1 and Pias2 were prioritized in the respective analyses and were found to be 
expressed within the developing GI system. For more detailed functional in vitro analyses targeting the 
neuronal specific relevance of the candidate genes, the generation of a suitable human neuronal cell 
culture model system was envisioned. Therefore, the CRISPR (Clustered Regularly Interspaced Short 
Palindromic Repeats)/Cas9 technology was selected for genome editing in the neuroblastoma cell line 
SHSY5Y. It was aimed to generate gene-specific KO cell clones for all candidate genes and the major 
HSCR susceptibility locus RET which should be characterized on various levels in comparative in vitro 
analyses. Genome edited clones for PIAS2 and RET were already generated but not validated for further 
usage (Master Thesis Mederer, 2015).  
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1.4 Aim of the project 
Taking previous data into account, this project focused on the establishment of a complementary 
research approach for HSCR based on genetic, bioinformatics, molecular and functional data.  
In a first step, it was aimed to confirm the initial candidate selection presented in 1.3 (part A). Therefore, 
WES data was re-evaluated on the basis of current literature and database states. Additionally, the 
patient’s genetics were dissected in more detail to identify rare coding variants in ENS related genes, 
common non-coding HSCR risk variants and CNVs. Transcriptome wide mRNA profiling of different 
embryonic murine ENS-relevant tissues was performed for experimental validation of the initial 
candidate gene selection. Additionally, further rare variant carriers for the candidate genes were 
identified to gain more genetic based evidence for their selection and strengthen their putative relevance 
for HSCR.  
In a second step, it was aimed to assess the candidate genes for their relevance in the HSCR aetiology 
in detail. To this end, candidate expression analyses on protein level, as outlined in 1.3 (part B), were 
extended within this project, as further tissues, developmental stages and cell types were analysed. The 
previously established genome editing strategy for the neuroblastoma cell line was modified and applied 
to all candidate genes. Moreover, a neuronal-like cell culture model system suitable for comparative 
analyses of the generated KO cell clones was established and applied. Various functional in vitro assays 
were implemented in the study pipeline and used for detailed characterization of the candidate genes.  
To allow a final risk evaluation and classification of the four candidate genes for HSCR, generated data 
was summarized in a binary scoring system which was established in another study (Bachelor Thesis 
Dawid, 2019).    
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2 MATERIAL AND METHODS 
2.1 Material 
 Bacterial strains, cell lines and mouse line 
Bacterial strains 
Chemocompetent DH5α E.Coli  
[supE44 lacU169 (80 lacZM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1] 
Chemocompetent XL10 Gold E.Coli (Agilent) 
[Tetr (mcrA)183 (mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F ́proAB lacIqZM15 Tn10 (Tetr) Amy Camr]  
Chemocompetent NovaBlue Singles Competent Cells (Merck Millipore) 
[endA1 hsdR17 (rK12– mK12+) supE44 thi-1 recA1 gyrA96 relA1 lac F′[proA+B+ lacIqZΔM15::Tn10] (TetR)]  
Cell lines 
Human embryonic kidney cells (HEK293TN) Biocompare 
Human epithelial neuroblastoma bone marrow cells 
(SHSY5Y) 
DSMZ  
 
Mouse line 
CD1 wildtype (WT) mice were housed in specific pathogen free (SPF) conditions at the Interfacultary 
Biomedical Faculty (IBF) (University of Heidelberg). Mice were fed ad libitum. The day of vaginal plug 
was defined as E0.5. CD1 WT mice were sacrificed by CO2 asphyxiation. 
 Reagents for bacterial culture 
Ampicillin Roth 
Bacto-Agar BD 
Bacto-Tryptone BD 
Glucose Merck 
Isopropyl β-D-1-thiogalactopyranoside (IPTG)/ 
X-Gal 
usb 
Kanamycin Roth 
Magnesium chloride (MgCl2) Merck 
Magnesium sulfate (MgSO4) Merck 
Potassium chloride (KCl) Merck 
Sodium chloride (NaCl) Sigma-Aldrich 
Yeast extract BD 
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 Media for bacterial cultures 
LB-Agar (ampicillin/kanamycin) 
LB medium + 1.5% Bacto-Agar + 50µg/mL ampicillin or 30µg/ml kanamycin  
LB-medium (ampicillin/kanamycin) 
1% Bacto-Tryptone + 0.5% Yeast extract + 1% sodium chloride + 50µg/mL ampicillin or 30µg/ml 
kanamycin  
SOB-medium 
10mM sodium chloride + 10mM magnesium chloride + 0.5mM potassium chloride + 10mM magnesium 
sulfate + 2% Bacto-Tryptone + 0.5% Yeast extract  
SOC-medium 
1L SOB-medium + 20mL glucose (20%)  
 Reagents for cell culture 
Acetic acid Merck 
Brain-derived neurotrophic factor (BDNF) Peprotech 
Collagen I (Col I) Thermo Fisher Scientific 
Collagen IV (Col IV) Sigma-Aldrich 
Distilled water Thermo Fisher Scientific 
Dulbecco’s modified eagle medium (DMEM)  
(high glucose) 
Thermo Fisher Scientific 
Dulbecco’s phosphate buffered Saline (PBS) Thermo Fisher Scientific 
Fetal bovine serum (FBS) Thermo Fisher Scientific 
Laminin Sigma Aldrich 
Matrigel Corning 
Neurobasal medium, without L-Glutamine Thermo Fisher Scientific 
Neuregulin1 (NRG1) Peprotech 
Neurotrophic growth factor (NGF) Peprotech 
Penicillin/Streptomycin Thermo Fisher Scientific 
Retinoic acid (RA) Sigma-Aldrich 
StemPro Accutase Thermo Fisher Scientific 
Vitamin D3 (Cholecalciferol) Sigma-Aldrich 
0.05% Trypsin-EDTA  Thermo Fisher Scientific 
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 Media and buffers for cell culture 
MACS buffer 
1X PBS +1% FBS + 2.5mM EDTA 
HEK293TN culture medium (HEK293TN CM) 
DMEM (high glucose) + 10% FBS  
SHSY5Y culture medium (SHSY5Y CM) 
DMEM (high glucose) + 15% FBS + 1% Pen/Strep 
SHSY5Y differentiation medium I (DM I) 
DMEM (high glucose) + 15% FBS + 1% Pen/Strep + 10µM RA 
SH-SY5Y differentiation medium II (DM II) 
DMEM (high glucose) + 1% Pen/Strep + 50ng/µL BDNF 
SHSY5Y differentiation medium III (DM III) 
DMEM (high glucose) + 1% Pen/Strep + 15% FBS + 10µm RA + 50ng/µL BDNF + 10ng/µL NRG1 + 
10ng/µL NGF + 24nM Vitamin D3  
 Vector constructs 
pSpCas9(BB)-2A-GFP (PX458) (#48138) Addgene 
pcDNA3.1-2xFLAG-SREBP-1c (#26802) Addgene 
pcDNA3-CASP3-MYC (#11813) Addgene 
pcDNA4-ATP7A-MYC 
kindly provided by Bart van de Sluis 
University of Groningen, The Netherlands 
pCMV_Flag_PIASxalpha (#15209) Addgene 
pEGFP-N1-ABCD1 
kindly provided by Dr. Imanaka, University of 
Toyama, Japan 
 
 Reagents for molecular analyses 
Acetic acid Merck 
LE Agarose Biozym 
Ammonium persulfate GR Healthcare 
AquaPolymount Polysciences 
Bovine Serum Albumin (BSA) – Fraction V, pH 7.0 Serva Electrophoresis 
Bromphenol blue Sigma-Aldrich 
Chloroform Sigma-Aldrich 
Citric acid  Merck 
Diethly pyrocarbonate (DEPC) Sigma-Aldrich 
Dimethylsulfoxide (DMSO) Sigma-Aldrich 
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DirectPCR Lysis-Reagent Cell Peqlab 
Ethanol (EtOH) Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
GeneRuler DNA Ladder (100bp /1 kb) Thermo Fisher Scientific 
Glycerol Sigma-Aldrich 
Glycine Sigma-Aldrich 
Hoechst 33342 trihydrochloride, trihydrate Thermo Fisher Scientific 
Hydrochloric acid (37%) Merck 
Igepal (NP-40) Chem-Cruz 
Immobilon FL-Polyvinylidene fluoride (PVDF) 
Membrane 
Merck 
Isopropanol Sigma-Aldrich 
Lipofectamine 2000 Thermo Fisher Scientific 
Methanol (MeOH) Sigma-Aldrich 
Midori Green DNA stain Nippon Genetics 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Normal goat serum (NGS) Thermo Fisher Scientific 
Odyssey blocking reagent (PBS) LI-COR Biosciences 
Opti Minimal Essential Medium (OptiMEM) Thermo Fisher Scientific 
Paraformaldehyde (PFA) Sigma-Aldrich 
Proteinase and phosphatase inhibitor cocktail Thermo Fisher Scientific 
Rotiphorese Gel 30 (37,5:1) Acrylamid-Bisacrylamid 
solution 
Carl Roth 
Sodium chloride  Sigma-Aldrich 
Sodium citrate AppliChem 
Sodium deoxycholate Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
Sucrose AppliChem 
Tissue freezing medium Jung 
TRIS (Tris-(hydroxymethyl)-aminomethan) Carl Roth 
Triton X-100 Sigma-Aldrich 
Trizol Thermo Fisher Scientific 
Tween-20 Carl Roth 
Vectashield antifade mounting medium for 
fluorescence 
Vector Laboratories 
  
Material and Methods  17 
 
 Buffers for molecular analyses 
All buffers were prepared with deionized water.  
50X TRIS-Acetate-EDTA (TAE) buffer (DNA gelelectrophoresis buffer) 
2M TRIS + 1M acetic acid + 50mM EDTA  
5X Laemmli Running buffer (Western blot) 
125mM TRIS + 960mM Glycine + 0.5% SDS 
10X PBS 
13.7M sodium chloride + 270mM potassium chloride + 800mM disodium hydrogenphosphate + 200mM 
potassium dihydrogen phosphate (pH 7.4) 
Citrate buffer 
1.8mM Citric acid + 8.2mM Sodium Citrate + 0.05% Tween-20 (pH 6) 
Radio Immuno Precipitation Assay (RIPA) buffer 
150mM sodium chloride + 1% NP-40 + 0.5% sodium deoxycholate + 0.1% SDS + 50mM TRIS (pH 8) 
Stacking Gel buffer (Western blot) 
1.5M TRIS (pH 8.8) 
Separating Gel buffer (Western blot) 
1M TRIS (pH 6.5) 
10X TBS  
200mM TRIS + 1.37M sodium chloride  
TBST  
1X TBS + 0.1% Tween-20 
10X Transfer buffer (Western blot) 
250mM TRIS + 1.92M Glycin  
1X Transfer bufffer 
1X Transfer buffer + 10% MeOH 
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 Kits 
Bioanalyzer RNA analysis Kit Agilent 
BrdU (Bromodeoxyuridine) Incorporation Kit Roche 
CombiMag OZ Biosciences 
Direct PCRLysis Reagent Peqlab 
FastDigest Restriction Enzymes       
             BamHI, BbsI, SrfI, XbaI 
Thermo Fisher Scientific 
GeneJET Plasmid MiniPrep Kit Thermo Fisher Scientific 
HotStarTaq DNA Polymerase Kit  Qiagen 
In Situ Cell Death Detection Kit, Fluorescein Roche 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 
pSTBlue-1 AccepTor Vector Kit  Merck Millipore 
Q5 High fidelity DNA Polymerase Kit New England Biolabs 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
Qubit RNA BR Assay Kit Thermo Fisher Scientific 
Quick DNA Microprep Kit Zymo Research 
QuickChange Lightning Site-Directed Mutagenesis 
Kit 
Agilent 
RNAqueous-Micro Total RNA Isolation Kit Thermo Fisher Scientific 
SensiFAST SYBR Lo-ROX Kit Bioline 
Superscript III First-Strand Synthesis System for  
reverse transcription PCR 
Thermo Fisher Scientific 
T4 DNA Ligase Thermo Fisher Scientific 
T4 PNK Kit Thermo Fisher Scientific 
ZymoPURE II plasmid prep Kit ZymoResearch 
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 Antibodies 
Table 1: Primary antibodies  
Primary antibody information and dilutions used for different purposes are listed below. Details about the 
permeabilization detergent and demasking used for immunofluorescence (IF) analysis of cryosections and for 
immunohistochemical (IHC) staining of formalin-fixed paraffin embedded (FFPE) sections are annotated. – not 
applicable 
 
Antibody Reactivity Supplier 
Annotations 
(dilution, permeabilization, demasking) 
IF of IHC of  
Western 
blot 
cells cryosections 
FFPE  
sections 
Rabbit anti- 
ABCD1 
Mouse, rat, 
human 
Abcam, 
ab197013 
1:100 1:100 
(0.1% Tween) 
1:100 1:5000 
Rabbit anti- 
ATP7A 
Mouse, rat, 
rabbit, human 
Abcam, 
ab125137 
1:75 1:75 
(0.1% Triton) 
- 1:250 
Rabbit anti- 
ATP7A 
Mouse, rat, 
human 
Elabscience,  
E-AB-16268 
- - 1:75 - 
Mouse anti- 
ECad 
Mouse, rat, 
horse, human 
Abcam, 
ab76055 
- 1:100 
(demasking; 
0.1% Triton) 
- - 
Mouse anti- 
FLAG 
 Sigma Aldrich, 
F3165 
1:100 - - - 
Mouse anti- 
GAPDH 
Mouse, rat, 
human, 
chicken, 
xenopus, dog, 
fish, pig,  
Abcam,  
ab8245 
 
- - - 1:2000 
Mouse anti- 
GAPDH 
Mouse, rat, 
human, pig, 
rabbit 
NovusBio, 
NB300-328SS 
- - - 1:10000 
Rabbit anti- 
GAP43 
Mouse, rat, 
human 
Abcam, 
ab75810 
1:100 - - - 
Mouse anti- 
GFP 
- Sigma Aldrich, 
G6539 
1:100 - - - 
Mouse anti- 
HuC/D-
Biotin 
Mouse, 
human 
Molecular 
Probe,  
A-21272 
- 1:100 
(0.1% Triton) 
- - 
Rabbit anti- 
Ki67 
Mouse, rat, 
human, 
marmoset 
Abcam, 
ab16667 
1:100 - - - 
Rabbit anti- 
MAP2 
Mouse, rat, 
human, 
monkey 
Cell signalling, 
4542 
1:35 - - - 
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Mouse anti- 
MYC 
- Cell signalling, 
2276 
1:100 - - - 
Mouse anti- 
PGP9.5 
Mouse, rat, 
human, 
rabbit, sheep, 
zebrafish 
Abcam, 
ab8189 
1:100 1:100 
(0.1% Triton) 
- - 
Rabbit anti- 
PIAS2 
Mouse, rat, 
human, 
chicken 
Biozol, 
GTX115180 
1:100 1:100 
(0.1% Triton, 
demasking) 
1:500 - 
Goat anti- 
PIAS2 
Human, 
predicted: 
mouse, rat, 
dog 
Biozol, 
ARG64201.100 
- - - 1:500 
Rabbit anti- 
P75 
Mouse, rat, 
human 
Upstate, 
07-476 
- - - - 
Rabbit anti- 
RET 
Mouse, rat, 
human 
Abcam, 
ab134100 
1:40 1:100 
(0.1% Triton) 
- 1:1000 
Mouse anti- 
SMA 
Mouse, rat, 
human, 
Bovine, 
chicken, 
rabbit, 
baboon 
Abcam, 
ab18147 
- 1:250 
(0.1% Triton) 
- - 
Mouse anti- 
SOX10 
Mouse, rat, 
human 
Affymetrix, 
14-5923 
- 1:50 
(0.1% Triton) 
- - 
Rabbit anti- 
SREBF1 
Mouse, rat, 
human 
Abcam, 
ab28481 
1:300 - 1:1000 -- 
Rabbit anti- 
SREBF1 
Mouse, rat, 
human, pig, 
hamster 
Abnova, 
PAB12021 
- 1:300 
(1% Triton) 
- 1:500 
Rabbit anti- 
SYP 
Mouse, rat, 
human 
Abcam, 
ab32127 
1:100 - - - 
Mouse anti- 
TAU 
Mouse, rat, 
human, 
predicted: 
cow 
Cell signalling, 
4019 
1:150 - - - 
Mouse anti- 
TUBB3 
mammals Promega, 
G7121 
1:500 1:500 
(0.1% Triton) 
- - 
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Table 2: Secondary antibodies  
Secondary antibody information and dilutions are listed below. – not applicable 
  
 Oligonucleotides 
Oligonucleotides for conventional PCR were designed with Primer3 and OligoAnalyzer 3.1. All primers 
were designed to be annealed to the target sequence at a temperature of 60°C. Oligonucleotides used 
for quantitative realtime PCR (qRT PCR) were designed with the Universal ProbeLibrary Assay Design 
Center from Roche. Mutagenesis primers were designed by using the web-based QuickChange Primer 
Design tool from Agilent. 
Table 3: Oligonucleotides 
Applications are annotated. Mutated bases are highlighted in bold. Overhang sequences for cloning are lowercased, 
restriction sequences for cloning are lowercased and underscored. 
Primer name Sequence (5' > 3') Application 
ABCD1_for ATGAAGGAGACAGCAGCACC 
Endogenous expression in 
SHSY5Y cells 
ABCD1_rev AGGGAATCATGGGGACTCGA 
ABCD1_Ex1_for ACTTCTCCCAGCAGACCTACTA 
Alternative splicing of  
edited clone 
ABCD1_Ex3_rev GCTCCTCCTCCTTCTTTTCCAA 
ABCD1_MUT_for GCGCTTCAGCCTGTTCCCCCGCCAG 
Mutagenesis experiment 
ABCD1_MUT_rev CTGGCGGGGGAACAGGCTGAAGCGC 
Antibody Conjugate Supplier 
Annotations  
(dilution) 
Immuno- 
fluorescence 
Western 
blot 
Goat anti-mouse IgG Alexa Fluor 488 Thermo Fisher Scientific 
(A-11029) 
1:250 - 
Goat anti-mouse IgG Alexa Fluor 647 Thermo Fisher Scientific 
(A-21236) 
Goat anti-rabbit IgG Alexa Fluor 568 Thermo Fisher Scientific 
(A-11011) 
Goat anti-rabbit IgG Alexa Fluor 647 Thermo Fisher Scientific 
(A-21245) 
Streptavidin Alexa Fluor 488 Thermo Fisher Scientific 
(S32354) 
 
Donkey anti mouse  IRDyeCW680 LI-COR (926-32222) 
- 1:10000 
Donkey anti goat  IRDyeCW680 LI-COR (932-32214) 
Donkey anti rabbit  IRDyeCW680 LI-COR (926-32223) 
Donkey anti mouse IRDyeCW800 LI-COR (926-32212) 
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ABCD1_qPCR_for4 TTCCTCATGAAGTATGTGTGGAG 
qRT PCR 
ABCD1_qPCR_rev4 CCTTCTTCACGGCCTCTG 
ATP7A_for CCCTTGTGAGTGCCTGGTAG 
Endogenous expression in 
SHSY5Y cells 
ATP7A_rev AGAACTCCATCCCCTACCCC 
ATP7A_Ex2_for TTGGACCATTGAGCAGCAGA 
Alternative splicing of  
edited clone 
ATP7A_Ex4_rev GCTGGAGGGAGAGTTTGAGG 
ATP7A_MUT_for 
TTAGAGCAAAGACAAAATTTATCT 
GAATCCTCTTGACTGTCTTTCTT 
Mutagenesis experiment 
ATP7A_MUT_rev 
AAGAAAGACAGTCAAGAGGATTCAG 
ATAAATTTTGTCTTTGCTCTAA 
ATP7a_qPCR_for3 TTTGCTGTCCTTTTTATTGTGTG 
qRT PCR 
ATP7a_qPCR_rev3 GTGCTTTATAAGCCTGAATGTAGAAG 
CASP3_qPCR_for TGGAATTGATGCGTGATGTT 
qRT PCR 
CASP3_qPCR_rev TCCAAAAATTATTCCTTCTTCACC 
CRISPR_Cas9_rev GTCTGCAGAATTGGCGCAC 
Sequence validation 
sgRNA cloning 
CRISPR_ABCD1_for TTGAGTTTGAGACCTGGCCC 
Genotyping of CRISPR  
clones 
CRISPR_ABCD1_rev CCACTTGAGCCTGGGAAGTT 
CRISPR_ATP7A_for TGGTAGAGTGTGAAGTGTTGGAG 
Genotyping of CRISPR  
clones 
CRISPR_ATP7A_rev CCATGAATTGCCAACCCAGC 
CRISPR_PIAS2_Ex2_T1_ 
for 
GCTTGAGGGTGACTTGGCTT 
Genotyping of CRISPR  
clones CRISPR_PIAS2_Ex2_T1_ 
rev 
CGGCCAAGTCAGGTTCTACA 
CRISPR_PIAS2_Ex2_T2_ 
for 
TGTGGAGGAAATGTTGCCCT 
Genotyping of CRISPR  
clones CRISPR_PIAS2_Ex2_T2_ 
rev 
GGCTAGTGGGAGAGGAGGAG 
CRISPR_PIAS2_Ex2_T3_ 
for 
TGATCCTCTTGTGTTGGCCTC 
Genotyping of CRISPR  
clones CRISPR_PIAS2_Ex2_T3_ 
rev 
AGAAACTGGAACCCTTGTGCA 
CRISPR_PIAS2_Ex6_for TCCCCTCACTTCCCAGTTTG 
Genotyping of CRISPR  
clones 
CRISPR_PIAS2_Ex6_rev TAACTTTAAGAATCTCCACACTGC 
CRISPR_RET_for AAGCTGTATGTGGACCAGGC 
Genotyping of CRISPR  
clones 
CRISPR_RET_rev CCAGCCTCACTTAACCCCTG 
CRISPR_SREBF1_Ex5_T1
_for 
TAACGACCACTGTGACCTCG 
Genotyping of CRISPR  
clones CRISPR_SREBF1_Ex5_T1
_rev 
ATAGGCAGCTTCTCCGCATC 
GAP43_qPCR_for CCATGCTGTGCTGTATGAGAA 
qRT PCR 
GAP43_qPCR_rev GACAGGGAAAATTCACACTTGAG 
GAPDH_for CGACCACTTTGTCAAGCTCA  
Conventional PCR  
(reference) 
GAPDH_rev AGGGGTCTACATGGCAACTG 
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GAPDH_qPCR_for CAGCCTCGTCCCGTAGAC 
qRT PCR 
GAPDH_qPCR_rev CGCTCCTGGAAGATGGTG 
GFAP_qPCR_for CAAGAGGAACATCGTGGTGA 
qRT PCR 
GFAP_qPCR_rev GCTCCTGCTTGGACTCCTTA 
HPRT1_qPCR_for TGATAGATCCATTCCTATGACTGTAGA 
qRT PCR 
HPRT1_qPCR_rev AAACATTCTTTCCAGTTAAAGTTGAG 
MAP2_qPCR_for CCTGTGTTAAGCGGAAAACC 
qRT PCR 
MAP2_qPCR_rev AGAGACTTTGTCCTTTGCCTGT 
MASH1_qPCR_for CGACTTCACCAACTGGTTCTG 
qRT PCR 
MASH1_qPCR_rev ATGCAGGTTGTGCGATCA 
NES_qPCR_for GAGGTGGCCACGTACAGG 
qRT PCR 
NES_qPCR_rev AAGCTGAGGGAAGTCTTGGA 
NPY_qPCR_for CTCCCCGACAGCATAGTA 
qRT PCR 
NPY_qPCR_rev GCCCCAGTCGCTTGTTAC 
P75_qPCR_for TCATCCCTGTCTATTGCTCCA 
qRT PCR 
P75_qPCR_rev TGTTCTGCTTGCAGCTGTTC 
PIAS2_for GCAAGCATGACCTCCTGATG 
Endogenous expression in 
SHSY5Y cells 
PIAS2_rev GAAGCAGCACAGAACCAACA 
PIAS2_Exon1_for ATGGCGGATTTCGAAGAGTTGA 
Alternative splicing of  
edited clone 
PIAS2_Exon3_rev CTCTAACTTGTTGAGGTGTCAAAGC 
PIAS2_Exon5_for GCAGAGACAAGTTGCCCTCA 
Alternative splicing of  
edited clone 
PIAS2_Exon7_rev GTGCTCTGGAATGATCAGGGT 
PIAS2_MUT_for 
GCTGATGTAAGCTGCCATACAAGATA 
TACAGACATAGAGTAATTC 
Mutagenesis experiment 
PIAS2_MUT_rev 
GAATTACTCTATGTCTGTATATCTTG 
TATGGCAGCTTACATCAGC 
RET_for CCTGGGAGAAGCTCAGTGTC 
Endogenous expression in 
SHSY5Y 
RET_rev GATGTTGGGGCACAAGAACT 
RET_Exon1_for ATGGCGAAGGCGACGTCCG 
Alternative splicing of  
edited clone 
RET_Exon3_rev GCAGGCTGGAAAGGAGGTGTTGA 
RET_overexpr_cloning_for gATGGCGAAGGCGACGTC 
Cloning overexpression 
construct  RET_overexpr_cloning_rev 
actgtctagaTTAACTATCAAACGTGTCCAT 
TAATTTTGC 
RET_rs2435357_for GTCAAAGCCAGTGGTGATGC 
Genotyping rs2435357 
RET_rs2435357_rev CAGAGTTAATCACCAGCCTCACT 
RET_rs2506030_for CGGCCAGTTCTACCTTCTCTG 
Genotyping rs2506030 
RET_rs2506030_rev AGAGCAAAACGACCCATGAGT 
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RET_rs7069590_for CTGGATCTGAGCCTGGTCTTG 
Genotyping rs7069590  
RET_rs7069590_rev GGTGAGGTTAGTGGTCAGGTG 
RET3_qPCR_for ACCACCCACATGTCATCAAA 
qRT PCR 
RET3_qPCR_rev TGGCGTACTCCACGATGA 
SDHA_qPCR_for TGGGAACAAGAGGGCATCTG 
qRT PCR 
SDHA_qPCR_rev CCACCACTGCATCAAATTCATG 
SEMA_rs11766001_for TGGGTGTGAAAGATGATGGTGT 
Genotyping rs11766001 
SEMA_rs11766001_rev TGCCTCCTTTGTAGCTTCTTGT 
SOX10_qPCR_for GACCAGTACCCGCACCTG 
qRT PCR 
SOX10_qPCR_rev CGCTTGTCACTTTCGTTCAG 
SREBF1_for CAGTGACTTCCCTGGCCTAT 
Endogenous expression in 
SHSY5Y 
SREBF1_rev TTCCTTGATACCAGGCCCAG 
SREBF1_Exon4_for TAACGACCACTGTGACCTCG 
Alternative splicing in 
edited clone 
SREBF1_Exon6_rev ATAGGCAGCTTCTCCGCATC 
SREBF1_MUT_for ACACCAGCTCCTCCACCGCAGTCTGAG 
Mutagenesis experiment 
SREBF1_MUT_rev CTCAGACTGCGGTGGAGGAGCTGGTGT 
SREBF1_FL_overexpr_ 
cloning_for 
actgggatccATGGACGAGCCACCCTTCA 
Cloning overexpression 
construct SREBF1_FL_overexpr_ 
cloning_rev 
actgtctagaTAGCTGGAAGTGACAGTGGT 
SREBF1_qPCR_for CGCTCCTCCATCAATGACA 
qRT PCR 
SREBF1_qPCR_rev TGCGCAAGACAGCAGATTTA 
SYP_qPCR_for CCAATCAGATGTAGTCTGGTCAGT 
qRT PCR 
SYP_qPCR_rev AGGGGTGGAGACCTAGGGTA 
TAC1_qPCR_for GCCTCAGCAGTTCTTTGGAT 
qRT PCR 
TAC1_qPCR_rev AGCCTTTAACAGGGCCACTT 
TAU_qPCR_for GGACTGGAAGCGATGACAA 
qRT PCR 
TAU_qPCR_rev GGCTAAGGCAAGGCCTATTT 
TUBB3_qPCR_for GCAACTACGTGGGCGACT 
qRT PCR 
TUBB3_qPCR_rev ATGGCTCGAGGCACGTACT 
UCHL1_qPCR_for AGATCAACCCCGAGATGCT 
qRT PCR 
UCHL1_qPCR_rev ACCGAGCCCAGAGACTCC 
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Prior to single guide RNA (sgRNA) design, in silico analyses for annotated isoforms using the NCBI and 
ENSEMBL databases of respective candidate genes were performed (tab. S4, Supplementary). Exons 
with a base number that was not a multiple of 3 and that were located at the most 5’ region of as many 
annotated isoforms as possible were selected as target sites. The CCTop CRISPR/Cas9 target online 
predictor was used for sgRNA design (Stemmer et al., 2015). sgRNAs were re-evaluated using the 
Optimized CRISPR Design portal and the CHOPCHOP web tool (Montague et al., 2014) (tab. S5, 
Supplementary). Oligonucleotides selected for genome editing are shown below. RET gRNAs and 
PIAS2 gRNAs specific to exon 6 had been designed previously and applied in a genome editing 
experiment as reported in the Master Thesis Mederer, 2015.  
Table 4: sgRNAs 
Gene Exon 
Sequence (5’>3’) 
(5’ overhang nucleotides necessary for cloning into the 
vector backbone are lowercased) 
RET    Ex2 
caccgTCTACGGCACGTACCGCACA 
aaacTGTGCGGTACGTGCCGTAGAc  
ATP7A Ex3 
caccGATCATAGTATGGCTCAAGC 
aaacGCTTGAGCCATACTATGATC 
SREBF1 Ex5 
caccGAGACCTGCCGCCTTCACAG 
aaacCTGTGAAGGCGGCAGGTCTC 
ABCD1 Ex2 
caccgCGCTCCACACATACTTCATG 
aaacCATGAAGTATGTGTGGAGCGc 
PIAS2 
Ex6 
 
 
Ex2_T1 
 
 
Ex2_T2 
 
 
Ex2_T2 
caccgTAATATTCAAGGGGCGTCCA 
aaacTGGACGCCCCTTGAATATTAc 
 
caccgCGATATCCACGAACTCTTGA 
aaacTCAAGAGTTCGTGGATATCGc 
 
caccgCCGAGAATTGTATAGACGCCGAT 
aaacATCGGCGTCTATACAATTCTCGGc 
 
caccgCCACGAACTCTTGAAGGACTTTC 
aaacGAAAGTCCTTCAAGAGTTCGTGGc 
 
Genomic modifications introduced by CRISPR/Cas9 editing were annotated by using the Mutationtaster 
webtool. The predicted list of the top 20 off-target sites generated by the CCTOP CRISPR/Cas9 target 
online predictor was further filtered for exonic off-target sites. In addition, putatively essential intra-
/intergenic off-target sites encoding e.g. non-coding RNAs or containing enhancer sites were identified 
using the UCSC Genome browser. Oligonucleotides specific to off-target sites selected for genotyping 
are shown below.  
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Table 5: Oligonucleotides used for off-target analysis 
Primer name Sequence (5‘>3‘) Application 
ARHGAP24_for TGACGGAAGGTTAAAGGCACA 
Off-targets_CRISPR ATP7A 
  
  
ARHGAP24_rev TTCCCCTGCTTCACTGTTGA 
DYRK1A_for GCTTTTGTGGGTGTAAGGGC 
DYRK1A_rev CCCAGGAGTCAGTTTGCAGT 
EGF_for GATGACACTTGGGAGCCTGG 
EGF_rev GGCTGGTCTCAAACTCCTGG 
NDRG3_for GTCAGGCCAAGTGTACCCTC 
NDRG3_rev GGCCTCAGTTACCCCATCTG 
RP11-146N_for TGCCACGATTCTTCCTCTGG 
RP11-146N_rev ACTGACCTACTGCCCTGCTA 
SMOX_for GTCCTGTCTTCCCCATGCAG 
SMOX_rev TATATGCCCCTTGGTGGTGC 
ZMAT5_for CAACAACGCTGACTGAAGGC 
ZMAT5_rev CCTTCCTTCTGCAACTGGGT 
ST8SIA5_rev TCCTCCTCCCAGCACTAACA 
  
Off-targets_CRISPR SREBF1 
  
ST8SIA5_for TTAACAGCCAAGCCACACCA 
CAMK1G_for  TCAGTAAACACGGACCGAGC 
CAMK1G_rev   TGGCATTTCTGAGCCTCCTG 
CLIC6_2_for TTAGGTGTTTGGGTGTCGGG 
CLIC6_2_rev CCATTGAGTCCTCCCGCAAA 
CTDSP1_for TGTAGAGACAGAGGGCAGCT 
CTDSP1_rev CGCTTTCCTCTCCCTCTGTG 
EEF1A2_2_for GTTGAGGTTCAGGTCTGGGG 
EEF1A2_rev  CCGCTCTTCTTCTCCACGTT 
MIR8073_for ATCCTGGGCTGCCTCTATCA 
MIR8073_rev AAGCCTGGAACCTACACAGC 
XYLB_for GAGCCCTGTGGTTTGCTTTG 
XYLB_rev AACCGGGTTGCAGAAGATGT 
SNORA23_for TGTATTCCCTCTCTTCAGCAGTG 
Off-targets_CRISPR ABCD1  
SNORA23_rev ACCCAGCAAGCCTTTTGTAAAA 
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 Hardware  
Automated Inverted Microscope DMI4000B Leica 
Biological Safety Cabinet Safe 2020 Thermo Fisher Scientific 
Centrifuges 
           Centrifuge 5418  
           Biofuge fresco 
 
Eppendorf  
Heraeus 
Cryostat-microtome CM3050S Leica 
DeNovix Spectrophotometer & Fluorometer DeNovix 
Microbiological incubator WTB Binder 
Odyssey Infrared Imager LI-COR Biosciences 
Olympus BX53 Upright microscope Olympus 
Orbital Climo-shaker Kuhner  
Orbital shaker VWR 
Polytron tissue homogenizer Polytron 
QUANTUM Gel Documentation System Peqlab 
Steri Cult CO2 incubator Thermo Fisher Scientific 
Thermal cyclers (Mastercycler pro –vapo    
 protect)  
Eppendorf 
Thermomixer Eppendorf 
 
 Software 
Affinity designer 1.7.0. Pantone 
CellSens Entry 2.1 Olympus 
GraphPad Prism Vers. 5 GraphPad 
Illustrator for biological sequences v1.0.3 GPS 
Image J National Institute of Health 
Image Studio LI-COR Biosciences 
Ingenuity Pathway Analysis Software Qiagen 
Leica Application Suite Advanced Fluorescence 
4.0.0.11706 
Leica 
Photoshop CS4 Vers. 11.0 Adobe 
Quantum Capt Vers. 15.12 Peqlab 
SnapGene Viewer Vers. 3.2.1 SnapGene 
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 Websites 
CCTop CRISPR/Cas9 target online predictor:  http://crispr.cos.uni-heidelberg.de/ 
CHOPCHOP web tool: https://chopchop.rc.fas.harvard.edu/ 
ENSEMBL genome browser: https://www.ensembl.org/index.html 
Expert Protein Analysis System (ExPASy): http://www.expasy.org/ 
Genecards: https://www.genecards.org/ 
Genome Aggregation Database (gnomAD): http://gnomAD.broadinstitute.org/ 
GTEx portal: https://gtexportal.org/home/index.html 
GWAS catalogue: https://www.ebi.ac.uk/gwas/ 
CADD SNV lookup: https://cadd.gs.washington.edu/snv 
Mutationtaster: http://www.mutationtaster.org/ 
National Center for Biotechnology Information (NCBI): http://www.ncbi.nlm.nih.gov/ 
OligoAnalyzer 3.1: http://eu.idtdna.com/calc/analyzer 
Online Mendelian Inheritance in Man (OMIM): https://www.omim.org/ 
Optimized CRISP Design portal: http://crispr.mit.edu/ 
Pfam database: https://pfam.xfam.org/ 
Primer3web (Vers. 4.0.0): http://primer3.ut.ee/ 
PROVEAN: http://provean.jcvi.org/seq_submit.php 
QuickChange Primer Design Program: https://www.agilent.com/store/primerDesignProgram.jsp 
SFARI Gene: https://gene.sfari.org/ 
The Human Protein Atlas: https://www.proteinatlas.org/ 
UCSC Genome Browser: https://genome.ucsc.edu/ 
UniProt: https://www.uniprot.org/ 
Universal ProbeLibrary Assay Design Center: https://lifescience.roche.com/en_de/brands/ 
universal-probe-library.html#assay-design-center) 
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2.2 Methods 
 In silico analyses 
Exome sequencing of HSCR patients and variant calling 
Two sporadic long-segment HSCR cases were analyzed in the context of a pilot study. Recruitment of 
HSCR patients was performed at the Pediatrics Surgery of the University Hospital Heidelberg by Prof. 
Dr. Holland-Cunz and Dr. Romero. The study has been approved by the Ethical board of the University 
Hospital Heidelberg (S509/2012, 08.02.2013: Genomweite Sequenzierung bei Patienten mit Morbus 
Hirschsprung). Parents provided written informed consent before DNA sample submission. Trio WES of 
patients and their non-affected family members followed by bioinformatics data filtering and candidate 
gene selection was carried out as reported in Volz’ Master Thesis in 2014 and as briefly summarized in 
chapter 1.3. In the context of this project, WES data was bioinformatically re-evaluated accordingly, 
applying the same filtering strategy. These analyses were kindly performed by Dr. Nagarajan 
Paramasivam (Theoretical Bioinformatics Division, DKFZ).  
CNV analysis 
WES data was also used for CNV analysis. To increase the number of samples used in the background 
coverage data set for XHMM (version 1.0), 220 samples were recruited, including the families of this 
project, sequenced with three different exome target kits (Agilent sureSelect V4, V5 and V6). The 
regions targeted by all three target kits were extracted using `bedtools multiinter` (version 2.24.0) and 
were merged if they were within a distance of 10bp. These regions were used as exome intervals. The 
XHMM analysis was performed following the recommended steps in the XHMM protocol (Fromer and 
Purcell, 2014).  
From the resulting cohort level variant files, the candidate CNVs in a family were selected if the CNV is 
present in the case and the same variant should not be present in more than four other samples in the 
background data. Further, the CNVs are classified into de novo or inherited based on the absence or 
presence of the CNV in the parent. All the candidate variants were visualized and potential causal 
variants were selected for downstream analysis.  
Ingenuity pathway analysis  
Network analysis for validation of initially depicted candidate genes was performed using the knowledge 
database, Ingenuity Pathway Analysis (IPA). IPA core analysis was performed applying a merged list of 
genes known to be relevant for ENS development and to be HSCR disease-causing (Gui et al., 2017; 
Lake and Heuckeroth, 2013; Luzón-Toro et al., 2015b) as well as for re-filtered lists of candidate genes 
from sequenced trios of the pilot study (Master Thesis Volz, 2014) (tab. S3, Supplementary). In total, 15 
networks were generated in the core analysis. Next, the four networks, which contained the candidate 
genes ATP7A, SREBF1, ABCD1 and PIAS2 were merged. Validated HSCR risk loci based on Luzon-
Toro et al., were manually added and connected to the merged network by the IPA software. 
Subsequently, indirect connections, which were not linked to any candidate gene product, were removed 
and networks were further modified as molecules were arranged corresponding to their subcellular 
localisation and non-connected factors were removed. 
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Genetic evaluation of candidate genes 
Further HSCR patients carrying exonic variants in the candidate genes SREBF1 and PIAS2 were 
collected from already available sequencing data (whole genome and exome sequencing data) 
generated within the International HSCR consortium (Stanislas Lyonnet, http://www.erare.eu/financed-
projects/hscr). Data analysis for ATP7A and ABCD1 is ongoing.  
Numbers of patients and controls used in the respective studies are summarized in the table below. 
Data from the following HSCR consortium members were taken into account: Prof. Dr. Robert Hofstra, 
Dr. Salud Borrego and Prof. Dr. Paul Kwong-Hang Tam. Phenotypic data of patients as well as genetic 
data from study specific control cohorts were accessible for the Spanish cohort only (tab. 6). 
Table 6: HSCR patient cohorts from International HSCR Consortium groups 
More detailed information for each cohort, which was taken into account for data analysis, is displayed. #: number 
Cohort 
# of HSCR patients  
(phenotype information) 
# of HSCR study controls 
(origin, genotype information) 
EUROPE 
The Netherlands  
 
 
 
Spain  
 
38  
(no phenotype information) 
 
 
56 
(familial/sporadic;  
S-/ L-HSCR phenotypes) 
 
212  
(combined controls from EUROPE and SOUTH 
ASIA, no genotype information)  
 
267  
(Spanish controls from the Medical Genome 
Project, genotype data accessible via the 
Collaborative Spanish variant server 
(http://csvs.babelomics.org/)) 
SOUTH ASIA 
Hongkong 
 
443 
(no phenotype information) 
 
493  
(controls from other sequencing studies,  
no genotype information) 
 
Lists of genetic variants found in HSCR patients were filtered in a second step in order to exclude 
common variants/SNPs (MAF >1%). First, all variants except for non-synonymous (missense mutations, 
stop loss and stop gain) were removed. Next, remaining variants were compared to variant data 
deposited in the gnomAD browser (population matched comparison). Variants were kept if MAF < 1%. 
To assess the putative functional relevance of the filtered variants, CADD scores were calculated using 
the CADD model GRCh37-v1.4 (https://cadd.gs.washington.edu/snv). 
Statistics 
All statistics were performed using the GraphPad Prism Software (version 5). The global significance 
level used was p=0.05. 
An exploratory data analysis was carried out for quantitative real time (qRT) PCR expression data. For 
this purpose, mean expression levels for a specific gene and an individual time point were compared 
between the mock control clone and each of the gene-specific KO clones using a two-sided unpaired T-
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Test (with Welch’s correction in case of significantly different standard deviations of the two means 
compared). Corresponding to this analysis, statistical results are purely descriptive.  
For functional in vitro assays targeting the cell proliferation, survival and migration capacity of the clones, 
mean values were compared between the mock control clone and each of the gene-specific KO clones 
using a one-way ANOVA. Results were Bonferroni corrected for multiple testing against the number of 
pairwise comparisons (mock control vs RET KO/ ATP7A KO/ SREBF1 KO/ ABCD1 KO).  
Candidate gene scoring 
To evaluate the functional relevance and potential predisposing role of selected candidate genes for 
HSCR, a scoring system taking complementary data into account was established within a Bachelor 
Thesis project (Bachelor Thesis Dawid, 2019). It was aimed to summarize candidate specific evidences 
annotated in different databases or generated by in silico (IPA Network analysis) and in vitro 
(Transcriptomics assay) analyses in a single score. Data was classified into different categories (Gene 
expression, Gene information, Gene interaction, Gene constraint, Gene mutation) and ranked by a 
binary system. Classifications and cut offs for the respective categories are listed in tab. 7. Primary data, 
which was taken into account for risk evaluation, is partially displayed in sections 3.1 and 3.2. Hyperlinks 
for the databases are given in 2.1.15. More detailed information is provided in Dawid’s Bachelor Thesis, 
2019. 
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 Cell biological methods 
All cells were cultivated at 37°C in a humidified atmosphere (95%) containing 5% CO2. 
Cell cultivation of HEK293TN cells 
HEK293TN cells were cultivated in HEK293TN culture medium (HEK293TN CM) and passaged at 80-
90% confluency. For passaging, media was aspirated and cells were washed once with pre-warmed 1X 
PBS. PBS was removed, pre-warmed 0.05% Trypsin-EDTA was added and cells were incubated at 
37°C until having completely detached from the flask’s surface. Trypsinization was stopped by the 
addition of pre-warmed HEK293TN CM. For further cultivation at 37°C, cell suspension was split and 
transferred into new cell culture flasks supplied with pre-warmed HEK293TN CM.  
Cell cultivation and neuronal differentiation of SHSY5Y cells 
SHSY5Y cells were cultivated in SHSY5Y culture medium (SHSY5Y CM) and passaged as previously 
described. Deviating from the outlined protocol, cell suspension was centrifuged at 1300 rounds per 
minute (rpm) for 3 minutes (min) before transferring it into new cell culture flasks. 
To establish a neuronal differentiation protocol for WT SHSY5Y cells, modified versions of already 
published differentiation protocols were tested (Pilot experiment A) (Agholme et al., 2010; Encinas et 
al., 2000; Raghavan and Bitar, 2014). Further modifications to these setups were applied in a second 
pilot experiment (Pilot experiment B). Complete media compositions are given in 2.1.5. Three different 
coatings based on collagen I (Col I), Matrigel or collagen I, collagen IV and laminin (Col I, Col IV, laminin) 
were used. Details are described in the sections below. The experimental strategies are illustrated 
schematically in figure 3.  
Figure 3: Establishment of a neuronal cell culture model system using SHSY5Y cells 
A and B: Two pilot experiments (A, B) in SHSY5Y cells were carried out. Coatings, media, media changes, cell 
dissociation steps are outlined in relation to the respective time frame. Col I (Collagen I), Col IV (Collagen IV), CM 
(SHSY5Y culture medium), DMI I/DM II/ DMIII (SHSY5Y differentiation medium I/ II/ III), d (days) 
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Pilot experiment A 
1x104 SHSY5Y cells/cm2 were seeded on 0.05mg/mL collagen coated culture dishes in SHSY5Y CM. 
The day after, medium was aspirated and SHSY5Y differentiation medium I (SHSY5Y DM I) containing 
10µM retinoic acid (RA) was applied. Medium was changed after 3-4 days (d) of cultivation. 7d after RA 
treatment, cells were further differentiated using three different experimental setups as described in the 
following:  
Protocol Ia Cells were washed three times with DMEM high glucose and SHSY5Y DM II was  
                          applied (modified from Encinas et al., 2000). 
Protocol IIa  Cells were washed once with pre-warmed 1X PBS and trypsinized as reported   
                         previously. 2x104 cells/cm2 were plated in SHSY5Y DM III on Matrigel (1:3 in DMEM   
                         high glucose) coated dishes (modified from Agholme et al., 2010). 
Protocol IIIa: Cells were washed once with pre-warmed 1X PBS and trypsinized as reported  
previously. 2x104 cells/cm2 were plated in SHSY5Y DM III on 800µg/mL Col I, 200µg/mL 
Col IV, 10µg/mL laminin, 1% FBS, 0.1% Pen/Strep (in DMEM high glucose, pH 7.6) 
coated dishes (modified from Agholme et al., 2010 and Raghavan and Bitar, 2014). 
Cells were differentiated for further 14d and harvested at specific time points (3d DM I, 7d DM I, 7+3d 
DM II/ DM III, 7+7d DM II/ DM III, 7+14d DM II/ DM III; n=1, each). 
Pilot experiment B 
Protocols Ia and IIa were further modified.  
Protocol Ib: Cell seeding and differentiation were performed as previously described (Protocol Ia). 
Cultivation period was extended to 7+42d.  
Protocol IIb:  Experimental procedure was comparable to protocol Ib. Instead of Col I coated dishes, 
Matrigel (1:3 in DMEM) coated cell culture dishes were used. SHSY5Y DM III was used 
instead of SHSY5Y DM II. 
Cells were harvested after 5d DM I, 7d DM I, 7+7d DM II/ DM III, 7+14d DM II/ DM III, 7+21d DM II/ DM 
III, 7+28d DM II/ DM III and 7+42d DM II/ DM III (n=2, each). 
For differentiation of genome edited cell clones, differentiation protocol Ib was further modified: Cells 
were plated in SHSY5Y CM at a density of 2x104 cells/cm2 on 0.05mg/mL Col I coated dishes. One day 
after seeding, medium was changed to SHSY5Y DM I containing RA which was changed after 3-4d of 
cultivation. 7d after RA treatment, cells were washed two times with DMEM high glucose. Cell 
differentiation in SHSY5Y DM II was performed for additional 28d (7+28d). Half of the media was 
changed every 4-7d.  
Cell transfection 
For evaluation of the candidate genes carrying the detected genetic variant, HEK293TN and SHSY5Y 
cells were transfected with respective overexpression constructs. For this purpose, coverslips were 
coated with Col I (0.05mg/mL) prior to cell seeding. 3.5x104 of HEK293TN and 1.2x105 of SHSY5Y cells 
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were seeded onto coated coverslips in 500µL of antibiotics free HEK293TN and SHSY5Y CM, 
respectively. Next day, HEK293TN cells were transfected using Lipofectamine 2000 following the 
manufacturer’s instructions (500ng of plasmid DNA; ratio DNA/Lipofectamine 1:3). Medium was 
changed 4 hours (h) after transfection and cells were further cultivated for 48h before fixation. For 
transfection of SHSY5Y cells, the Magnetofectamine Kit (CombiMag/Lipofectamine 2000) was used. 
Transfection mixes were prepared as outlined in the manual and added dropwise to the cells (500ng of 
plasmid DNA; ratio DNA/Lipofectamine 1:4; ratio plasmid DNA/CombiMag 1:1). After 20min of 
incubation on a magnetic plate under standard conditions at 37°C, medium was changed. Cells were 
cultivated for further 48h before fixation. 
CRISPR/Cas9 genome editing of SHSY5Y cells 
Genome editing of SHSY5Y cells was performed as described in Master Thesis Mederer, 2015. In brief, 
7.5x105 cells were seeded per 6 well in a total volume of 2.5mL of SHSY5Y CM without the antibiotics 
penicillin and streptomycin. Next day, cells reached 80-90% confluency and were transfected with 
Lipofectamine 2000 and gene-specific sgRNAs cloned into the expression vector pSpCas9(BB)-2A-
GFP. Transfection was carried out corresponding to the manufacturer’s instructions (2.5µg of plasmid 
DNA; ratio DNA/Lipofectamine 1:3). For the generation of a mock control clone, 2.5µg of the empty 
cloning plasmid (pSpCas9(BB)-2A-GFP) were transfected. 4h after transfection, medium was changed 
to SHSY5Y CM and cells were cultured for further 48h at standard conditions.  
For clonal isolation of genetically modified cells, fluorescent-activated cell sorting (FACS) at the FACS 
Core Facility (Dr. Volker Eckstein, University Hospital Heidelberg) was performed. Therefore, cells were 
harvested 48h after transfection corresponding to the aforementioned passaging procedure. To 
guarantee for single cell suspension, dissociated cells were resuspended with SHSY5Y CM and passed 
through a cell strainer (40µm). Next, cells were centrifuged at 1300rpm for 3min, supernatant was 
removed and the cell pellet was resuspended in 1–1.5mL ice-cold MACS buffer. Cell suspensions were 
kept on ice until FACS was performed. Single cells were sorted into single wells of up to four 96 well 
plates containing SHSY5Y CM. Cell clones were expanded for at least 21d before replica plates were 
prepared. To this end, cells were washed once with pre-warmed PBS and trypsinized as described 
previously. Trypsinization was stopped by cell resuspension in pre-warmed SHSY5Y CM and cell 
suspension was split into two 96 wells. Next day, medium was changed to remove remaining Trypsin-
EDTA. Replicated 96 wells of individual clones were used for DNA extraction as described below.  
The mock control, RET KO and PIAS2_Ex6 KO clones have already been generated in a previous study 
(Master Thesis Mederer, 2015). Gene-specific KO clones for ATP7A, SREBF1 and ABCD1 were 
generated in the context of this actual PhD project. 
Boyden Chamber migration assay 
Cell migration capacities of undifferentiated and differentiated genome edited cell clones were 
investigated by Boyden Chamber assays. In brief, 6.5mm transwell inserts (5µm pore size/ 
polycarbonate (PC) membrane) were coated with 0.05mg/mL Col I.  
In the undifferentiated state, 1.2x105 cells were seeded on coated inserts in serum-free media (DMEM 
high glucose). To measure the directed migratory behaviour of the cells, lower compartments were either 
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filled with SHSY5Y CM (FBS as chemoattractant; positive control) or DMEM high glucose only (no 
chemoattractant; negative control) (fig. 4 A). 
To assess migration capacity in the differentiated state, cells were dissociated with Accutase 7d after 
initiation of neuronal differentiation. 1.5x105 cells were seeded on Col I coated inserts as previously 
described. SHSY5Y DM II (BDNF as chemoattractant; positive control) or DMEM high glucose only (co 
chemoattractant; negative control) were added to lower compartments (fig. 4 A). 
24h after incubation at standard conditions, cells from the inside of the inserts were removed using 1X 
PBS wetted cotton swabs. Migrated cells were fixed in ice-cold MeOH for 20min at room temperature 
(RT). After washing with 1X PBS, cells were counterstained with Hoechst (1:5000 in 1X PBS, 4min at 
RT) and mounted with Vectashield on a glass slide. For image analysis, membranes were imaged at 
five spots (20X magnification) as illustrated below using the Leica Automated Inverted Microscope 
DMI4000B (fig. 4 B). Nuclei were counted using the ImageJ software and the mean cell 
number/membrane was calculated. At least, three biological replicates were used for data analysis. 
 
 
 
 
 
 
 
Cell proliferation assay 
To assess the proliferative capacity of undifferentiated and differentiated genome edited cell clones, the 
Bromodeoxyuridine (BrdU) Incorporation Kit from Roche was used. For analysis of undifferentiated cells, 
2.25x105 cells were seeded on Col I (0.05mg/mL) coated coverslips. After 24h, medium was aspirated 
and BrdU labelling solution (10µM BrdU) diluted in SHSY5Y CM was added to the cells. After 10h of 
further cultivation under standard conditions, cells were washed and fixed corresponding to the 
manufacturer’s instructions. For the analysis of differentiated cells, neuronal differentiation was initiated 
by 7d RA treatment as described earlier. Thereafter, the medium was changed to SHSY5Y DM II and 
the next day, BrdU labelling solution (10µM BrdU) diluted in SHSY5Y DM II was added, cells were 
cultivated for further 10h and processed as described previously for undifferentiated cells. Nuclei were 
counterstained with Hoechst (1:5000 in 1X PBS, 4min at RT). After mounting with Vectashield, cells 
were imaged with the Leica Automated Inverted Microscope DMI4000B. 10 fields of view (20X 
magnification) per cell clone were analysed using the ImageJ software. The mean percentage of BrdU 
positive cells/field of view was calculated. At least three biological replicates were used for data analysis. 
 
Figure 4: Boyden chamber migration assay  
A: Schematic showing the experimental setup in a well of a 24 well plate. Upper and lower 
compartments are separated by a Transwell membrane. B: Imaged areas of the Transwell 
polycarbonate (PC) membrane are highlighted. 
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Cell death detection assay 
To determine the number of apoptotic cells, the in situ cell death detection Kit from Roche was used. 
TdT-mediated dUTP-X nick end labelling (TUNEL) of apoptotic cells was performed as outlined in the 
protocol. For analysis of undifferentiated clones, 2.5x105 cells were seeded cells on Col I (0.05mg/mL) 
coated cover slips and fixed in 4% PFA/ 1X PBS (20min at RT) after 24h. Differentiated cell clones after 
7+7d of neuronal differentiation were investigated accordingly. Counterstain with Hoechst (1:5000 in 1X 
PBS, 4min at RT) was performed for undifferentiated and differentiated cell clones. Cells were mounted 
with Vectashield and imaged with the Leica Automated Inverted Microscope DMI4000B. 10 fields of 
view per cell clone (20X magnification) were used for image analyses (ImageJ software). The mean 
percentage of TUNEL positive cells/field of view was calculated from at least three biological replicates. 
Preparation of cryosections 
For preparation of whole mount cryosections, CD1 WT mice were sacrificed by CO2 asphyxiation before 
the uterus was dissected. Embryos at stages E9.5, E10.5, E11.5 and E13.5 were prepared and collected 
in 1X PBS on ice. For preparation of adult tissue specimens, CD1 WT mice were sacrificed by CO2 
asphyxiation, part of the colon was dissected and rinsed multiple times with 1X PBS. 
Fixation of whole mounts and gut tissue was carried out for 24h at 4°C in 4% PFA/ 1X PBS under gentle 
agitation. Next, tissues were washed twice with 1X PBS and incubated for 24h at 4°C in 30% sucrose 
(in DEPC-PBS) under gentle agitation. Finally, specimens were embedded in Tissue Freezing Medium, 
snap frozen in liquid nitrogen and stored at -80°C until cryosectioning with the cryostat-microtome 
CM3050S. Cryosections of 10µm thickness were prepared, placed on a glass slide and stored at -80°C 
until immunofluorescence (IF) staining. 
IF staining of cryosectioned tissue 
All antibody specific details are given in table 1 and 2. 
For IF analyses, frozen cryosections were allowed to adapt to RT and then washed once with 1X PBS. 
Depending on the applied primary antibody, heat-induced antigen retrieval was performed for 25min in 
pre-warmed citrate buffer (pH 6) in a glass cuvette using a heat steamer. Sections were allowed to cool 
for 20min at RT before washing once with 1X PBS. After permeabilization for 7 min at RT using an 
antibody specific detergent (Triton X-100 or Tween-20) at a specific concentration, blocking was carried 
out for 1h at RT in 1% BSA/ 10% NGS/ 1X PBS supplemented with the respective antibody specific 
detergent. Primary antibodies diluted in blocking solution were incubated overnight (o/n) at 4°C in a 
humidified chamber. Next day, cryosections were washed three times with 1X PBS (each 5min) in a 
glass cuvette under gentle agitation. Secondary antibody dilutions were prepared in blocking solution 
and specimens were incubated for 1h at RT in the dark. After three washing steps with 1X PBS (each 
5min), nuclear counterstain with Hoechst (1:5000 in 1X PBS) was performed for 4min in the dark. Next, 
sections were rinsed once with 1X PBS followed by a final washing step with H2O. Stained slices were 
mounted with Vectashield and stored at 4°C until imaging using the Leica Automated Inverted 
Microscope DMI4000B. 
For triple IF staining of cryopreserved tissue sections, slices were permeabilized, blocked and incubated 
with primary antibody solution (anti-SMA and the candidate specific antibody) o/n at 4°C. IF analyses of 
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these antigens were finalised as previously described. However, before nuclear counterstaining was 
applied, slices were blocked again and stained by anti-TUBB3 as outlined above. Next day, after 
secondary antibody incubation, cryosections were counterstained and mounted.  
As negative control for the staining of cryoconserved tissue sections, no primary antibody incubation 
was carried out (fig. S2, Supplementary).  
Preparation of formalin-fixed paraffin embedded sections 
Fetal and adult formalin-fixed paraffin embedded (FFPE) tissue sections were kindly prepared by Dr. 
Cornelia Thöni and Jutta Scheuerer (Institute of Pathology, University Hospital Heidelberg, research 
team of Dr. Felix Lasitschka). Human fetal gut tissue originates from a fetus acardius amorphous (25th 
week of gestation (wog)) while adult colon samples originated from a non-affected part of the colon of a 
patient suffering from Inflammatory bowel disease (IBD).  
Immunohistochemical staining of human tissue slices 
Primary antibody specific details are given in table 1. 
Immunohistochemical (IHC) staining of fetal and adult FFPE tissue sections were kindly performed by 
Dr. Cornelia Thöni and Jutta Scheuerer (Institute of Pathology, University Hospital Heidelberg, research 
team of Dr. Felix Lasitschka). In brief, FFPE samples of 3µm thickness were deparaffinized and 
rehydrated. Heat induced antigen retrieval was performed in 10mM EDTA (pH 9) for 5min. Slices were 
blocked in antibody diluent solution (Thermo Fisher Scientific) supplemented with 15% NGS (Vector 
Laboratories). Specimens were incubated with primary antibodies diluted in blocking solution o/n at 4°C. 
Next day, slides were washed three times with TBST (0.5% Tween-20), 10min each. Peroxidase-
conjugated AffiniPure Goat Anti-Rabbit (Jackson ImmunoResearch) was diluted in blocking solution and 
secondary antibody incubation was carried out for 1h at RT. Again, slides were washed three times with 
TBST (10min each) before 3,3′-Diaminobenzidine (DAB) solution (ImmPACT DAB Peroxidase Substrate 
Kit) was added onto the slices. DAB reaction was stopped when signal intensity of choice was reached 
by washing with ddH2O. Slides were counterstained with Hematoxylin for 1min. After washing with 
ddH2O, slides were differentiated in running tap water and mounted with Aquatex. 
Staining was imaged using the Olympus Light Microscope BX53 and the Olympus SC30 camera 
(Institute of Pathology, University Hospital Heidelberg).  
As negative control for the staining of FFPE tissue sections, no primary antibody incubation was carried 
out (fig. S3, Supplementary).  
IF staining of cells 
Antibody specific details are given in table 1 and 2. 
For cell fixation, respective media was removed, and cells were washed once with 1X PBS. Fixation 
was carried using 4% PFA (in PBS). After 20min of incubation at RT, fixative was removed, and cells 
were washed three times with 1X PBS. Coverslips were stored in 1X PBS at 4°C until IF staining were 
carried out. Differentiated genome edited cell clones were cultivated on 3.5cm ibidi imaging dishes until 
fixation with 4% PFA/ 1X PBS which was performed as previously described. 
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IF staining of fixed cells was performed corresponding to the following protocol: for staining of nuclear 
antigens, fixed cells were permeabilized with 0.1% Triton (in 1X PBS) for 7min at RT prior to blocking 
for 1h at RT in 1% BSA/ 10% NGS/ 1X PBS. After blocking, cells were incubated with primary antibodies 
diluted in blocking solution in a humidified chamber for 1h at RT. Next, cells were washed three times 
with 1X PBS and incubated for 1h with secondary antibody dilution (in blocking reagent) at RT in a 
humidified chamber in the dark. Again, cells were washed three times with 1X PBS before nuclear 
counterstaining with Hoechst (1:5000 in 1X PBS) was performed for 4min under light protection. After 
two washing steps with 1X PBS and a final washing step with H2O, cells were prepared for fluorescent 
microscopy using the Leica Automated Inverted Microscope DMI4000B. Therefore, coverslips were 
mounted with Vectashield on a glass slide while cells on ibidi dishes were mounted with AquaPolymount.  
 Molecular biological methods 
Total RNA isolation 
Total RNA extraction was performed with TRIzol reagent either following the manufacturer’s instructions 
or combined with the RNAqueous-Micro Total RNA Isolation Kit protocol. To this end, TRIzol samples 
were thawed on ice and 200µL of chloroform/mL were added. The samples were mixed vigorously for 
15 seconds (sec). After incubation for 5min at RT, specimens were centrifuged for 15min at 4°C at 
13000rpm. The upper phase was transferred into a new tube and 0.5volumes of EtOH were added. 
After vigorous mixing for 5sec, 150µl of the sample was transferred onto the column of the RNAqueous-
Micro Total RNA Isolation Kit. All further steps were carried out corresponding to the manual.  
Before further usage, the quality and quantity of the RNA samples were assessed by a 
spectrophotometer from DeNovix.  
Transcriptomics assay (Clariom S array mouse) 
RNA samples from different murine embryonic tissue were used for transcriptomics analyses at the 
DKFZ Genomics and Proteomics Core Facility using the Clariom S assay (mouse) (Thermo Fisher 
Scientific). Regions containing pre-migratory vagal NCCs at stage E8.75 and E9.5 as well as the 
embryonic gut at E13.5 were dissected from CD1 WT murine embryos.  
Dissected embryonic tissues from each litter were pooled. Three litters were analysed for each stage. 
Total RNA was extracted using TRIzol reagent according to the manual. In addition to the RNA analysis 
by the DeNovix system, the RNA amount was quantified and checked for integrity by the Qubit 2.0 
Fluorometer and the Agilent 2100 Bioanalyzer System according to the manufacturer’s instructions, 
respectively. 500ng of total RNA (RIN from 9.8-10) of each preparation were submitted for microarray 
profiling at the DKFZ Genomics and Proteomics Core Facility (Dr. Melanie Bewerunge-Hudler).  
For gene expression profiling, biotinylated antisense cDNA was subsequently prepared according to the 
standard labelling protocol with the GeneChip WT Plus Reagent Kit and the GeneChip Hybridization, 
Wash and Stain Kit (both from Thermo Fisher Scientific). Afterwards, the hybridization on the chip was 
performed on a GeneChip Hybridization oven 640, then dyed in the GeneChip Fluidics Station 450 and 
thereafter analysed by a GeneChip Scanner 3000. All of the equipment used was from the Affymetrix. 
Data analysis was kindly performed by Dr. Carolina De La Torre from the Medical Faculty Mannheim. 
In brief, a Custom CDF Version 22 with ENTREZ based gene definitions was used to annotate the 
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arrays (Dai et al., 2005). The raw fluorescence intensity values were normalized applying quantile 
normalization and robust multi-array (RMA) background correction.  
The expression profile of undifferentiated human fetal gastrointestinal colon cells (FGIC_C, ATCC) was 
assessed in the context of another project by microarray profiling according to the previously presented 
pipeline (Dr. Stefanie Schmitteckert, unpublished data). Respective data was used for the establishment 
of the scoring system (Bachelor Thesis Dawid, 2019). 
cDNA synthesis 
cDNA synthesis was performed with the SuperScript III First-Strand Synthesis kit. Deviating from the 
manual, 50pmol Oligo dT and 50ng random hexamer primers were used. For reverse transcription of 
differentiated genome edited cell clones, 800ng of total RNA were used per sample. For conventional 
PCR, cDNA was diluted 1:10, whereas for quantitative realtime (qRT) PCR cDNA was diluted 1:5. 
Conventional PCR 
Conventional PCR analyses were performed with the HotStarTaq DNA Polymerase PCR Kit or the Q5 
High fidelity DNA Polymerase Kit either using cDNA or genomic DNA as template. Thermal cycling was 
carried out in Mastercycler pro – vapo protect. Depending on the amplicon size, PCR products were 
separated by gel electrophoreses using 1%, 1.5% or 2% TAE agarose gels, respectively. 
GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (GAPDH) was used as control to assess 
RNA integrity and RT quality. For Sanger sequencing, PCR product purification was performed using 
the QIAquick PCR Purification Kit according to the instructions given in the manual. Sanger sequencing 
was carried out by GATC, EUROFINS or GENEWIZ.  
qRT PCR 
Quantitative gene expression analysis of in vitro differentiated gene-specific KO cell clones was 
performed using the SYBR Green Lo-ROX Fast Mix from Bioline. PCR conditions are shown in tab. S7 
(Supplementary). A set of different markers was used for characterization of differentiating cells. 
Oligonucleotide specific sequences are given in table 3. Respective standard curves were generated by 
using cDNA of human whole brain or SHSY5Y 7d DM I. qRT PCR analysis for each marker and condition 
was performed as duplicate, while up to three biological replicates were used for each time point. 
Relative mRNA expression levels were calculated by the relative standard curve method and via 
normalization to the expression of the two reference genes (SUCCINATE DEHYDROGENASE 
COMPLEX FLAVOPROTEIN SUBUNIT A (SDHA) and HYPOXANTHINE 
PHOSPHORIBOSYLTRANSFERASE 1) HPRT1 for WT SHSY5Y, and SDHA and GAPDH for all edited 
cell clones and the mock control clone. 
Total Protein isolation 
Undifferentiated cells were harvested by trypsinization as previously described. Differentiated and 
transfected cells were washed once with 1X PBS before scraping in 1X PBS on ice. Cell suspension 
was transferred into a tube and cells were pelleted by centrifugation for 3min at 1300rpm. Cell pellets of 
undifferentiated, differentiated as well as transfected cells were resuspended in the appropriated amount 
of RIPA buffer complemented with proteinase and phosphatase inhibitor cocktail.  
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For protein isolation of murine tissue, embryonic and adult GI and brain tissues were dissected and 
rinsed with sterile 1X PBS before resuspension in RIPA buffer complemented with proteinase and 
phosphatase inhibitor cocktail. Adult murine specimens were homogenized on ice using the polytron 
tissue homogenizer. Embryonic tissues were minced using a pistil.  
Cell lysis was performed for 45min at 4°C under rotation. After centrifugation for 15min at 13000rpm at 
4°C, the supernatant was transferred into a new tube and used for protein quantification with the Pierce 
BCA Protein Assay Kit. 
Protein gel electrophoresis and Western blot analysis  
8 or 10% SDS-polyacrylamid Laemmli gels were casted in Novex Gel cassettes and used for Western 
blot analyses of anti-RET, anti-SREBF1 and anti-PIAS2 specific investigations. 5-60μg of total protein 
per sample were prepared with 5X sample loading buffer and denatured for 5min at 95°C. Samples 
were loaded onto the gel and gelelectrophoresis in 1X Laemmli running buffer was carried out at 150 
Volt (V) for 1.5-2h at 4°C.  
Precasted NuPAGE 4-12% Bis-Tris gradient gels and the NuPAGE Bis-Tris Gel Protocol were used for 
protein gel electrophoresis of anti-ATP7A and anti-ABCD1 specific investigations. 5-60μg of total protein 
per sample were prepared with NuPAGE 4X sample loading buffer and denatured for 10min at 75°C. 
Gel electrophoresis in 1X MOPS running buffer was carried out at 200V for 1-1.5h at 4°C.  
For protein transfer, a PVDF membrane was used. To this end, the membrane was wetted with MeOH 
before preparing the blotting sandwich as indicated below: 
• two blotting pads soaked with transfer buffer 
• two Whatman papers soaked with transfer buffer 
• gel 
• PVDF membrane 
• two Whatman papers soaked with transfer buffer 
• two blotting pads soaked with transfer buffer 
Blots were run at 150mA for 2.5h at RT. Blotting for anti-ATP7A and anti-ABCD1 was carried out at 25V 
for 75min at RT using the NuPAGE Transfer buffer.  
After protein transfer, the membranes were blocked in Odyssey blocking reagent (PBS) for 1h at RT. 
Primary antibodies were diluted in Odyssey blocking reagent (PBS) + 0.2% Tween-20 and incubation 
was carried out o/n at 4°C under gentle agitation. Next day, membranes were washed three times with 
1X TBST for 5min each. Secondary antibodies were diluted in Odyssey blocking reagent (PBS) + 0.2% 
Tween-20. Incubation was carried out for 1h at RT in the dark under gentle agitation. Before imaging 
with the Odyssey Infrared Imaging System was performed, membranes were washed three times for 
5min with 1X TBST and once with 1X TBS. 
Respective antibody dilutions are listed in table 1 and 2. 
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Cloning of expression constructs 
For cloning of sgRNA expression constructs into the pSpCas9(BB)-2A-GFP vector backbone, BbsI 
digested plasmid DNA was ligated with annealed and phosphorylated sgRNA oligonucleotides. Ligation 
was performed corresponding to the manual’s instruction of the T4 DNA ligase Kit. Details are given in 
the Supplementary (tab. S6, fig. S8).  
For cloning of gene-specific overexpression constructs, the pcDNA3.1-2xFLAG vector backbone was 
used. Inserts were generated using the Q5 High fidelity DNA Polymerase Kit. SHSY5Y cDNA served as 
template. Respective oligonucleotides are shown in table 3. PCR products were purified using the  
QIAquick PCR purification kit. After quantification with the DeNovix spectrophotometer, restriction 
digestion using FastDigest restriction enzymes was performed according to the manufacturer’s 
instructions. Restriction enzymes used for gene-specific overexpression construct generations are listed 
below.  
Insert Restriction enzymes used 
RET_FL SrfI, XbaI 
SREBF1b_FL BamHI, XbaI 
 
Digested inserts and plasmids were loaded onto a 1% agarose gel, respective gel bands cut out and 
the DNA isolated with the QIAquick Gel extraction Kit and quantified with the DeNovix 
spectrophotometer. 10-50ng of linearized plasmid DNA were ligated with respective excess amounts of 
insert DNA using the T4 DNA ligase corresponding to the instructions given in the protocol. Vector maps 
are displayed in the supplementary (fig. S9 and S10). 
In case of compound heterozygous events, allele specific genomic modifications caused by 
CRISR/Cas9 genome editing in individual alleles were separated using the pSTBlue-1 AccepTor Vector 
Kit. All experimental steps were carried out corresponding to the instructions given in the manual. 
NovaBlue Singles Competent cells (>1.5x10⁸ colony forming units (CFU)/µg plasmid DNA) were used 
for bacterial transformation following the manufacturer’s instructions. To allow blue white screening, 
ampicillin containing LB agar plates were coated with IPTG/XGal before plating of the transformed 
bacterial cell suspension.  
Patient-specific mutations were introduced into the respective overexpression constructs using the 
QuickChange Lightning Site-Directed Mutagenesis Kit following the manufacturer’s instructions. 
Deviating from the manual, 1µl of DMSO was added to the ATP7A and ABCD1 mutant strand synthesis 
reactions. Agilent Technologies XL10-Gold Ultracompetent Cells (≥5x109 colony forming units/μg 
plasmid DNA) were used for bacterial transformation. Instructions of the manual were followed. 
If not otherwise stated, chemo-competent DH5α E.Coli cells (>1x106 CFU/μg plasmid DNA) were used 
for transformation. Bacterial cells were thawed on ice for 5min and 1µL of the ligation reaction was 
added. Cells were shortly mixed and incubated for 8min on ice before 250µL of pre-warmed SOC 
medium were added. For bacterial outgrowth, cells were incubated up to 60min at 37°C under constant 
agitation (350rpm). LB agar plates containing 50µg/mL ampicillin or 30µg/mL kanamycin were pre-
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warmed at 37°C before up to 100µL of the transformed bacterial cell suspension were plated. Plates 
were incubated o/n at 37°C. 
Plasmid preparation from bacteria 
To sequence validate bacterial clones, 5mL of LB medium containing the respective antibiotics were 
inoculated with a single colony. After o/n incubation at 37°C under constant shaking (1000rpm), the 
GeneJET Plasmid MiniPrep Kit was used for plasmid preparation. Sanger sequencing was carried out 
at GATC, EUROFINS or GENEWIZ. 
For midi plasmid preparations 50-100mL LB medium containing the respective antibiotics were 
inoculated with up to 20µL of an o/n mini prep culture. After bacterial outgrowing at 37°C o/n, the 
ZymoPURE II plasmid prep Kit was used for plasmid preparation.  
Glycerol stocks of bacterial cultures were prepared by mixing 300µL of glycerol with 700µL of an o/n 
bacterial culture. After snap-freezing, glycerol stocks were stored at -80°C. 
Genomic DNA extraction and genotyping 
To detect micro indels in the CRISPR/Cas9 targeted genomic regions, Sanger sequencing of a PCR 
product spanning the region of interest was performed. To this end, replicated SHSY5Y cell clones were 
trypsinized as previously described and cell suspension was pelleted at 2000rpm for 4min. Genomic 
DNA extraction was performed using the DirectPCR Lysis-Reagent Cell following the manufacturer’s 
instructions. Oligonucleotides used for genotyping are listed in table 3. The respective PCR product was 
purified using the QIAQuick PCR Purification Kit and sequenced at GATC or EUROFINS. 
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3 RESULTS 
3.1 Evaluation of WES data and genotyping for non-coding HSCR SNPs 
In two investigated families, ATPase COPPER TRANSPORTING ALPHA (ATP7A) and STEROL 
REGULATORY ELEMENT BINDING TRANSCRIPTION FACTOR (SREBF1) as well as ABC 
SUBFAMILY MEMBER 1 (ABCD1) and PROTEIN INHIBITOR OF ACTIVATED STAT 2 (PIAS2), 
represented most promising HSCR candidate genes. Bioinformatic data revision (performed by Dr. 
Nagarajan Paramasivam, Theoretical Bioinformatics Division, DKFZ) on the basis of current database 
states, confirmed this gene selection and reduced the lists of filtered candidate genes from 19 to 11 
candidate genes for family I and from 20 to 15 candidate genes for family II (tab. S1 and S2, 
Supplementary). After variant calling, filtered WES data of both patients were as well checked for the 
presence of rare variants residing in ENS-relevant genes (tab. S3, Supplementary). Patient I harboured 
heterozygous variants in three ENS/HSCR-associated genes: ECE1 (rs141146885), SERPIN FAMILY 
I MEMBER 1 (SERPINI1) (rs61750375) and SUPPRESSOR OF FUSED HOMOLOG (SUFU) 
(rs34135067) while for patient II no variants in any ENS-relevant genes could be identified (fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Schematic overview on the bioinformatics filtering of WES data 
Variant calling and candidate selection of a previous study were re-evaluated and 
initial gene selection could be confirmed. MAF (Minor allele frequency), comp. 
(compound), indel (insertion/deletion)  
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Additionally, WES data was used for CNV analyses in both families (performed by Dr. Nagarajan 
Paramasivam, Theoretical Bioinformatics Division, DKFZ). These investigations led to the identification 
of several deleted and duplicated chromosomal regions which are summarized in fig. 6 A. For example, 
patient I carried an inherited, 30kb deletion within the PROTO-CADHERIN GAMMA SUBFAMILY 
(PCDHG) gene cluster affecting PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGB1 and 
PCDHGB2 (fig. 6 A’). Patient II carried a 9.5kb deletion on chromosome 8 affecting the CLN8 
TRANSMEMBRANE ER AND ERGIC PROTEIN (CLN8) and a 60kb duplication in the GLYCEROL-3-
PHOSPHATE ACYLTRANSFERASE 3 (AGPAT9) residing on chromosome 4 (fig. 6 A’’).  
Except for genetic alterations in the coding part of the genome, all individuals of family I and II were 
genotyped for four non-coding HSCR risk SNPs located in REARRANGED DURING TRANSFECTION 
(RET) (rs2435357, rs7069590, rs2506030) and the CLASS 3 SEMAPHORIN (SEMA3) cluster 
(rs11766001). All genotype information on the above-mentioned variants is summarized in fig. 6 B.   
 
Genetic data from all individuals of the two families is summarized in fig. S1 (Supplementary). 
Figure 6: Results for CNV analysis and genotyping for non-coding HSCR risk SNPs 
A: Deleted and duplicated chromosomal regions detected in the individuals of the two families are shown. Except 
for the chromosomal position (based on GRCh37/hg19) and the size (in kb), the affected gene is annotated in 
brackets (Family I (A’): PCDHGA1/2/3/4, PCDHGB1/2: members of the PROTO-CADHERIN GAMMA SUBFAMILY 
A/B; MICA: MHC CLASS I POLYPEPTIDE-RELATED SEQUENCE A; UHRF1BP1L: UHRF1 BINDING PROTEIN 
1 LIKE; Family II (A’’): CLN8: CLN8 TRANSMEMBRANE ER AND ERGIC PROTEIN; AGPAT9: GLYCEROL-3-
PHOSPHATE ACYLTRANSFERASE 3). B: Genotype information of all four non-coding HSCR risk SNPs are listed 
for each individual. Risk alleles are highlighted in red.  
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3.2 Candidate gene validation 
 IPA Network analysis 
To put the detected candidates into biological context, an Ingenuity Pathway Analysis (IPA) was 
performed and revealed multiple direct and indirect protein interactions between depicted candidates 
and genes relevant in ENS formation or proven to be causative for HSCR (fig. 7). ATP7A displayed an 
indirect connection to the LOW-DENSITY LIPOPROTEIN (LDL) complex to which RETINOL BINDING 
PROTEIN 4 (RBP4) was directly connected. RBP4 was one of the ENS-relevant factors uploaded for 
network analysis. The very-long chain fatty acid (VLCFA) transporter ABCD1 was found to be directly 
connected to the HSCR risk factor DNA METHYLTRANSFERASE 3 BETA (DNMT3B). For the 
candidates SREBF1 and PIAS2, several direct protein interactions were assessed using the IPA 
knowledge base. Amongst others, both candidates showed a direct connection to the ENS-relevant 
factor NEURON NAVIGATOR 2 (NAV2). In addition, SREBF1 was identified to directly interact with the 
T-BOX3 transcription factor (TBX3) while for PIAS2 a direct connection to the PHOSPATASE AND 
TENSIN HOMOLOG (PTEN) was elucidated. Both candidate interactions partners are known regulators 
of ENS development. 
 
Figure 7: Network generated based on IPA  
After core analysis using the Ingenuity Pathway Analysis (IPA) knowledge base, networks (4/15) containing the four 
candidate genes of interest were merged. Additionally, gene products of validated HSCR risk loci were added and 
connected to the network. Indirect interactions were only kept if they were linked to candidate gene products. 
Proteins known to be relevant for ENS development are marked in green. In addition, validated HSCR risk factors 
are shown in red. Candidates are colored in yellow. Interactions between candidates and ENS/HSCR relevant 
factors are highlighted in red. All proteins are arranged corresponding to their subcellular localization. 
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 Genetic evaluation of candidate genes 
To confirm the genetic relevance of the depicted candidate genes, additional mutation carriers needed 
to be identified. For this purpose, data from the International HSCR consortium was used. This genetic 
evaluation was already performed for two of the four selected candidate genes (SREBF1 and PIAS2) in 
the context of this project while ATP7A and ABCD1 will be investigated accordingly as soon as 
respective data is available. 
Filtering of genetic variants within the respective patient cohorts (from Europe and South Asia) led to 
the identification of 11 additional HSCR patients carrying novel mutations within SREBF1 (fig. 8 A and 
A’) and 6 additional HSCR cases presenting with novel mutations within PIAS2 (fig. 8 B and B’). The 
identified initial variants of SREBF1 and PIAS2 were not found in a second carrier. To determine if these 
filtered variants might have a functional relevance, CADD scores were taken into account, which showed 
that all filtered variants displayed scores >13. The corresponding data is summarized in fig. 8. 
Figure 8: Results of genetic evaluation of candidate genes 
A and A’: Filtered rare variants residing in SREBF1 are listed in a table format (A) and are schematically shown 
corresponding to their localisation on protein level (A’). B and B’: Filtered rare variants residing in PIAS2 are listed 
in a table (B) and are schematically shown on protein level (B’). Variants were identified in additional HSCR patients 
who have been analysed by different groups from the International HSCR consortium 
(http://www.erare.eu/financed-projects/hscr). For filtering, population matched control data deposited in the 
gnomAD browser were used (EUR (European), SA (South Asian)). CADD scores were calculated using the CADD 
model GRCh37-v1.4 (https://cadd.gs.washington.edu/snv).Nucleotide and aminoacid positions refer to SREBF1b 
(ENST00000261646.5) or PIAS2ß (ENST00000585916.1) (A, B). The gene-specific variants identified in the index 
cases of this project are highlighted in red (A’, B’). Protein domains were annotated based on database entries 
(Pfam, NCBI, Uniprot). TM (Transmembrane), HLH (Helix loop Helix), LMNA (LAMININ A/C), ABC (ATP binding 
cassette), SAP (scaffold attachment factor-A/B, acinus and PIAS), PINIT (Pro-Ile-Asn-Ile-Thr), ZF-SP-RING (Zinc 
Finger – Really Interesting New Gene), SUMO (small Ubiquitin-related modifier), NLS (Nuclear localisation signal) 
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 Expression analyses on mRNA level 
Transcriptional profiles of ENS-relevant tissues were assessed by microarray analysis. Regions with 
pre-migratory vagal NCCs at E8.75 and E9.5 as well as the developing gut at E13.5 were dissected and 
analysed (fig. 9 A).  
Based on hierarchical clustering of the mean values of the data distribution (overall mean expression), 
the three specimens could be distinguished (data analysis performed by Dr. Carolina de la Torre, Center 
of Medical Research, Mannheim). Correlation coefficients for comparisons between E8.75 and E9.5 
were higher than respective coefficients for E13.5 and E9.5 or E8.75 (fig. 9 B). 
log2 mRNA expression values of known HSCR risk loci ranged between 4-12 with Neuregulin 3 (Nrg3) 
showing lowest and Transcription factor 4 (Tcf4) displaying highest expression levels in general (fig. 9 
C). The most prominent HSCR risk genes Ret, Glial-derived neurotrophic factor (Gdnf), Gdnf family 
receptor alpha 1 (Gfra1), Endothelin receptor type B (Ednrb), Endothelin 3 (Edn3), Ece1, SRY box 10 
(Sox10) and Paired like-homeobox 2b (Phox2b) were expressed at intermediate to high levels and  
 
Figure 9: Transcriptomics data generated from murine tissue samples at relevant developmental stages 
A: Murine embryonic tissues of three developmental stages (E8.75, E9.5, E13.5) were prepared, whereas pre-
migratory vagal NCCs were extracted at stages E8.75 and E9.5, embryonic gut tissue was dissected at stage E13.5. 
Dissected regions are highlighted in red. Pictures are modified from: https://www.hhmi.org/content/zhang-yi-
research-abstract-slideshow. B: Transcriptome profiling results of total RNAs extracted from the investigated 
specimens are illustrated as hierarchical clustered heatmap. Color code represents the Pearson’s coefficient (red: 
high/blue: low similarity between samples). Overall mean expression data of E13.5, E8.75 and E9.5 were used for 
clustering analysis. C and C’: Transcriptional profiling of examined embryonic tissues displayed as column bar 
graphs. Exemplarily, expression profiles of known HSCR risk loci (C) and candidate genes (C’) are presented. Most 
prominent HSCR risk genes are lettered in bold (C). Bar plots show normalized mean + standard error of mean 
(SEM) (n=3). 
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showed an increase in mRNA expression during embryonic development from E8.75 to E13.5. An 
upregulation in the gene expression during development applied as well to the majority of the other 
HSCR risk genes, while for Persephin (Pspn), all genes of the Prokineticin (Prok) family, Nrg3 and 
Sema3b stable mRNA expression values in all investigated tissues were detectable (fig. 9 C). 
The novel candidate genes were expressed at comparable levels as the currently known HSCR risk 
genes (fig. 9 C‘). Lowest log2 mRNA expression values of 5-6 were detectable for Srebf1 and Abcd1 
while expression values of Atp7a and Pias2 ranged between 7-10. Each candidate gene was expressed 
at almost similar levels in the three investigated tissues. 
 Expression analyses on protein level 
Murine tissues 
Complementary to transcriptional profiling, IF analyses using cryosections of whole mount embryos at 
corresponding developmental stages (E9.5, E10.5, E11.5, E13.5) were carried out. Immunoreactivity of 
candidates was investigated in cell lineages relevant for ENS development and function, such as NCCs, 
neuronal, epithelial as well as smooth muscle cells. In order to assess specific cell types, pre-migratory 
vagal NCCs at stages E9.5 and E10.5 or ENCDCs at stage E11.5 were visualized by Sox10. Neuronal 
progeny at stages E11.5 and E13.5 was stained with the neuronal markers Beta III-Tubulin (Tubb3), 
Ubiquitin C-Terminal Hydrolase L1 (Pgp9.5) or Hu-Antigen C/D (HuC/D). Epithelial as well as smooth 
muscle cells were identified by Epithelial cadherin (ECad) and Smooth muscle actin (Sma), respectively. 
Results for all four candidates are described in more detail in the subsequent paragraphs and displayed 
in the following figures. 
Protein expression analyses for Atp7a showed an almost ubiquitous expression pattern in all 
investigated ENS-relevant tissues and stages (fig. 10). An expression of Atp7a and the NCC marker 
Sox10 within the same cell might be concluded based on antigen specific IF signals in close proximity 
to each other. This was observable at stages E9.5, E10.5 and E11.5 (fig. 10 A-C, arrows). At E9.5 and 
E10.5, Sox10+ cells located in close proximity to the neck of the embryo were investigated and indicated 
the presence of pre-migratory vagal NCCs. At higher magnification, signals of the NCC marker and 
Atp7a were observable in close spatial proximity suggesting antigen co-expression (fig. 10 A and B, 
arrows). At E11.5, only a small number of invading ENCDCs (Sox10+) were detectable but again a partial 
co-staining with Atp7a might be suggested (fig. 10 C, arrow). Using a set of different neuronal cell fate 
markers (Tubb3, Pgp9.5, HuC/D), Atp7a was shown to be partially expressed in or in close proximity to 
these cell types at E11.5 (fig. 10 D’-D’’’, arrows) and E13.5 (fig. 10 E’- E’’’, arrows), respectively. While 
immature neurons in presented midgut loops were disorganized at E11.5, neuronal cells at E13.5 were 
already structured in a ring-like shape indicating the premature myenteric plexus. Comparable to this, 
smooth muscle cells immunoreactive for Sma were arranged in a ring-like structure at E13.5 and showed 
probably a partial co-expression with Atp7a (fig. 10 D’, arrow). No overlapping expression was 
observable for Atp7a and the epithelial marker ECad at stages E11.5 (fig. 10 D’’’’) and E13.5 (fig. 10 
E’’’’). 
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The transcription factor Srebf1 was almost ubiquitously expressed in all investigated tissue regions and 
stages (fig. 11). Srebf1 was found to be partially co-expressed with the NCC marker Sox10 in vagal pre-
migratory NCCs at E9.5 (fig. 11 A, arrow) and E10.5 (fig. 11 B, arrow) as well as in gut invading NCC-
derived progenitors at E11.5 (fig. 11 C, arrow). A partial overlap of Srebf1 with the neuronal markers 
Tubb3, Pgp9.5, HuC/D was detectable at E11.5 (fig. 11 D’-D’’’, arrows) and E13.5 (fig. 11 E’-E’’’, arrows), 
respectively. Additionally, IF analyses showed a co-expression between Srebf1 and the muscular 
marker Sma at E13.5 (fig. 11 E, E’, arrow). While almost all enterocytes within the epithelial lining of the 
gut lumen (ECad+) at stage E11.5 co-expressed Srebf1 (fig. 11 D’’’’, arrow), this ubiquitous expression 
pattern of Srebf1 in the epithelial layer seemed to be more restricted at E13.5 (fig. 11 E’’’’, arrow). 
However, a partial overlap in the expression of ECad and Srebf1 was still detectable for epithelial cells 
at the basal side. 
 
52  Results 
 
 
Figure 10: Expression analyses of Atp7a in cryosectioned whole mount embryos 
A-C: Regions harbouring pre-migratory vagal NCCs in close proximity to the neck of the embryo, at stages E9.5 
(A) and E10.5 (B), and a midgut loop at stage E11.5 (C) were stained for the candidate Atp7a (in red) and the NCC 
marker Sox10 (in green). Cranial and caudal positions (A, B) and the gut lumen are indicated (C). IF signals in close 
spatial proximity to each other suggesting a co-expression of the antigens are highlighted by white arrows. D: 
Expression analyses of Atp7a (in red) in the developing gut at stage E11.5 using several neuronal markers (Tubb3 
(D’), Pgp9.5 (D’’), HuC/D (D’’’)) as well as the epithelial marker ECad (D’’’’) (all in green) for co-labelling. Midgut 
loops with gut lumen are displayed. Atp7a expressing cells presumably of neuronal origin are highlighted by white 
arrows while no epithelial cells display immunoreactivity for the candidate. E: At stage E13.5, co-labelling with Atp7a 
(in red) and cell type specific markers (Tubb3 (in green) and Sma (in cyan) (E’); Pgp9.5 (E’’), HuC/D (E’’’), ECad 
(E’’’’) (all in green)) were performed. Midgut loops with lumen are shown. Double positive cells are highlighted by 
white arrows but were only detectable for neuronal and muscular lineage.  
Lower images show magnifications of the areas highlighted in the upper images. Nuclei were counterstained with 
Hoechst (blue). Scale bar: 50µm. 
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Figure 11: Immunocytochemical analyses of Srebf1 in whole mount embryo sections 
A-C: Double labelling of Srebf1 (in red) and Sox10 (in green) at stage E9.5 (A), E10.5 (B) or E11.5 (C). Co-
expressing cells are marked by white arrows. Pre-migratory vagal NCCs (Sox10+) located in close proximity to the 
neck of the embryo were analysed; cranial and caudal positions are indicated (A, B). A midgut loop with gut lumen 
is shown for E11.5 (C). D: Co-staining of Srebf1 (in red) with various cell type specific markers (neuronal: Tubb3 
(D’), Pgp9.5 (D’’), HuC/D (D’’’), epithelial: Ecad (D’’’)) (all in green) at stage E11.5. Midgut loops with gut lumen are 
displayed. Immature neurons and epithelial cells show co-expression with Srebf1 as highlighted by white arrows. 
E: Visualization of Srebf1 (in red) expression in the midgut at E13.5 (lumen is labelled). Triple (Tubb3 (in green), 
Sma (E’) (in cyan)) or double-staining (Pgp9.5 (E’’), HuC/D (E’’’), ECad (E’’’’) (all in green)) are shown. White arrows 
highlight co-stained cells.  
Lower images are magnifications of highlighted regions in the upper images. Nuclei were counterstained with 
Hoechst (blue). Scale bar: 50µm. 
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Abcd1 was shown to be almost ubiquitously expressed in relevant ENS tissues of early stages (fig. 12 
A and B) but its expression was slightly more restricted to individual cells at later phases of GI tract 
formation (fig. 12 C-E). In general, the staining pattern suggested a Golgi or vesicular specific protein 
localisation. IF signals of Abcd1 and the NCC marker Sox10 resided in close spatial proximity to each 
other at E9.5 (fig. 12 A, arrow), at E10.5 (fig. 12 B, arrow) and at E11.5 (fig. 12 C, arrow), and therefore 
pointed towards a co-expression of both proteins at these stages. Staining of the neuronal progeny at 
E11.5 using the neuronal markers Tubb3, Pgp9.5 and HuC/D (fig. 12 D’-D’’’, arrows) in the developing 
midgut led to comparable observations as previously described. A positive immunoreactivity of Abcd1 
was also observable at E11.5 in ECad+ epithelial cells of the developing gut mucosa (fig. 12 D’’’’, arrow). 
At stage E13.5, a partial co-expression of Abcd1 in immature neuronal cells (Tubb3+, Pgp9.5+, HuC/D+) 
(fig. 12 E’-E’’’, arrows), epithelial cells (ECad+) (fig. 12 E’’’’, arrow) as well as smooth muscle cells (Sma+) 
(fig. 12 E’, arrow) might be concluded based on a partial overlap in respective antigen specific IF signals.  
The expression pattern of Pias2 pointed towards a cytoplasmic protein localisation (fig. 13 A-E). 
Comparable to Srebf1, Pias2 was also almost ubiquitously expressed in all investigated tissues of 
interest and developmental stages. Sox10+ vagal NCCs located in close proximity to the otic vesicle at 
E9.5 and E10.5 displayed Pias2-specific IF signals in their spatial proximity (fig. 13 A and B, arrows). 
This might indicate a co-expression of both proteins. Comparable observations were documented for 
gut invading ENCDCs (Sox10+) at E11.5 (fig. 13 C, arrow) suggesting that these cells maintain candidate 
protein expression. IF analyses showed Pias2 immunoreactivity in close proximity to immature neurons 
of the developing gut at E11.5 labelled with Tubb3, Pgp9.5 and HuC/D (fig. 13 D’-D’’’, arrows). 
Additionally, an epithelial cell specific expression for Pias2 was observable at this stage (fig 13 D’’’’, 
arrow) and at E13.5 (fig.13 E’’’’, arrow) by co-staining with ECad. At E13.5, again a putative co-staining 
of Pias2 with the neuronal cell type markers (Tubb3, Pgp9.5, HuC/D) (fig. E’-E’’’, arrows) and the smooth 
muscle marker (Sma) (fig. 13 E’, arrow) might be suggested based on a putative, partial overlap of the 
respective IF signals.  
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Figure 12: Expression analyses of Abcd1 in murine embryos 
A-C: Immunocytochemical analysis of Abcd1 (in red) and Sox10 (in green) in cryosectioned embryos of stage E9.5 
(A), E10.5 (B) and E11.5 (C). At E9.5 and E10.5, Sox10+ cells caudally to the otic vesicle are shown and cranial 
and caudal positions are illustrated (A, B). At E11.5, a midgut loop with gut lumen is displayed (C). Arrows highlight 
regions where IF signals are detectable in close spatial proximity to each other indicating a putative co-expression 
of both antigens. D: Expression analyses of Abcd1 (in red) in the developing gut at stage E11.5 using different cell 
type specific markers for co-labelling (immature neurons are stained with Tubb3 (D’), Pgp9.5 (D’’), HuC/D (D’’’), 
epithelial cells are stained with ECad (D’’’)) (all in green). Midgut loops with gut lumen are displayed. Individual cells 
or regions showing immunoreactivity for Abcd1 and the cell type specific marker are highlighted by an arrow. E: IF 
analyses of Abcd1 (in red) and a set of cell type specific markers (Tubb3 (in green), Sma (E’) (in cyan); Pgp9.5 (E’’), 
HuC/D (E’’’), ECad (E’’’’) (all in green)) in the developing gut at stage E13.5. The gut lumen is indicated. Putatively 
Abcd1 expressing neuronal, muscular or epithelial cells as concluded by means of partially overlapping IF signals 
are marked (white arrow).  
Magnifications of selected regions are displayed in the lower images. Nuclei were counterstained with Hoechst 
(blue). Scale bar: 50µm. 
 
56  Results 
 
 
Figure 13: IF staining of Pias2 in cryosectioned murine embryos at several developmental stages 
A-C: IF analyses of Pias2 (in red) and Sox10 (in green) at early developmental stages E9.5 (A), E10.5 (B) and 
E11.5 (C). While pre-migratory vagal NCCs at the respective position are shown for E9.5 and E10.5 (A, B), Sox10+ 
cells in the developing midgut at E11.5 are displayed (C). Cranial and caudal positions (A, B) and the gut lumen (C) 
are highlighted. IF signals for the candidate and Sox10 reside in close spatial proximity to each other as indicated 
by white arrows. D: At stage E11.5 expression analyses of Pias2 (in red) with respective neuronal markers (Tubb3 
(D’), Pgp9.5 (D’’), HuC/D (D’’’)) and the epithelial marker ECad (D’’’’) (all in green) were performed. Midgut loops 
with gut lumen are displayed. Cells or regions immunoreactive for both investigated antigens are highlighted (white 
arrow). E: Pias2 (in red) expression in the developing gut at stage E13.5. The gut lumen is indicated. Co-labelling 
of the candidate was performed with different cell type specific markers (Tubb3 (in green), Sma (E’) (in cyan); 
Pgp9.5 (E’’), HuC/D (E’’’), ECad (E’’’’) (all in green)). Presumably, Pias2 co-expressing cell types concluded based 
on partially overlapping IF signals, are marked (white arrow).  
Lower images show magnifications of the regions highlighted in the upper images. Nuclei were counterstained with 
Hoechst (blue). Scale bar: 50µm. 
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Complementary immunocytochemical analyses were performed in adult murine colon cryosections 
assessing the expression of candidates and respective cell type specific markers in enteric ganglia. All 
candidates were shown to be expressed in neuronal cells of the ganglionated plexus by co-staining with 
Tubb3 or HuC/D, respectively (fig. 14). IF analyses of Atp7a in adult murine colon sections revealed 
prominent IF signals in the cell soma of Tubb3+ or HuC/D+ neurons (fig 14 A and A’). A nuclear restricted 
staining was detectable for Srebf1. Srebf1+ cells partially co-expressed the neuronal markers Tubb3 and 
HuC/D. In addition, Srebf1 signals were as well detectable in cells not being immunoreactive for the 
depicted neuronal markers but residing in close proximity to enteric ganglia (fig. 14 B and B’). A partial 
overlap in the expression of Tubb3 or HuC/D with the candidates Abcd1 (fig. 14 C and C’) and Pias2 
(fig. 14 D and D’) was as well demonstrated in the respective analyses. Both candidates indicated a 
dotted-like staining pattern. 
 
To assess candidate specific immunoreactivity as well as expression levels in different murine 
embryonic and adult GI and brain tissues, Western blot analyses were carried out (fig. 15 A-D). Protein 
lysates of HEK293TN cells, transiently transfected with candidate gene-specific overexpression 
constructs, were used as internal controls.  
Western blot analyses for Atp7a showed multiple bands between 35-50kDa. The Atp7a-specific signal 
at around 190kDa was confirmed based on protein lysate of the positive control (HEK293TN transiently 
transfected with ATP7A MYC-tagged overexpression construct). In general, highest protein expression 
levels for Atp7a (predicted size: 163kDa) were observable in embryonic gut and brain tissues. Minimal 
protein expression based on the presence of faint bands at the respective size could be concluded for 
adult duodenum and adult colon specimens. In adult jejunum/ileum, brain and cortex samples, an 
expression of Atp7a was not detectable (fig. 15 A).  
For Srebf1, again embryonic tissues showed highest protein expression levels for the full-length (FL) 
(predicted size: 121kDa) and the mature (MAT) protein variant (predicted size: 70kDa). All adult 
specimens containing ENS or CNS relevant cell types displayed only marginal expression of the MAT 
Srebf1 protein form but no expression of the FL variant. Srebf1-specific signals in the samples of interest 
were confirmed based on protein lysates of the two positive controls as in general a multiple of bands 
Figure 14: Expression analyses of candidates in adult murine colon sections 
A-D’: IF analyses of candidates (all in red) co-stained with the neuronal markers Tubb3 (A-D) and HuC/D (A’-D’) 
(both in green) in adult murine colon cryosections (Atp7a (A, A’), Srebf1 (B, B’), Abcd1 (C, C’), Pias2 (D, D’)). Nuclei 
were counterstained with Hoechst (blue). Scale bar: 50µm. 
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was observable in Western blot analyses. While the transient transfection of the FL overexpression 
construct led to the generation of one Srebf1-specific band in the respective protein lysate, the control 
sample transfected with the MAT overexpression construct displayed three signals of variable sizes 
ranging between 70-110kDa (fig. 15 B).  
For Abcd1, GI tissues showed most prominent protein expression in general. Specifically, expression 
was detected to be highest in adult duodenum and lowest in adult jejunum/ileum. In addition to a band 
at around 80kDa indicating for the monomeric form of Abcd1, a signal at around 130kDa was observable 
in all adult GI tissues, which most probably represent the dimeric protein form. Due to the Green 
fluorescent protein (GFP) tag, recombinantly expressed ABCD1 (in HEK293TN cells) indicated a larger 
protein size than endogenously expressed murine Abcd1. Expression of Abcd1 in adult brain tissues 
and the embryonic brain specimen was weak but detectable except for the adult cortex specimen (fig. 
15 C).  
Western blot analyses for Pias2 indicated an endogenous expression of the two major isoforms Pias2ß 
(predicted size: 68kDa) and Pias2α (predicted size: 63kDa) with highest levels in embryonic gut and 
brain specimens. Besides these Pias2-specific signals at around 70-80kDa as validated by means of 
the positive control protein lysate, multiple other bands of lower sizes were observable in immunoblot 
analyses. Except for adult duodenum, where no endogenous candidate protein expression was 
detectable, all other investigated tissues displayed expression of at least one isoform but at low levels. 
The α isoform was found to be predominantly expressed in brain tissues as adult brain and adult cortex 
did not display an endogenous expression of the ß isoform (fig. 15 D). 
 
Figure 15: Western blot analyses in murine GI and brain tissues 
A-D: Candidate specific protein expression was assessed in different GI (adult: duodenum, jejunum/ileum, colon; 
embryonic (E15.5): gut) and brain tissues (adult: brain, cortex only; embryonic (E15.5): brain) (Atp7a (A), Srebf1 
(B), Abcd1 (C), Pias2 (D)). Protein lysates of HEK293TN cells transiently transfected with respective candidate 
specific overexpression constructs were implemented as antibody positive controls. Gapdh was used as loading 
control. Predicted protein sizes are annotated. FL (full-length), MAT (mature) 
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Human tissues 
Complementary IHC staining of all four candidates was performed using FFPE sections of human fetal 
and adult colon. 
In the fetal colon, ATP7A and PIAS2 were shown to be prominently expressed within enteric ganglia 
(fig. 16 A, D). In contrast, SREBF1 was only marginally expressed in enteric ganglia and surrounding 
tissue displayed comparable signal intensities (fig. 16 B). ABCD1 was not expressed in respective 
neuronal tissue structures (fig. 16 C). However, all candidates showed a positive immunoreactivity in 
the gut epithelium. ATP7A displayed an almost ubiquitous expression in cells of the epithelial lining and 
the lamina propria while SREBF1 was distinctly expressed in individual cells at the crypt’s base (fig. 16 
A’ and B’). Comparable to ATP7A, ABCD1 showed as well an almost ubiquitous expression presumably 
in immune cells within the lamina propria (fig. 16. C’). For PIAS2, immunocytochemical signals were 
observable in the cells located at the base of the crypts (fig. 16 D’).  
In the adult colon, protein expression patterns of ATP7A and PIAS2 were highly comparable to those 
observed in fetal tissues as both candidates were strongly expressed in enteric ganglia as well as in 
epithelial cells of the crypts and cells of the lamina propria (fig. 16 E, E’, H, H’). In contrast to the fetal 
stage, SREBF1 showed a distinct staining pattern in individual cells of the adult enteric ganglia. 
Moreover, prominent signals were as well observable in individual cells of the lamina propria (fig. 16 F 
and F’). This was comparable to observations for ABCD1 as specific signals were as well detectable 
Figure 16: IHC staining of candidates in fetal and adult human colon sections 
A-D: IHC staining of candidates (ATP7A (A), SREBF1 (B), ABCD1 (C), PIAS2 (D)) in human fetal colon tissue 
originating from a fetus acardius amorphous. E-H: IHC staining of candidates (ATP7A (E), SREBF1 (F), ABCD1 
(G), PIAS2 (H)) in human adult colon tissue of an IBD patient.  
Upper images show enteric ganglia highlighted by a red triangle (A-H). Lower images show epithelial tissue layers 
(A’-H’). Candidates (DAB brown staining). Nuclei were counterstained with Hematoxylin (blue). Scale bar: 20µm. 
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within adult enteric ganglia and cells of the lamina propria (fig. 16 G, G’). In contrast to the SREBF1-
specific staining, ABCD1 expression in the epithelium was more ubiquitous as cells at the crypt’s base 
showed an immunoreactivity for this candidate too.  
3.3 Candidate gene characterization 
For candidate gene characterization on functional level, the generation of gene-specific knockout (KO) 
cell clones applying the CRISPR/Cas9 technology to the human neuroblastoma cell line SHSY5Y was 
carried out. Except for the four candidate genes, the major HSCR susceptibility locus RET was 
implemented as proof-of-principle control into the study pipeline. A control transfected and Fluorescent-
activated cell (FAC) sorted mock control clone was already generated in a previous study and served 
as internal reference (Master Thesis Mederer, 2015). 
 Genome editing 
Endogenous expression of all targeted genes within the chosen cell source was demonstrated prior to 
editing (fig. S4, Supplementary). FAC sorted single cell clones were evaluated according to their cell 
morphology by brightfield microscopy as only clones with neuronal-like morphology were included for 
genotyping and further investigations.  
The RET-specific sgRNA targeted exon 2, whereas Cas9 mediated DNA double strand break caused 
the homozygous insertion of a cytosin at the respective position of the protospacer adjacent motif (PAM) 
(c.231_232insC) (fig. 17 A’; fig. S5, Supplementary) (Master Thesis Mederer, 2015). The CRISPR/Cas9 
induced KO of RET was validated by Western blot analysis as no RET protein was detectable at the 
corresponding size (predicted size: 124kDa) in the clone (p.T78Hfs5*). Furthermore, no shortened 
protein version of RET was observable. A FLAG-tagged RET overexpression construct transiently 
transfected in HEK293TN cells was used as control in immunoblot analyses. Endogenous expression 
levels of RET in the parental cell line SHSY5Y and the mock control clone were comparable (fig. 17 A’’). 
The sgRNA targeting ATP7A was specific to exon 3. The generated ATP7A KO clone carried a 
compound heterozygous genome modification at the probable Cas9 cutting site as validated by Sanger 
sequencing (c. 500_501insT/500_501insA) (fig. 17 B’; fig. S5, Supplementary). In Western blot 
analyses, total protein lysates of HEK293TN cells transiently transfected with a MYC-tagged ATP7A 
overexpression construct, lysates of SHSY5Y cells and of the mock control clone served as controls. All 
investigated samples except for the ATP7A KO clone (p.Q167Hfs*4/p.A168Sfs*3) showed a band at 
190kDa indicating ATP7A was successfully knocked-out in the genome edited clone. A truncated protein 
was not detectable in total protein lysate of the ATP7A KO clone either. Endogenous ATP7A expression 
in the mock control clone was higher than in the parental cell line SHSY5Y (fig. 17 B’’). 
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Figure 17: CRISPR/Cas9 gene mediated knockout of RET and candidate genes in the neuroblastoma cell 
line SHSY5Y  
A’-D’: Gene-specific sgRNAs were designed against marked exons (in grey). Cas9 mediated double-strand breaks 
were repaired by non-homologous end joining (NHEJ) causing homozygous or compound heterozygous genome 
modifications at the respective positions as verified by Sanger sequencing. Four coloured sequencing 
chromatograms are shown for each gene (RET (A’), ATP7A (B’), SREBF1 (C’), ABCD1 (D’)). PAM sites are 
underscored. Putative Cas9 cutting sites are highlighted by red arrowheads. A’’-D’’: Knockout (KO) on protein level 
was validated by Western blot analyses using different protein lysates as internal controls (HEK293TN cells 
transiently transfected with a gene-specific, tagged overexpression construct, SHSY5Y cells, mock control cells) 
(RET (A’’), ATP7A (B’’), SREBF1 (C’’), ABCD1 (D’’)). GAPDH was used as loading control in all Western blot 
analyses. Predicted protein sizes are annotated. Images show modified blots as individual lanes of one blot were 
rearranged if necessary. FL (full-length), MAT (mature) 
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Genome editing of SREBF1 was achieved by using a sgRNA specific to exon 5. Allele specific cloning 
and respective Sanger sequencing confirmed a compound heterozygous genome modification 
(c.874_875insT/c.874_875insTT), introduced 3-4 nucleotides upstream of the PAM (fig. 17 C’; fig. S5, 
Supplementary). The CRISPR/Cas9 induced SREBF1 KO could be also confirmed by Western blot  
analysis as no bands indicating FL or MAT SREBF1 were observable for the respective KO clone 
(p.K293Efs*70/K293*). Protein lysates from HEK293TN cells transiently expressing the FL and the MAT 
form of SREBF1 as well as from SHSY5Y cells and the mock control clone were used as positive  
controls. In general, a multitude of bands was detectable in immunoblot analyses. 
Endogenous expression levels of the FL SREBF1 (predicted size: 121kDa) in the mock control clone 
was lower than in SHSY5Y cells. A band indicating for the MAT form of SREBF1 (predicted size: 70kDa) 
was not detectable in the total protein lysate of the mock control clone (fig. 17 C’’).   
The candidate gene ABCD1 was CRISPR/Cas9 edited in exon 2 via the homozygous insertion of a 
guanosin nucleotide at the respective DNA cutting site (c.1004_1005insG) (fig. 17 D’; fig. S5, 
Supplementary). On protein level, Western blot analyses demonstrated the complete protein loss as no 
specific band at 83kDa or any additional band at a lower protein size was observable in total protein 
lysate of the ABCD1 KO clone (p.K336Efs*65). Protein lysates of HEK293TN cells transiently 
transfected with a GFP-tagged ABCD1 overexpression construct as well as of SHSY5Y cells and the 
mock control clone served as controls (fig. 17 D’’). 
Results for forward and reverse Sanger sequencing of the edited genomic region for all clones are 
shown in the supplementary data (fig. S5). In addition, all KO clones were evaluated but negatively 
tested for alternative splicing events of the genome edited exon on transcript level (fig. S6, 
Supplementary). Additionally, selected off-target regions were assessed for unintended genomic 
modifications. Except for a heterozygous one-nucleotide insertion in the intronic region of EUKARYOTIC 
TRANSLATION ELONGATION FACTOR 1 ALPHA 2 (EEF1A2) in the SREBF1 KO clone, no off-target 
effects were identified in any of the other clones. As in silico investigations did not suggest any functional 
relevance of this heterozygous variant in the EEF1A2 intron, the SREBF1 KO was validated for further 
utilization (fig. S7, Supplementary). 
For genome editing of PIAS2, different sgRNAs were applied in individual experiments (fig. 18). 
Targeting of exon 6 in a first setup, led to the homozygous insertion of an adenosin nucleotide at the 
putative Cas9 cutting sites (c.774_775insA) (Master Thesis Mederer, 2015). Alternative splicing of exon 
6 was demonstrated by conventional reverse transcription PCR on transcript level using exon 6 flanking 
primers. Specifically, primers resided in the adjacent exons 5 and 7. Gelelectrophoresis analysis of the 
generated PCR products demonstrated that only for WT SHSY5Y cells an amplicon of 319bp containing 
exon 6 was generated. In contrast, for the edited clone a PCR product of 184bp indicating a PIAS2 
amplicon with skipped exon 6 was detectable (fig. 18 A). Sequence identity of the alternatively spliced 
transcript in the PIAS2 edited clone was confirmed by Sanger sequencing. 
In a second experimental approach, sgRNAs for PIAS2 were designed specific to exon 2 (fig. 18 B). In 
total, three different sgRNAs (I-III) were used in individual experiments. After single cell cloning, only 
clones of epithelial-like morphology survived if sgRNA I was used. These clones were excluded from 
genotyping and further analyses. Transfection of sgRNAs II and III, resulted as well almost exclusively 
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Figure 18: Genome editing approaches for PIAS2 
A: sgRNAs specific to exon 6 were used in a first approach for genome editing of PIAS2 (Master Thesis Mederer, 
2015). Four coloured sequencing chromatogram of the edited clone is shown. Analyses of alternative splicing were 
carried out by conventional PCR on CDAN level. This analysis shows skipping of exon 6 in the edited PIAS2 clone, 
as a PCR product of 184bp but not of 319bp (as for WT SHSY5Y cells) was detectable. B: Different sgRNAs specific 
to exon 2 (I-III) were used for genome editing of PIAS2 in a second approach. Conventional reverse transcription 
PCR was carried out for transcript detection and shows the complete absence of the FL PIAS2ß transcript in the 
clone edited with sgRNA III. PAM sites are underscored. Putative Cas9 cutting sites are highlighted by red 
arrowheads. Asterisks indicate putatively CRISPR/Cas9 introduced genome modifications. Primers are illustrated 
by red arrows. GAPDH was used as a control gene for RNA integrity. Expected and observed amplicon sizes are 
annotated. FL (Full-length) 
 
in epithelial-like cell clones after FACS. Editing with sgRNA II led to the generation of a clone with 
neuronal-like morphology harbouring an inserted fragment of the CRISPR/Cas9 cloning vector 
backbone in its genome and was therefore excluded. A putatively edited clone of neuronal-like 
morphology was generated after transfection with sgRNA III. Genotyping was not possible as no PCR 
product spanning the putatively edited region could be generated. Further expression analyses on 
transcript level revealed the complete absence of the longest annotated isoform (PIAS2ß, 1866 bp) in 
this putatively edited clone.  
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 Establishment of a neuronal differentiation protocol 
As outlined in section 2.2.2, the establishment of a neuronal differentiation protocol for SHSY5Y cells 
was based on results generated by two pilot experiments (A, B) (fig. 3). Differentiating cells were 
monitored by brightfield microscopy and assessed for their expression profile by qRT PCR using a set 
of various cell type markers. 
Pilot experiment A 
In general, no expression of the stem/progenitor marker SOX10 was detected at any investigated time 
point of differentiation using any of the differentiation protocols (Ia, IIa, IIIa) (fig. 19). 
WT SHSY5Y cells, differentiated according to protocol Ia, displayed lower expression levels for the 
neuronal progenitor markers LOW-AFFINITY NEUTROPHIN RECEPTOR P75NTR (P75NTR) and 
NESTIN (NES) with advancing differentiation. The neuronal cell fate marker TACHYKININ 
PRECURSOR 1 (TAC1) was not expressed throughout differentiation while the MICROTUBULE 
ASSOCIATED PROTEIN TAU (TAU) showed only minimal expression levels at early differentiation time 
points. The pan-neuronal markers UBIQUITIN C-TERMINAL HYDROLASE L1 (UCHL1) and TUBB3 
were almost stably expressed in all investigated samples. In contrast, expression levels of ACHAETE-
SCUTE FAMILY BHLH TRANSCRIPTION FACTOR 1 (ASCL1) first increased after 7+3d DM II and 
then decreased again with further differentiation. During neuronal cell fate induction, expression levels 
for the more advanced neuronal cell fate markers MICROTUBULE-ASSOCIATED PROTEIN 2 (MAP2), 
SYNAPTOPHYSIN (SYP), GROWTH-ASSOCIATED PROTEIN 43 (GAP43) and NPY gradually 
increased. Compared to all assessed markers, NEUROPEPTIDE Y (NPY) showed the highest 
expression values with peak expression at differentiation stage 7+14d DM II. In contrast, MAP2, SYP 
and GAP43 were only expressed at low to intermediate levels (fig. 19 A). Morphological changes were 
investigated by brightfield microscopy (fig. 19 A’). Cells differentiated for 7+3d in DM II displayed 
outgrowing neurites which led to the formation of a neuronal-like network after 7+14d of cultivation in 
DM II. At the later time point of differentiation, cell bodies clustered to aggregates (fig. 19 A‘). 
Comparing protocol IIa with Ia only minor differences were detectable on transcript level (fig. 19 A and 
B). Expression levels of P75NTR did not decrease during differentiation as it was shown for protocol Ia. 
In addition, cells differentiated with protocol IIa showed increased mRNA expression values for ASCL1 
after 7+7d in DM III and for GAP43 after 7+3d in DM III compared to the respective results generated 
with protocol Ia. For TAC1, a marginal expression was detectable in the 7+3d DM III specimen. 
Expression patterns of all other markers were comparable to the results described for protocol Ia (fig. 
19 B). No obvious differences in the cell morphology at the analysed time points were observable if 
protocol IIa (fig. 19 B‘) instead of protocol Ia was used (fig. 19 A‘). 
Transcriptional profiles of cells differentiated with protocol IIIa were highly comparable to the previously 
described ones for protocol Ia except for TAC1 and SYP (fig. 19 A-C). Expression levels for the neuronal 
subtype specific marker TAC1 increased gradually during in vitro differentiation although expression 
levels remained low. For the synaptic specific marker SYP, expression levels at later differentiation 
stages were slightly lower than in cells differentiated with protocol Ia or IIa (fig. 19 C). Based on 
brightfield microscopy analyses, this protocol was excluded from further investigations. Cells after 7+3d 
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in DM III of differentiation showed less and shorter neuronal-like outgrowths compared to differentiated 
cells of protocol Ia or IIa. This phenotype persisted as well at a later stage of neuronal maturation (7+14d 
in DM III) when a neuronal-like network was only marginally developed and floating cells indicative for 
apoptotic cells were detectable (fig. 19 C‘).  
Figure 19: Results of pilot experiment A for the establishment of a neuronal differentiation protocol 
A-C: Relative mRNA expression levels of differentiating SHSY5Y cells (protocol Ia (A), IIa (B), IIIa (C)) were 
assessed by qRT PCR using a set of different cell type markers. Column bar graphs show mean of two technical 
replicates (n=1). A’-C’: Cells were investigated for their morphology by brightfield microscopy after 7+3d or 7+14d 
under respective differentiating conditions. Scale bar: 75µm. 
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Pilot experiment B 
In a second setup, protocol Ia and IIa were further modified. qRT PCR analyses were carried out for two 
biological replicates each and undifferentiated cells were investigated as well. Differentiation time was 
increased to up to 49 days in total. 
Comparable to results of the first pilot experiment (A) (protocol Ia and IIa, fig. 19 A, B), no expression 
for the neuronal progenitor marker SOX10 was detected using any of the experimental strategies 
(protocol Ib, IIb). Additionally, TAC1 was as well only minimally expressed in respective differentiated 
cells (fig. 20 A, B). 
SHSY5Y cells differentiated according to protocol Ib showed that relative mRNA expression levels for 
the neuronal progenitor marker NES slightly decreased during differentiation except for the latest 
investigated time point (7+42d in DM II). However, high standard deviations for this and other samples 
need to be taken into account. Contrastly to NES, the neuronal progenitor marker P75NTR was only 
marginally expressed in the cell population and decreased only during early phases of differentiation. 
After 7+14d DM II, P75NTR mRNA expression was upregulated again. 
Comparable to results of the first pilot experiment, the pan-neuronal markers UCHL1 and TUBB3 were 
almost stably expressed at intermediate levels throughout differentiation. The expression of ASCL1 was 
strongly reduced comparing undifferentiated and 5d DM I differentiated samples. However, from 7+7d 
on, its expression was again strongly upregulated and then remained stable. In general, relative mRNA 
expression levels of TAU, MAP2, SYP and GAP43 showed a gradual increase during differentiation 
although their overall expression levels were low to intermediate. NPY showed the highest mRNA 
expression levels among all neuronal markers. Neuronal cell fate induction caused first a decline in the 
transcript expression of this neuronal subtype specific gene, but further differentiation resulted in an 
expression upregulation (fig. 20 A).  
Results of brightfield microscopy at early time points were highly comparable to the previously described 
findings of protocol Ia. Further differentiation led to the generation of a complex neuronal-like network 
after 7+28d DM II with cells displaying a high number of neuronal-like branches and synaptic-like 
contacts. The amount of dead cells floating in the cell culture dish was higher at later than at earlier 
stages of differentiation (fig. 20 A‘). 
Results for relative mRNA expression analyses of cells differentiated with protocol IIb were highly 
comparable to results previously described for protocol Ib. Minor differences were detectable with regard 
to the mRNA expression levels of P75NTR as these were slightly higher compared to cells differentiated 
with protocol Ia. In contrast, the majority of the more advanced neuronal cell fate markers as MAP2, 
SYP, GAP43 and NPY displayed slightly reduced expression levels especially at later differentiation 
time points compared to respective results of protocol Ib. Moreover, ASCL1 expression was not stable 
in cells differentiated for longer periods but declined from 7+21d to 7+28d using protocol IIb (fig. 20 B). 
In comparison to brightfield microscopy results of protocol IIa and protocol Ib, cell densities were 
considerably higher at all differentiation stages using this protocol. Additionally, the neuronal-like 
network was only marginally developed based on the presence of short neurite-like outgrowths after 
7+28d of differentiation (fig. 20 B‘). Based on these observations, this protocol was excluded from further 
investigations and instead an optimized version of protocol Ib was selected for differentiation of all 
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genome edited and a mock control SHSY5Y clone. Specifically, the initial cell plating density and the 
cultivation time were modified (section 2.2.2). 
 
Figure 20: Results of pilot experiment B for the establishment of a neuronal differentiation protocol 
A and B: Relative mRNA expression levels of undifferentiated and differentiating SHSY5Y (protocol Ib (A), IIb (B)) 
cells were assessed by qRT PCR using a set of different cell type markers. Bar plots show mean + standard 
deviation (STD) (n=2). A’ and B’: Cells were investigated for their morphology by brightfield microscopy after 7d, 
7+14d and 7+28d of culture under respective conditions. Scale bar: 75µm. 
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 Neuronal differentiation of SHSY5Y clones 
Genome edited SHSY5Y clones were differentiated and assessed for neuronal maturation by brightfield 
microscopy. Morphological changes in the mock control clone during neuronal induction served as 
reference for observations.  
Undifferentiated cells of the mock control clone showed a neuronal-like morphology with elongated cell 
bodies carrying several neurite-like outgrowths (fig. 21 A and A‘). Induction of neuronal maturation 
applying an optimized version of protocol Ib caused an accentuation of this phenotype after 7d of culture 
as neurite-like outgrowths further elongated (fig. 21 B and B‘). After 7+7d of differentiation, cell bodies 
started to accumulate in neuronal-like clusters (fig. 21 C and C‘). This phenotype became more 
pronounced after 7+14d of culture (fig. 21 D and D‘). From this stage on, neuronal-like clusters were 
highly organized and connected by semi adherent neurite-like connections. A slight increase in the 
clusters’ diameter was observable with proceeding differentiation time (fig. 21 D-F‘).  
Figure 21: Neuronal-like maturation of the mock control clone 
A-F’: Morphological changes in the cellular phenotype over the culturing period (undifferentiated (A, A’), 7d (B, B’), 
7+7d (C, C’), 7+14d (D, D’), 7+21d (E, E’), 7+28d (F,F’) differentiated) were assessed by brightfield microscopy. 
Images are representatives of different experiments. Scale bar: A-F: 100µm, A’-F’: 75µm. 
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In the undifferentiated state, RET KO cells showed as well a neuronal-like morphology (fig. 22 A and 
A‘). Again, induction of neuronal maturation led to an elongation of cell bodies and neuronal-like 
outgrowths (fig. 22 B and B‘). A neuronal-like network started to form between 7d and 7+7d of 
differentiation when neuronal-like processes connected to each other (fig. 22 C and C‘). Neuronal-like 
clusters were first observable after 7+14d of differentiation but cellular organization was not as highly 
ordered as in the mock control clone (fig. 22 D and D‘). The number and diameter of clusters slightly 
increased with further cultivation time (fig. 22 E and E‘). After 7+28d, clusters were roundly shaped and 
cellular organization was comparable to observations for mock control cells (fig. 22 F and F‘). 
 
 
 
Figure 22: Differentiation of the RET KO clone into a neuronal-like phenotype 
A-F’: Brightfield microscopy images were taken at different time points of neuronal differentiation (undifferentiated 
(A, A’), 7d (B, B’), 7+7d (C, C’), 7+14d (D, D’), 7+21d (E, E’), 7+28d (F,F’) differentiated). Images show 
representatives of different experiments. Scale bar: A-F: 100µm, A’-F’: 75µm. 
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ATP7A KO cells displayed a neuronal-like morphology in their undifferentiated state. Besides an 
elongated cell body, individual cells presented already with neuronal-like outgrowths (fig. 23 A and A‘). 
In contrast to the mock control clone, ATP7A genome edited cells have formed a confluent monolayer 
after 7d of differentiation (fig. 23 B and B‘). An increase in the length of neuronal-like outgrowths was 
not observable before 7+7d of differentiation (fig. 23 C and C‘). The cell density was considerably higher 
at all time points of differentiation compared to the mock control clone (fig. 23 B-F‘). After 7+14d, a 
neuronal-like network was observable although cells tend to show less cell to cell connections than the 
mock control clone (fig. 23 D and D‘). Deviating to results obtained for the mock control clone, ATP7A 
KO cells did not show the formation of neuronal-like clusters at any stage of differentiation. In addition, 
the amount of presumably dead cells detaching from the culturing surface was higher - especially after 
7+21d and 7+28d - compared to respective results of mock control clone (fig. 23 E-F‘).   
 
Figure 23: Neuronal-like cell fate maturation of the ATP7A KO clone 
A-F’: Cell morphologies of differentiating ATP7A KO cells were assessed by brightfield microscopy at various 
stages of neuronal differentiation (undifferentiated (A, A’), 7d (B, B’), 7+7d (C, C’), 7+14d (D, D’), 7+21d (E, E’), 
7+28d (F,F’) differentiated). Images display representatives of different experiments. Scale bar: A-F: 100µm, A’-F’: 
75µm. 
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Results of brightfield microscopy for the differentiating SREBF1 KO clone were highly comparable to 
observations made for the RET KO clone. Based on their cellular morphology, SREBF1 KO cells could 
be classified as neuronal-like in the undifferentiated state (fig. 24 A and A‘). The length of neurite-like 
outgrowths increased after 7d of differentiation (fig. 24 B and B‘). Further cultivation under differentiating 
conditions caused the formation of a neuronal-like network with increasing neuronal-tree like structures 
(fig. 24 C and C‘). Clustering of cell bodies started after 7+14d. A gain in the diameter and the 
organization of neuronal clusters was detectable at later stages of differentiation (fig. 24 D-F‘). However, 
the arrangement of neuronal-like clusters was not as highly ordered as in the mock control clone at any 
of the investigated time points. 
 
 
Figure 24: Neuronal-like cell fate induction in the SREBF1 KO clone 
A-F’: Brightfield microscopic analyses were performed to monitor the cellular morphology during neuronal 
differentiation (undifferentiated (A, A’), 7d (B, B’), 7+7d (C, C’), 7+14d (D, D’), 7+21d (E, E’), 7+28d (F,F’) 
differentiated). Images are representatives of different experiments. Scale bar: A-F: 100µm, A’-F’: 75µm. 
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Neuronal-like cells were as well observable for the undifferentiated ABCD1 KO clone (fig. 25 A and A‘). 
An interconnection between individual cells via neuronal-like outgrowths started to form after 7d of 
differentiation (fig. 25 B and B‘). Neurite-like structures extended in length and cell bodies aggregated 
in neuronal-like clusters with further cultivation time (fig. 25 C-D‘). After 7+21d of differentiation, the 
cellular pattern of ABCD1 KO cells was highly comparable to the organization of mock control cells at 
the respective differentiation stage. Neuronal clusters were highly structured, roundly shaped and 
connected by semi-adherent neurite-like connections (fig. 25 E-F‘). 
 
 
 
Figure 25: Differentiation of the ABCD1 KO clone into neuronal-like cells 
A-F’: Differentiating cells were investigated by brightfield microscopy at different time points of cultivation 
(undifferentiated (A, A’), 7d (B, B’), 7+7d (C, C’), 7+14d (D, D’), 7+21d (E, E’), 7+28d (F,F’) differentiated). Images 
reflect representatives of different experiments. Scale bar: A-F: 100µm, A’-F’: 75µm. 
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 Expression analyses of SHSY5Y clones 
Besides the morphological assessment, all genome edited clones as well as the mock control clone 
were further investigated on transcript and protein level (fig. 26-30).  
In general, the progenitor marker SOX10, and the glial marker (GLIAL FIBRILLARY ACIDIC PROTEIN) 
GFAP were not expressed on mRNA level in any of the clones. An exploratory data analysis was carried 
out for qRT PCR expression data of all KO clones in order to to obtain first indications about putatively 
deregulated markers. To this end, the mean relative mRNA expression level of a marker at a specific 
differentiation stage was compared between the mock control and a specific KO clone using a two-sided 
unpaired T-Test (with/without Welch’s correction). Table 8 provides an overview about all differentially 
expressed genes in the individual gene-specific KO clones at specific time points of differentiation. 
However, respective data can therefore just be interpreted on descriptive level. These significant, 
quantitative discrepancies between the individual KO clones in comparison to the mock control clone 
will not be addressed in the description of the following figures (fig. 26-30 A). In contrast, only general 
differences in the overall marker expression profiles comparing the KO clones and the mock control 
clone will be described.  
A subset of neuronal markers was selected for expression validation on protein level by IF analyses. 
Specifically, to assess proceeding neuritogenesis and neuronal maturation at 7+14d and 7+28d of 
differentiation, the cytoskeleton proteins TUBB3, MAP2, TAU, the growth cone specific protein GAP43 
and the synaptic marker SYP were chosen. To study the proliferative behaviour of the differentiating 
clones, the proliferation marker ANTIGEN Ki-67 (Ki67) was included into the analyses (fig. 26-30 B and 
C).  
In the mock control clone, expression levels of the progenitor marker P75NTR increased until 7+7d, 
whereas with progressing differentiation, a gradual decrease was observed. The progenitor marker NES 
showed higher expression levels than P75NTR but a similar expression pattern. The majority of neuronal 
cell fate markers, such as UCHL1, TUBB3, MAP2, SYP, GAP43 and NPY showed a clear upregulation 
of expression after induction of neuronal differentiation at 7d in DM I. Compared to expression levels of  
UCHL1, TUBB3, GAP43 and NPY, the markers MAP2 and SYP displayed considerably lower 
expression in differentiated cells. TAU expression was generally low but gradually increased during 
differentiation. In contrast, ASCL1 levels first strongly declined from undifferentiated to 7d differentiated 
cells and then remained almost stable during further cultivation. The neuronal subtype specific marker 
TAC1 was expressed at low levels in undifferentiated and 7d differentiated cells, while samples at later 
differentiation stage showed higher but highly variable expression levels based on respective standard 
errors. The apoptotic marker CASPASE 3 (CASP3) displayed increased but stable expression levels in 
differentiated samples compared to the undifferentiated specimens (fig. 26 A).  
Expression of selected neuronal cell fate markers could be confirmed by IF analyses. Corresponding to 
their respective protein functions, TUBB3, MAP2, GAP43 and TAU localised to neuronal-like outgrowths 
and showed a partial expression overlap in corresponding IF double staining. The synaptic specific 
marker SYP generated a dotted-like staining pattern along TAU+ neurite-like structures. IF staining of 
Ki67 demonstrated that only a subfraction of TUBB3+ cells remained mitotically active after 7+14d and 
7+28d of differentiation, respectively (fig. 26 B and C). Corresponding to brightfield microscopy results, 
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IF analyses of cells after 7+14d and 7+28d displayed proceeding neuronal-like maturation (fig. 21, 26 B 
and C). 
 
 
Overall, results of mRNA expression profiling were highly comparable between the mock control clone 
and the RET KO clone (fig. 26 A and 27 A). Significant differences in the relative expression levels of 
all markers comparing both clones on descriptive level are summarized in table 8. Major differences in 
the general expression profile of individual markers are described in the paragraph below. 
The relative mRNA expression profile of the progenitor marker P75NTR varied, comparing both clones. 
Specifically, a strong upregulation in the relative P75NTR mRNA expression was observable comparing 
undifferentiated and 7d differentiated RET KO cells. During further differentiation, transcript levels of this 
marker slightly increased. Minor differences were as well detectable for NES. Comparable to the mock 
control clone, expression of this progenitor marker increased during early stages of differentiation but 
then decreased after 7+21d in the RET KO clone. Comparable observations were made for the neuronal 
markers SYP and GAP43 as marker expression levels decreased as well in the latest differentiation 
Figure 26: Expression analyses of the differentiating mock control clone 
A: mRNA expression profiles were assessed at various time points of neuronal differentiation by qRT PCR (n=3, 
mean + SEM (standard error of mean). B and C: Differentiated cells after 7+14d (B) and 7+28d (C) of cultivation 
were investigated by IF analyses for selected marker expression. Images are representatives of different 
experiments. Cell type specific markers are indicated in red (neuronal: MAP2, GAP43, SYP; proliferation: Ki67) and 
green (TUBB3, TAU). Nuclei were counterstained with Hoechst (blue). Scale bar: 50µm.  
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specimen in the RET KO clone but not in the mock control clone. The pan-neuronal marker UCHL1 
displayed a strong decline in the relative mRNA expression comparing undifferentiated and 7d 
differentiated cells while further cultivation caused again an increase. For TAC1 only the 7d DMI sample 
displayed a minimal mRNA expression. The relative mRNA expression of the apoptotic marker CASP3 
increased just after 7d of differentiation and then remained stable. Expression patterns for all other 
markers were comparable as described for the mock control clone (fig. 27 A). 
Results of IF analyses were as well highly comparable between the mock control clone and the RET 
KO clone. Marker staining validated an expression of the neuronal cytoskeleton proteins TUBB3, MAP2 
and TAU as well as of the growth cone specific protein GAP43 in differentiating RET KO cells. Staining 
patterns indicated neuronal-like morphologies after 7+14d and 7+28d of differentiation. SYP signals 
displayed the presence of synaptic-like contacts scattered along the neurite-like structures 
immunoreactive for TAU. Comparable to the mock control clone, only a minority of differentiating cells 
were positive for the proliferation marker Ki67 (fig. 27 B and C). 
 
Figure 27: Marker gene expression in the differentiating RET KO clone 
A: qRT PCR analyses using RET KO cells of various maturation states (n=3, mean + standard error of mean (SEM), 
two-sided unpaired T-Test with/without Welch’s correction *p<0.05; ** p<0.01; *** p< 0.001). B and C: Cells after 
7+14d (B) and 7+28d (C) of differentiation were investigated by IF analyses for marker expression patterns. Images 
are representatives of different experiments. Cell type specific markers are indicated in red (neuronal: MAP2, 
GAP43, SYP; proliferation: Ki67) and green (TUBB3, TAU). Nuclei were counterstained with Hoechst (blue). Scale 
bar: 50µm.  
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Figure 28: Marker expression profiling in the differentiating ATP7A KO clone 
A: mRNA expression profiling by qRT PCR using undifferentiated and differentiated ATP7A KO cells of various 
differentiation states (n=3, mean + standard error of mean (SEM), two-sided unpaired T-Test with/without 
Welch’s correction *p<0.05; ** p<0.01; *** p< 0.001). B and C: 7+14d (B) and 7+28d (C) differentiated cells 
were investigated for marker expression by IF analyses. Images are representatives of different experiments. 
Cell type specific markers are indicated in red (neuronal: MAP2, GAP43, SYP; proliferation: Ki67) and green 
(TUBB3, TAU). Nuclei were counterstained with Hoechst (blue). Scale bar: 50µm.  
Exploratory data analyses of mRNA expression profiles between the mock control clone and the ATP7A 
KO clone revealed some differences (fig. 26 A and 28 A). Again, all differentially expressed genes and 
the respective time points are summarized in table 8.  
In contrast to the mock control clone, mRNA expression levels for both neuronal progenitor markers, 
P75NTR and NES, remained almost stable throughout differentiation, except for stage 7+21d that 
showed upregulated transcript levels. Expression of the pan-neuronal marker UCHL1 increased only 
during later stages of in vitro differentiation while expression levels of TUBB3 were stable comparing 
undifferentiated and all differentiated specimens. In contrast to the mock control clone, mRNA 
expression levels of TAU were higher in the undifferentiated and 7d differentiated samples than in cells 
differentiated for longer periods. Moreover, TAC1 expression was not detectable in any specimen. 
mRNA levels of the neuronal subtype specific marker NPY first declined from the undifferentiated to the 
7+7d differentiated state before increasing at later stages of differentiation. The apoptotic marker CASP3 
was almost stably expressed at low levels in all samples (fig. 28 A). 
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IF analyses did validate respective neuronal marker expression for TUBB3, MAP2, GAP43 and SYP 
after 7+14d of differentiation. In contrast to the mock control clone, no neuronal-like clusters were 
observable, and the axonal marker TAU did not generate a distinct staining pattern at this stage (fig. 28 
B). While after 7+14d only a minority of cells was immunoreactive for the proliferation marker Ki67, after 
7+28d the number of this subpopulation was elevated. Generally, at this time point of differentiation, the 
overall cell density was high and a neuronal-like network was only poorly developed. This caused 
problems during cell fixation and IF analyses as cells easily detached from the surface, which was 
observable in IF analyses of TAU/GAP43 and TAU/SYP. Consequently, TAU, GAP43 and SYP specific 
signals were hardly observable in these samples (fig. 28 C). 
Overall, relative mRNA expression profiles of the SREBF1 KO were highly comparable to results 
obtained for the mock control clone although a number of markers was differentially expressed at 
specific time points of neuronal differentiation (tab. 8, fig. 26 A and 29 A). This was revealed by an 
exploratory data analysis strategy. 
Expression patterns of NES, TAU, TUBB3, SYP, GAP43 and NPY were highly comparable to results 
described for the mock control clone as they showed generally upregulated expression levels comparing 
undifferentiated and differentiated specimens. In comparison to the mock control clone, transcript levels 
of the neuronal progenitor marker P75NTR increased drastically from undifferentiated to 7d 
differentiated SREBF1 KO cells. Additionally, the pan-neuronal marker UCHL1 and the apoptotic marker 
CASP3 showed higher expression levels in differentiated than in undifferentiated samples while stable 
relative transcript levels for both genes were reached only after 7+7d in this KO clone. The 
downregulation in the relative expression for ASCL1 comparing undifferentiated and differentiated 
SREBF1 KO cells was not as pronounced as in the mock control clone. Moreover, although MAP2 
increased during early phases of differentiation, this upregulation was not maintained as well at later 
stages. For TAC1, all samples displayed only a minimal expression without any regulation (fig. 29 A).  
On protein level, results of IF analyses confirmed respective neuronal marker expression in the 
differentiated SREBF1 KO after 7+14d and 7+28d of cultivation, respectively. In general, proceeding 
neuronal maturation was observable as e.g. TAU specific signals were more prominent after 7+28d than 
after 7+14d. Staining patterns e.g. in neurite-like structures were in line with respective protein functions 
as in the case of the cytoskeletal protein TUBB3, the dendrite marker MAP2 and the axonal marker 
TAU. Again, comparable to the mock control clone only a minority of cells remained proliferatively active 
as it was observable based on Ki67 specific nuclear signals (fig. 29 B and C). 
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Expression profiling results of the ABCD1 KO clone displayed only minor differences in comparison to 
the mock control clone (fig. 26 A and 30 A). In table 8, all differentially expressed genes and the 
corresponding time points of differentiation, which were identified by exploratory data analysis, are 
summarized.  
Differences between both clones were observable for the two investigated neuronal progenitor markers 
P75NTR and NES, as expression levels of P75NTR slightly increased during differentiation, while 
relative transcript levels of NES decreased in the context of differentiation. Moreover, in contrast to the 
mock control clone, UCHL1 did not display any upregulation during in vitro differentiation and TUBB3 
transcript levels only increased at later stages of differentiation. Comparable to the mock control clone, 
the expression of most of the advanced neuronal cell fate markers as MAP2, SYP and GAP43 gradually 
increased in the context of differentiation but - deviating to the mock specific results - reached stable 
and most prominent expression levels already at 7+14d to 7+21d. Another striking difference comparing 
Figure 29: Expression profiling of the SREBF1 KO during neuronal in vitro differentiation 
A: Expression analyses of undifferentiated and differentiated SREBF1 KO cells assessed by qRT PCR. Several 
neuronal differentiation states were analyzed (n=3, mean + standard error of mean (SEM), two-sided unpaired T-
Test with/without Welch’s correction *p<0.05; ** p<0.01; *** p< 0.001). B and C: Differentiated cells (7+14d (B) and 
7+28d (C)) were fluorescently labelled with a subset of selected markers. Images are representatives of different 
experiments. Cell type specific markers are indicated in red (neuronal: MAP2, GAP43, SYP; proliferation: Ki67) and 
green (TUBB3, TAU). Nuclei were counterstained with Hoechst (blue). Scale bar: 50 µm.  
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both clones was detectable for NPY, as this neuronal subtype specific marker first decreased directly 
after neuronal cell fate induction before increasing with progressive differentiation time. Expression 
patterns for ASCL1 and TAU in differentiated ABCD1 KO samples were comparable to the results 
described for the mock control clone. Stable but low or minimal expression levels were detectable for 
the apoptotic marker CASP3 and the neuronal subtype specific marker TAC1, respectively (fig. 30 A).  
Neuronal marker expression on protein level was validated for TUBB3, MAP2, TAU, SYP and GAP43 
and respective staining patterns confirmed expected subcellular protein localisation. Proceeding 
neuronal-like maturation was observable based on larger neuronal-like clusters and more complex 
neuronal-like networks comparing cells after 7+14d and 7+28d of differentiation. Similar to the mock 
control clone, only a few TUBB3+ cells displayed immunoreactivity for Ki67 (fig. 30 B and C). 
 
 
 
Figure 30: Expression profiling of the differentiating ABCD1 KO 
A: qRT PCR investigations of undifferentiated and differentiated ABCD1 KO cells. Various neuronal maturation 
states were analysed (n=3, mean + standard error of mean (SEM), two-sided unpaired T-Test with/without Welch’s 
correction *p<0.05; ** p<0.01; *** p< 0.001). B and C: 7+14d (B) and 7+28d (C) differentiated cells were analysed 
by IF staining for the expression of selected markers. Images are representatives of different experiments. Cell type 
specific markers are indicated in red (neuronal: MAP2, GAP43, SYP; proliferation: Ki67) and green (TUBB3, TAU). 
Nuclei were counterstained with Hoechst (blue). Scale bar: 50µm.  
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Figure 31: mRNA expression profiling of HSCR candidate genes and RET in individual 
clones 
A and B: qRT PCR investigations of the mock control (A) and the RET KO (B) clones for 
RET and the HSCR candidate genes ATP7A, SREBF1 and ABCD1. C-E: Transcriptional 
profiling of RET and the respective genome edited loci in ATP7A KO (C), SREBF1 KO (D) 
and ABCD1 KO (E) clones. Undifferentiated and differentiated cells of various neuronal 
differentiation stages were analysed by qRT PCR, respectively (n=3, mean + standard error 
of mean (SEM), two-sided unpaired T-Test with/without Welch’s correction. *p<0.05; ** 
p<0.01; *** p< 0.001). Results for the genome edited loci of the corresponding KO clone are 
faded.  
Besides the presented cell type specific markers, mRNA expression profiles of the selected HSCR 
candidate genes (ATP7A, SREBF1 and ABCD1) and the major HSCR risk locus RET were assessed 
as it was aimed to determine if candidate genes might act up- or downstream of the RET signalling 
pathway. Therefore, only the mock control clone and the RET KO clone were analysed for the 
expression of all previously listed genes, while all candidate specific clones were only investigated for 
RET and the edited loci.  
In the mock control clone, transcript levels of all investigated genes strongly increased after 7d of 
neuronal induction and then decreased gradually with further differentiation. In general, ABCD1 relative 
expression levels were lowest (fig. 31 A). 
Candidate gene-specific results were comparable between the mock control clone and the RET KO 
clone. Contrastly to these similarities, RET expression levels increased at stage 7+21d in the RET KO 
clone which was not observable in the mock control clone (fig. 31 B). 
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Although a strong upregulation in the expression upon neuronal induction of RET was observable in all 
three KO clones, while expression patterns at later differentiation stages varied between the clones and 
the mock control clone. Specifically, in the ATP7A KO clone, respective gene expression decreased 
again after the initial upregulation and then remained almost stable in all differentiated specimens (fig. 
31 C). For the SREBF1 KO clone, RET expression was almost stable throughout differentiation while 
for the ABCD1 KO clone the respective expression gradually diminished after 7+7d (fig. 31 D, E). 
Differences in the transcript expression profiles were as well detectable for the genome edited loci in 
the respective candidate specific KO clone in comparison to the mock control clone. Specifically, ATP7A 
relative expression levels in the ATP7A KO clone were generally low and stable - except for the 7d 
sample. Relative transcript levels of SREBF1 in the SREBF1 KO clone increased after 7d and then 
remained constant; respective levels of ABCD1 in the corresponding KO clone were as well low but 
almost stable in all samples (fig. 31 C-E). 
Results of the exploratory mRNA expression data analyses are summarized for all cell type specific 
markers and RET in table 8. Specifically, changes in expression profiles (up- or downregulation) which 
were revealed by the descriptive statistical data evaluation comparing respective KO clones to the mock 
control clone, are indicated. As it can be seen, in all gene-specific KO clones a variety of cell type 
markers was detected to be differentially expressed at individual stages of differentiation. The type of 
deregulation (up-/downregulation) for a specific gene was mostly stable throughout differentiation in the 
respective clone (tab. 8). 
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 Functional analyses of SHSY5Y clones 
Genome edited clones were characterized regarding functional impairments in comparative analyses 
with the mock control clone. In vitro assays targeting cell proliferation, cell survival and cell migration 
capacity were performed. Besides the undifferentiated clones, differentiated clones of stage 7+1d or 
7+7d were investigated. These stages were chosen due to specific experimental based reasons as 
outlined below or as they were regarded as most informative. The fact that cell clones tend to form 
extensive cell clusters at later differentiation time points made it impossible to reliably determine 
proliferative or apoptotic percentages by microscopic image analyses.    
Cell proliferation 
Cell proliferation rates of undifferentiated and 7+1d differentiated cells were determined by BrdU assays 
(fig. 32 A). Percentages of BrdU positive cells in the undifferentiated state ranged between 50-65% for 
mock control, RET KO, ATP7A KO and SREBF1 KO clones. In comparison to the mock control clone 
significantly less proliferative cells were detectable for the ABCD1 KO (~30% BrdU positive cells) (fig. 
32 A‘). 
In the differentiated state, no significant differences were observable comparing the respective edited 
clones to the mock control clone. Only for the ABCD1 KO a slight trend towards upregulated proliferative 
levels (adjusted p-value 0.08) was observable (fig. 32 A‘‘). The 7+1d differentiation state was selected 
for analyses to determine if cell clones differ in their ability to induce neuronal maturation. After 7d of 
cultivation in DM I (containing FBS), media was changed to DM II (contained no FBS). Corresponding 
to this, proliferative levels of clones were expected to be low after 7+1d in case neuronal cell fate 
induction was successful. Due to the experimental procedure of cell fixation, clones differentiated for 
longer periods could not be investigated accordingly as they tend to easily detach from the surface. 
Consequently, later differentiation stages were excluded from respective analyses. 
Cell survival 
The number of apoptotic cells in undifferentiated and 7+7d differentiated cells was determined by 
TUNEL assays (fig. 32 B). The percentage of TUNEL+ cells in the undifferentiated state was below 1% 
for all clones except for the ABCD1 KO clone (~ 5%) with significant more TUNEL+ cells in comparison 
to the mock control clone (fig. 32 B‘). 
The amount of apoptotic cells within the differentiated cell populations was overall higher compared to 
the undifferentiated states, respectively. A significant increase in the TUNEL+ cell fraction compared to 
the mock control clone was detected for the SREBF1 KO clone (fig. 32 B‘’).  
Cell migration 
The cell migration capacity was assessed by a Boyden Chamber assay. Undifferentiated and 7+1d 
differentiated cells of all clones were investigated using a positive/chemoattractant and a negative/non-
chemoattractant experimental setup, respectively (fig. 32 C). A significant reduction in the cell migration 
capacity of undifferentiated cells was detectable for the RET KO clone compared to mock control clone 
in the positive setup (using FBS as chemoattractant). All other investigated clones showed a similar 
migration capacity as the mock control clone (fig. 32 C‘). 
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Cell clones differentiated for 7+1d did not significantly differ in their migratory capacity. At this stage, 
BDNF was applied as chemoattractant in the positive control. However, high experimental variations 
indicated by larger SEM need to be considered. Mean numbers of migrated cells/membrane for 
differentiated cells were lower compared to undifferentiated numbers (fig. 32 C‘‘). Based on the 
experimental strategy, which required an enzymatic dissociation, later differentiation time points could 
not be evaluated accordingly.  
 Characterization of genetic variants 
Patient-specific mutations residing in selected candidate genes were analysed on different levels. 
On genetic level, variant specific frequencies annotated in the gnomAD dataset (control individuals (non-
Finnish Europeans only) were assessed. Except for the single nucleotide variant (SNV) in ABCD1 
(c.G241C) which was annotated in the database with a frequency of 0.0009132 none of the other 
variants was found in gnomAD. Moreover, the CADD score as a measure of deleteriousness of the 
genetic variant was considered. Respective scores ranged between 15.39 for the SNV in ABCD1 and 
above 25 for the three other candidate variants (ATP7A (c.G4067A): 26.9; SREBF1 (c.G3172C): 25.5; 
PIAS2 (c.C889T): 26.9) (fig. 33 A). 
On protein level, respective variants for domains for ATP7A, SREBF1 and ABCD1 were shown not to 
reside in any functionally annotated (fig. 33 B-D). Specifically, the variant detected in ATP7A (p.R1356Q) 
localised to the C-terminal part of the transporter protein adjacent to the second-last transmembrane 
Figure 32: Comparative functional analyses of genome engineered clones compared to the mock control  
A: The proliferation capacity of undifferentiated (A’) and differentiated (7+1d) (A’’) clones was assessed by BrdU 
Assays. B: The number of apoptotic cells in undifferentiated (B’) and differentiated (7+7d) (B’’) clones were 
determined by TUNEL assay. C: Cell migration capacity of undifferentiated (C’) and differentiated (7+1d) (C’’) cell 
clones was measured by Boyden Chamber assays. In the positive control, FBS was applied as chemoattractant for 
undifferentiated whereas BDNF was applied as chemoattractant for differentiated cells (negative: basal medium 
only). Bar plots show mean + standard error of mean (SEM) (n≥3), one-way ANOVA, Bonferroni corrected, *p<0.05; 
** p<0.01; *** p< 0.001, **** p< 0.0001.  
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(TM) domain and in proximity to the phosphorylation domain (P-domain) (fig. 33 B). For SREBF1, the 
patient-specific missense variant localised to the C-terminal end of the protein (p.D1058H) (fig. 33 C), 
while for ABCD1 the amino acid substitution resided close to the N-terminus (p.T14R) (fig. 33 D). In 
contrast, the de novo variant in PIAS2 (p.R297W) caused an amino acid change in the most C-terminal 
end of the PINIT (Pro-Ile-Asn-Ile-Thr) region (fig. 33 E). 
Subcellular localisation of recombinantly expressed WT and mutated (MUT) candidate protein versions 
were assessed by IF staining. In addition to the candidate protein, the specific tag staining revealed a 
co-labelling pattern. IF staining patterns of recombinantly expressed WT and MUT ATP7A indicated an 
endoplasmic reticulum (ER) or Golgi specific protein localisation. No differences between both protein 
versions were observable neither in HEK293TN nor in SHSY5Y cells (fig. 33 F and F‘). 
 
Figure 33: Characterization of variants detected in the candidate genes on different molecular levels 
A: Patient-specific variants in the selected candidate genes were assessed for their presence in the European 
(EUR) (non-Finnish) control population of the gnomAD dataset. The variant specific CADD score was calculated 
using the CADD model GRCh37-v1.4 (https://cadd.gs.washington.edu/snv). B-E: Protein domain structures of 
candidates and localisation of patient-specific mutations. Protein domains in specific isoforms were annotated 
based on database entries (Pfam, NCBI, Uniprot) or additional literature findings (Andreoletti et al., 2017; Gourdon 
et al., 2012) (ATP7A (B), SREBF1b (C), ABCD1 (D), PIAS2ß (E)). F-I’: Subcellular investigation of wildtype (WT) 
and mutated (MUT) protein versions in HEK293TN and SHSY5Y cells transiently transfected with candidate specific 
overexpression constructs (ATP7A (F, F’), SREBF1 (G, G’), ABCD1 (H, H’), PIAS2 (I, I’)). Candidate (red), protein-
tag (green). Nuclei were counterstained with Hoechst (blue). Scale bar: 25µm. HMA (Heavy metal associated), TM 
(Transmembrane), A (Actuator), N (Nucleotide), P (Phosphorylation), HLH (Helix loop Helix), LMNA (LAMININ A/C), 
ABC (ATP binding cassette), SAP (scaffold attachment factor-A/B, acinus and PIAS), PINIT (Pro-Ile-Asn-Ile-Thr), 
ZF-SP-RING (Zinc Finger – Really Interesting New Gene), SUMO (small Ubiquitin-related modifier), NLS (Nuclear 
localisation signal)  
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Analyses for SREBF1 showed comparable results as described for ATP7A. Signal accumulation around 
the nuclei pointed towards a protein localisation within the ER. Staining patterns were comparable 
between WT and MUT proteins and between different cell lines, HEK293TN and SHSY5Y cells, 
respectively (fig. 33 G and G‘). 
A vesicular-like staining pattern in HEK293TN and SHSY5Y cells was observable for recombinantly 
expressed ABCD1 WT. Introduction of the patient-specific variant into the overexpression construct did 
not cause any alteration in the subcellular localisation of ABCD1 (fig. 33 H and H‘). 
The recombinantly expressed transcriptional co-regulator PIAS2 showed a nuclear restricted staining 
pattern in both investigated cell sources. Again, mutagenesis of the overexpression construct did not 
affect the protein localisation (fig. 33 I and I‘). 
3.4 Candidate gene risk assessment 
To evaluate the candidate gene-specific relevance for the HSCR aetiology, a scoring system was 
applied. 
Database entries, literature findings and specific data generated within this project were summarized 
using a binary ranking system (tab. 9). Score Σ1 was based on evidence generated in the categories: 
gene expression, information, interaction and constraint. In score Σ2, additionally gene-specific mutation 
predictions were taken into account. For score Σ3, significant differences detected in comparative 
functional in vitro analyses using the gene-specific KO cell clones of this project were considered 
(sections 3.3.4 and 3.3.5).  
To allow a classification of the selected candidate genes of this project, risk scores for the established 
disease-causing factors RET, SOX10, EDNRB, GDNF and PHOX2B were calculated and implemented 
(data modified from Bachelor Thesis Dawid, 2019). Σ2 scores for these known HSCR risk genes ranged 
between 8-13, with PHOX2B showing the lowest and SOX10 displaying the highest risk score. RET, 
EDNRB and GDNF showed each a score of 12. However, no available information about PHOX2B in 
different databases must be considered. Additionally, no rare disease-causing variant was applicable 
and hence no scores could be attributed in the gene mutation category (Σ1=Σ2) (Bachelor Thesis Dawid, 
2019). 
ATP7A displayed the highest risk score among all selected candidate genes when only gene and 
mutation specific data was evaluated (Σ2=13). SREBF1 and PIAS2 were annotated with a Σ2 risk score 
of 11 and 12 each, while for ABCD1 a Σ2 score of 10 was calculated. Again, missing data in the Human 
Protein Atlas database must be considered for the evaluation of this candidate. 
Taking in vitro function based data, respective Σ3 risk scores for the candidates ATP7A, SREBF1 and 
ABCD1 as well as for the major HSCR susceptibility loci RET increased. Specifically, the candidate 
genes ATP7A and SREBF1 as well as RET displayed a score Σ3 of 14 each. For ABCD1 a Σ3 score of 
13 was calculated. As no KO clone for PIAS2 could be generated within this project and as SOX10, 
EDNRB, GDNF and PHOX2B were not included in the presented study pipeline, Σ3 was not applicable 
for these genes.
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4 DISCUSSION 
4.1 Selection of candidate genes underlying HSCR 
 Genetic heterogeneity on multiple levels 
HSCR has been classified as an oligogenic trait and lately evidence has been accumulated terming it a 
multifactorial condition. To date, more than 500 rare coding variants in the major HSCR risk loci (n > 20) 
have been identified (Tilghman et al., 2019). However, the genetic etiology remains unclear for a large 
proportion of HSCR patients, as in fact in 70% of the cases the underlying genetics is yet unknown 
(Bahrami et al., 2017). Moreover, authors of recently published sequencing studies claimed, that HSCR 
is most probably caused by a multitude of different rare and common, coding as well as non-coding 
variants residing in various genes that can act in concert (Luzón-Toro et al., 2015b; Tilghman et al., 
2019; Zhang et al., 2017).  
Genetic profiles of two-sporadic L-HSCR patients had been assessed by WES and bioinformatic data 
filtering. This strategy indicated ATP7A, SREBF1, ABCD1 and PIAS2 as promising candidate genes 
(fig. 5). Large-scale reference datasets (ExAC and gnomAD browser) are now available and were used 
for bioinformatic data filtering. They are particularly useful, especially in the case of low-frequency 
variants (MAF), which were used to narrow down the most promising candidate genes. Consequently, 
these reference data can facilitate gene prioritization and selection of most promising causal variants in 
a disease context (Lek et al., 2016). However, a general problem in genetic data filtering is the availability 
of control datasets. Ideally, respective controls should represent “healthy” individuals who are not 
affected by any phenotypic condition. Databases such as the ExAC and gnomAD include mostly genetic 
information from patients affected by various disorders ranging from metabolic syndromes to 
neuropsychiatric diseases (gnomAD browser; Lek et al., 2016). Moreover, “non-diseased” individuals 
who served as controls in individual projects might present with other not reported phenotypes. 
To find out if the two patients carry any rare variants in genes already described in the context of HSCR 
or ENS development, filtered WES data was compared to a dataset containing approximately 150 
ENS/HSCR relevant loci (tab. S3, Supplementary). Patient II did not carry any rare variants in 
corresponding genes. In contrast, variants in ECE1 (rs141146885), SUFU (rs34135067) and SERPINI1 
(rs61750375) were identified in patient I (fig. 5). ECE1 is classified as HSCR risk gene (Luzón-Toro et 
al., 2015b). This enzyme regulates maturation of the EDN ligands and therefore plays a crucial role in 
EDNRB signalling during ENS formation (Heanue and Pachnis, 2007; NCBI, Gene ID 1889). HSCR-
associated variants in ECE1 were so far only identified in a few patients (Hofstra et al., 1999; Luzón-
Toro et al., 2015a). SUFU encodes a negative regulator of the SONIC HEDGEHOG (SHH) pathway, 
which is involved in the regulation of ENCDC proliferation, differentiation and migration during ENS 
formation (Fu et al., 2004; Gui et al., 2017; Nagy et al., 2016; NCBI, Gene ID 51684). The synapse-
associated serine proteinase inhibitor Serpini1 has been described to be expressed in the developing 
murine ENS (Gui et al., 2017; Heanue and Pachnis, 2006; NCBI, Gene ID 5274). While SNPs in SUFU 
and SERPINI1 have so far not been reported in the context of HSCR, rs141146885 in ECE1 has already 
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been detected in a male sporadic S-HSCR patient. This patient carried additional genetic variants in the 
HSCR susceptibility loci RET and SOX10. Furthermore, in silico analyses for the SNP in ECE1 did not 
predict any functional relevance suggesting that this variant does not represent a major disease-causing 
factor (Luzón-Toro et al., 2015a).  
Except for a large number of coding variants, few common non-coding variants have been described in 
the context of HSCR (Emison et al., 2005; Kapoor et al., 2015; Tilghman et al., 2019).  
The SNP rs2435357 in intron 1 of the RET gene has been the first non-coding variant identified to 
significantly increase the HSCR risk. Specifically, the presence of the risk allele within the intronic 
enhancer region disrupts SOX10 binding and thereby reduces RET transactivation. This common low 
penetrance variant has been described to be present in about 80% of all HSCR cases (Emison et al., 
2010; Emison et al., 2005). SNP genotyping showed that patient I carried the risk allele at rs2435357 in 
the heterozygous state while patient II revealed the risk variant in the homozygous state. Genotyping 
was also performed for two other cis-regulatory variants, rs7069590 and rs2506030, residing upstream 
of the RET transcriptional start site. Only for patient II, additional non-coding risk alleles were identified 
for rs2506030 while patient I carried the major, non-risk alleles at both cis-regulatory sites in a 
homozygous state (fig. 6 B). Risk alleles at both sites were shown to affect binding and target gene 
regulation by GATA BINDING PROTEIN 2 (GATA2) and RETINOIC ACID RECEPTOR BETA (RARB), 
respectively. Furthermore, a synergistic effect between all RET non-coding HSCR risk variants with 
regard to gene expression activation has been demonstrated (Chatterjee et al., 2016). Due to its crucial 
role during ENS formation, reduced RET receptor expression contributes to the HSCR aetiology e.g. by 
impairing the migratory behaviour of pre-enteric NCCs at early stages or by reducing ENCDC 
proliferation at a later stage (Sasselli et al., 2012).  
The fourth genotyped non-coding SNP rs11766001resides in the SEMA3 gene cluster. Although the 
functional impact of rs11766001 is so far not understood, this SNP has been classified as HSCR risk 
locus based on allelic association tests (Jiang et al., 2015; Kapoor et al., 2015; Tilghman et al., 2019). 
Only patient I carried the risk allele in a heterozygous state at this locus (fig. 6 B).  
Tilghman et al. reported recently that the disease risk was only significantly increased when at least five 
risk alleles in the four disease-associated non-coding SNPs (rs2435357, rs7069590, rs2506030, 
rs11766001) were present (Tilghman et al., 2019). Taking the previously described data of both patients 
into account, none of them exceeded the proposed HSCR risk allele dosage for these common SNPs. 
Besides genetic alterations on single nucleotide level, large structural variations have been rated 
relevant for HSCR (Jiang et al., 2011b; Tang et al., 2012). Different techniques are available to detect 
these large structural variations. For known candidate regions, CNVs can be identified e.g. by multiplex 
ligation-dependent probe amplification (MLPA) while comparative genomic hybridization (CGH) assays 
can be used as a hypothesis free approach. However, WES data is also suitable for CNV identification 
although it needs to be taken into account that only the coding-part of the genome is analysed (Fromer 
and Purcell, 2014; Pfundt et al., 2017). CNV-based evidence for the two patients was obtained based 
on the generated WES data. After filtering, three rare CNVs in patient I and two rare CNVs in patient II 
were identified which were inherited in all cases (fig. 6 A). 
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Specifically, patient I carried a heterozygous deletion within the PCDHG gene cluster, which encodes 
for neural adhesion proteins probably involved in neuronal cell-cell connections (NCBI, Gene ID 56115). 
In this patient, 6 out of 22 genes, contained in that cluster, presented with the detected structural 
variation. PCDHG has so far not been linked to HSCR, but members of the alpha gene subfamily have 
already been shown to be expressed in the developing ENS and mutations in PCDHA9 were just 
recently associated with the phenotype (Heanue and Pachnis, 2006; Shen et al., 2018). Consequently, 
a functional relevance of PCDHG for HSCR is very likely. However, taking the mother’s genotype into 
account, the presence of this structural variation is not sufficient to cause the disease. The patient 
carried additional copy number gains affecting MHC CLASS I POLYPEPTIDE-RELATED SEQUENCE 
A (MICA) and UHRF1 BINDING PROTEIN 1 LIKE (UHRF1BP1L) (fig. 6 A’). A direct association to 
HSCR has not been described for any of the genes but annotated tissue expression profiles and protein 
functions suggest a functional relevance for both in HSCR-causing mechanisms. The stress induced 
antigen MICA has been annotated to be expressed in the GI system and genetic variations have already 
been linked to CNS disorders such as Autism Spectrum Disorder (ASD) or schizophrenia (The Human 
Protein Atlas, MICA; Psychiatric Genomics Consortium, 2017; NCBI, Gene ID 100507436). For 
UHRF1BP1L an expression in brain and GI tissue has already been reported (The Human Protein Atlas, 
UHRF1BP1L). Taken together, SNVs at these loci might contribute to the individual’s HSCR risk. 
However, before drawing any general conclusions, more detailed investigations are necessary. 
For patient II, a copy number loss affecting the CLN8 TRANSMEMBRANE ER AND ERGIC PROTEIN 
(CLN8) and a copy number gain in the GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 3 (AGPAT9) 
region were identified (fig. 6 A’’). No HSCR associations have been reported, but their expression in 
brain and GI tissue annotated. Interestingly, CLN8 underlies neuronal Ceroid lipofuscinosis, which is as 
well characterized by neurological symptoms as epilepsy (The Human Protein Atlas, CLN8; NCBI, Gene 
ID 2055; OMIM # 600143). Structural variants at both loci were inherited from the non-affected father, 
suggesting that their combined presence is not causing HSCR. However, further analyses are necessary 
as well as the recurrence of all detected CNVs affecting the genes needs to be assessed in additional 
HSCR patients.  
In conclusion, CNV-based evidences were in line with published data, which suggest that not only 
syndromic but also non-syndromic HSCR subjects are frequently affected by structural variations (Tang 
et al., 2012). Remarkably, some of the loci presenting with structural abnormalities have already been 
reported in the context of CNS-related disorders, such as ASD or neuronal Ceroid lipofuscinosis. In turn, 
ASD patients frequently present with GI symptoms (Rao, 2016). In this manner, commonalities in ENS 
and CNS regulatory molecular pathways and respective disorders are also reflected in the genetic data 
of this project (Tilghman et al., 2019).  
Combining all findings for the individuals of each family (fig. S1, Supplementary) and considering the 
previously outlined genetic heterogeneity in HSCR, leads to two conclusions. First, although parents in 
both families were not affected by the HSCR phenotype, their genotypes suggest the presence of GI 
dysfunctions. Deep phenotyping based on medical records and questionnaires to assess functional GI 
disorders using the Rome IV diagnostic questionnaire would be of particular interest (Palsson et al., 
2016). Second, albeit a variable number of probable HSCR risk loci could be identified in both patients 
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by CNV analyses and SNP genotyping, the presence of additional susceptibility variants in further, novel 
risk loci is very likely based on the multifactorial disease origin. 
 Network analyses confirmed candidate selection 
To put the candidate genes into biological context and most recent knowledge, an in silico network 
analysis using the IPA knowledge base was performed. ATP7A, SREBF1, ABCD1 and PIAS2 were 
identified to be directly and indirectly linked to factors involved in ENS formation and/or HSCR aetiology 
(fig. 7).  
An indirect connection was identified between ATP7A and RBP4 via the LDL complex, which has 
already been described in the context of atheriosclerosis (Qin et al., 2010; Zhou et al., 2018). RBP4 
belongs to the lipocalin family where protein family members have been correlated with pro-
atheriosclerotic processes (NCBI, Gene ID 5950; Oberoi et al., 2015). Vitamin A (Retinol) has already 
been shown to be relevant in ENS development, as respective deficiency in Rbp4-/- mice causing distal 
bowel aganglionosis (Fu et al., 2010).  
IPA network analysis displayed a direct interaction between ABCD1 and DNMT3B, as this DNA 
methyltransferase has been identified to bind to CpG islands of the candidate gene’s promoter (Jeong 
et al., 2009). DNMT3B-mediated epigenetic regulation is known to be involved in NCC specification as 
well as in the onset of HSCR (Martins-Taylor et al., 2012; Torroglosa et al., 2014). A similar regulation 
of ABCD1 might contribute to HSCR.  
Direct interactions between NAV2 and PIAS2 or SREBF1 have been identified in different in vitro assays 
(Ebmeier and Taatjes, 2010; Rolland et al., 2014). NAV2 plays a role in cellular growth and migration, 
and gene dosage effects have been reported in the context of HSCR (NCBI, Gene ID 89797; Turner, 
2013). The transcriptional regulators SREBF1 and PIAS2 might be involved in the NAV2 expression 
regulation. Furthermore, due to its function as E3 SUMOylation ligase, PIAS2 might affect respective 
protein stability by posttranslational protein modification (NCBI, Gene ID 6720 and 9063). This functional 
interaction applied as well to the direct interaction between PIAS2 and the ENS-relevant factor PTEN 
(Wang et al., 2014). As the Pten gene deletion has been described to cause intestinal 
pseudoobstruction, posttranslational protein modifications mediated by PIAS2 might also contribute to 
HSCR (Puig et al., 2009). 
Additionally, SREBF1 was identified to be directly connected to the transcription factor TBX3, which is 
expressed in the developing ENS (Heanue and Pachnis, 2006; Lee et al., 2014b).  
In conclusion, the candidate gene selection made sense and could be integrated with known genes by 
IPA network analyses. The complex genetics and pathomechanisms of HSCR suggest, that candidates 
might represent modifiers affecting major ENS regulating genes and HSCR susceptibility pathways 
(Amiel et al., 2008; Wallace and Anderson, 2011). Candidate specific protein functions will be addressed 
in more detail in the following paragraphs. 
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 Genetic based evidence for selected candidates 
To strengthen the putative relevance of the selected candidate genes on a genetic level, further rare 
variant carriers were identified for SREBF1 and PIAS2 in additional cases. However, the same variant 
as in the index patient could not be detected a second time (fig. 8). Nevertheless, CADD scores (> 13) 
suggested a functional relevance of all filtered, rare variants in the respective HSCR patients. In general, 
this score allows the unbiased annotation of various variants (SNVs as well as insertion/deletions) in the 
human genome by integrating data from existing tools in an innovative quantitative manner. Amongst 
others, annotations from conservation, population frequency as well as regulatory, functional and 
structural information are evaluated through a machine learning algorithm. A CADD score of 13 indicates 
that this variant is predicted to be among the 5% of most deleterious substitutions of the human genome 
(Kircher et al., 2014).  
ATP7A and ABCD1 will be evaluated in the future according to the two other candidate genes. 
Interestingly, for both genes and for PIAS2 rare variants were identified in patients suffering from chronic 
intestinal pseudoobstruction (personal communication Isabella Ceccherini, Genoa, Italy, data not 
shown). This fact points towards a relevance of these candidates in GI phenotypes. 
To calculate if patients harbour a significantly increased number of rare variants in a specific candidate 
gene - compared to unaffected controls -, a genetic burden calculation could be performed in the future. 
However, genotype information used in respective studies of the International HSCR consortium for the 
control individuals were not accessible (section 2.2.1). The use of public data annotated in the ExAc or 
the gnomAD browser as controls is challenging, since e.g. sequencing platforms and variant-calling 
procedures differ between individual studies contributed to the browser data (Guo et al., 2018). Multiple 
statistical methods are available to calculate the genetic burden, e.g. by testing for rare variant 
associations. However, these have different strengths and weaknesses with regard to robustness and 
statistical power and also require advanced bioinformatics tools as well as the availability of large 
datasets, which were not accessible in the context of this study (Lee et al., 2014c).  
 Expression patterns suggest a functional relevance of candidates in ENS 
formation 
mRNA expression validation of candidates in murine tissues 
Due to its neurodevelopmental character, HSCR pathogenesis originates in early embryogenesis. Thus, 
assessing a candidate-specific relevance for the aetiology via expression analyses can only be achieved 
by using embryonic tissues. Transcriptional profiling interrogating more than 20 000 annotated genes in 
three murine, embryonic tissues was carried out. Specifically, specimens comprising pre-migratory 
vagal NCCs at stages E8.75 and E9.5 as well as the embryonic gut at stage E13.5 were analysed (fig. 
9).  
Vagal NCC delamination is initiated at E8.5 in mouse (Sasselli et al., 2012). Therefore, dissected murine 
tissues at E8.75 and E9.5 include the respective pre-migratory vagal NCC population. This highly 
comparable cell type and tissue identity was displayed by means of hierarchical clustering of the overall 
mean expression values. As expected, correlation coefficients between samples of E8.75 and E9.5 were 
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higher than respective coefficients between E8.75 and E13.5 or E9.5 and E13.5 specimens, respectively 
(fig. 9 B). 
Expression levels of the most prominent HSCR risk genes Ret, Gdnf, Gfra1, Ednr, Edn3, Ece1, Sox10 
and Phox2b confirmed tissue identity and reflected the molecular mechanisms underlying embryonic GI 
tract formation (fig. 9 C). Vagal NCCs at E8.75 and E9.5 mainly express Sox10, Phox2b and Ret, as 
these factors are responsible for the maintenance of multipotency (Sasselli et al., 2012). Higher 
expression levels for these markers in early stages of ENS development (E8.75 and E9.5) compared to 
the latest investigated developmental time point (E13.5) indicate different facts. While increasing Sox10 
levels can be attributed to enteric glial cell fate commitment, upregulated expression values for Phox2b 
and Ret reflect enteric neuronal differentiation (Sasselli et al., 2012). 
The HSCR risk gene Ednrb is as well crucial for progenitor maintenance during early ENS development. 
However, in the literature an ENCDC-specific expression of Ednrb is described to be initiated only 
around E10.5 (Barlow et al., 2003; Sasselli et al., 2012). Increasing expression levels for Ednrb 
comparing tissues at E8.75, E9.5 and E13.5 might partially be reflected by this fact. Furthermore, this 
observation might as well indicate its crucial function during ENCDC migration, which is more 
pronounced at the latest investigated stage. The Ednrb-associated signalling factors Edn3 and Ece1 
were also expressed in all investigated tissues. Again, increasing transcript levels might reflect their 
crucial roles as migratory guiding cues for Ednrb+ progenitors (Sasselli et al., 2012). However, Edn3 is 
not endogenously expressed in ENCDCs but gets secreted by the surrounding tissue, which might 
explain reduced gene expression values compared to Ednrb (Heanue and Pachnis, 2007). Comparable 
conclusions might be drawn for the Ret-specific ligand and the HSCR risk gene Gdnf. In contrast to 
Edn3, Gdnf does not only mediate rostro-caudal gut colonization by ENCDCs, but also gut invasion by 
vagal NCCs at E9.5 (Sasselli et al., 2012; Young et al., 2001). Interestingly, the Ret co-receptor Gfra1 
was expressed at higher levels than Gdnf, which most probably demonstrates that the first-mentioned 
factor is not only expressed by the surrounding gut mesenchyme, but also endogenously in ENCDCs 
(Chalazonitis et al., 1998; Sasselli et al., 2012).  
The four selected candidate genes were expressed at comparable levels as the known HSCR risk 
genes, which points towards a putative relevance of these factors for HSCR and ENS development (fig. 
9 C’). In the future, obtained transcriptional profiling data generated within this project will be useful as 
a valuable resource for HSCR candidate gene evaluation. However, these mRNA expression profiles 
are not suited to conclude about the functional relevance of a specific gene during ENS development. 
Additionally, it must be considered that dissected tissues did not only consist of ENS-specific cell types 
but contained various other cell lineages. Therefore, further analyses had to be carried out. 
Protein expression analyses for detailed candidate characterization 
Various protein expression analyses of the candidates were performed to complement transcriptional 
profiling results. Before jointly discussing all findings for each candidate, the purposes and limitations of 
the selected experimental strategies will be addressed in the subsequent paragraph.  
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Evaluation of the experimental strategies 
IF analyses in the developing murine GI system were carried out to identify candidate-expressing cell 
types (fig. 10-13). Cell type markers selected for co-labelling with candidates illustrated proceeding GI 
tract formation and maturation.  
At E9.5 and E10.5, multipotent pre-migratory vagal NCCs were identified by labelling with Sox10 and 
based on their position in close proximity to the neck. However, Sox10 is a general NC marker which is 
not specific to the vagal subpopulation (Simões-Costa and Bronner, 2015). At E11.5, Sox10+ cells did 
not show any specific cell arrangement within the midgut and might either reflect gut invading, 
multipotent ENCDCs or immature glial cells (Lake and Heuckeroth, 2013; Sasselli et al., 2012). As no 
additional immature glial marker was used for protein expression analyses, these lineages could not be 
differentiated in the respective analyses.  
Three different pan-neuronal markers (Tubb3, Pgp9.5 and HuC/D) were used to detect the presence of 
immature enteric neurons at E11.5 and E13.5. While respective cells at the earlier stage were not 
connected to each other and did not display any cell organization pattern, a concentric neuronal cell 
layer indicative for the myenteric plexus was observable at E13.5. Formation of the submucosal plexus 
via a radial directed migration of ENCDCs did not occur before E15.5 and was therefore not observable 
in the respective investigations (Uesaka et al., 2013).  
Additionally, markers indicative for cell lineages residing in the ENS microenvironment were included 
into the candidate protein expression analyses. The importance of the ENS microenvironment has been 
investigated in chicken embryos. Specifically, ENS development was shown to be affected by inhibition 
of smooth muscle development and by Shh secretion from the epithelium (Graham et al., 2017; Nagy 
et al., 2016). The expression pattern of the smooth muscle marker Sma revealed the presence of the 
circular muscle layer in the developing midgut at E13.5. Smooth muscle differentiation is initiated when 
gut colonization by ENCDCs is still in progress, but in contrast to ENS development, generation of the 
circular and longitudinal muscle layer occurs by an outward-development (Fu et al., 2004; Wallace and 
Burns, 2005). IF analyses of ECad illustrated a pseudostratified epithelium, which increased in thickness 
from E11.5 to E13.5 (Grosse et al., 2011).  
To obtain more experimental-based evidence for a putative neuronal specific role of the candidates, 
adult murine colon sections were also investigated for the expression of candidates. Enteric ganglia 
were visualized using the neuronal markers Tubb3 or HuC/D (fig. 14).  
Although IF analyses offer the possibility to study protein expression patterns in detail, this kind of 
analysis has disadvantages as well. First, using tissue slices antigen co-expression in individual cells 
can only be assessed in case of an overlapping subcellular localisation of both proteins. Otherwise, a 
presumable co-expression can only be suggested based on IF signals in close spatial proximity to each 
other. Second, this technique requires a reliable antibody, which might not be available for all proteins 
of interest. Consequently, future studies focusing on the characterization of further novel HSCR 
candidate genes might apply multiplex RNAscope strategies instead or in an addition to IF analyses. 
This in situ RNA hybridization-based approach uses a specific probe design setup that allows signal 
amplification and simultaneous background suppression and therefore enables the detection of single 
molecules. Probes can be designed for any gene of interest and this technique can be easily applied at 
larger scales (Wang et al., 2012).  
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Mechanisms and signalling molecules of ENS development are highly conserved between mouse and 
human, though there are also remarkable differences between both species. Comparative expression 
analyses in stage-matched human and murine tissues revealed differences in the expression patterns 
and dynamics of certain transcription factors (Memic et al., 2018). Therefore, candidate protein 
expression patterns were as well investigated in human GI tissues in this study (fig. 16). Equivalent 
stage-matched human tissue sections to the analysed embryonic murine stages were so far not 
available but might be accessible in the future. Instead, fetal colon tissue was used, originating from a 
fetus acardius amorphous of the 25th week of gestation. At this developmental stage, the fetal gut has 
already reached its mature appearance with both plexus being present (Singh et al., 2015). 
Nevertheless, due to its human specific prenatal background and as ENS maturation also continues 
postnatally, the generated data is highly valuable (Hao et al., 2013; Rao and Gershon, 2018). 
Quantitative assessment of candidates was performed by Western blot analyses using embryonic 
(E15.5) and adult GI and brain tissues. Findings were correlated with IF analyses in adult colonic ganglia 
to dissect a putative enteric neuronal specific role of the candidates (fig. 15). 
 
Candidate protein expression patterns 
Atp7a is a transmembrane protein, regulating intracellular copper transport as well as copper efflux in 
an Adenosine triphosphate (ATP)-dependent manner. This transporter is the main genetic determinant 
for Menkes disease – a multisystemic disorder characterized as well by progressive neurodegeneration 
(NCBI, Gene ID 538; Telianidis et al., 2013). 
IF analyses validated an Atp7a expression in or in close proximity to embryonic ENS-relevant cell types. 
These findings could be correlated with investigations in transgenic Drosophila melanogaster larvae as 
DmATP7 has been expressed in neuronal and intestinal tissues – including the ENS (Burke et al., 2008). 
Additionally, IF analyses suggested an Atp7a expression in enteric smooth muscle cells at E13.5. 
Protein expression in vascular smooth muscle cells has been reported previously; and on a functional 
level, a role in respective cell migration was suggested (Ashino et al., 2010). This correlation might also 
apply to ENS formation. 
Besides this cell type specific expression, atp7a has been shown to be ubiquitously expressed in early 
zebrafish embryos with most abundant signals in the notochord (Mendelsohn et al., 2006). This data 
suggests a putative regulatory relevance of the copper transporter in early embryonic development. 
Due to its relevance in Menkes disease, most detailed expression analyses for Atp7a have so far been 
performed in CNS-relevant tissues. Consequently, a multitude of different cell types e.g. neurons and 
glial cells, residing in various brain regions have been identified to express Atp7a (Telianidis et al., 2013). 
An enteric neuron-specific expression in adult murine and human specimens was demonstrated in this 
study. However, ATP7A signals were also present in cells of the human intestinal epithelium. This was 
in line with its annotated copper delivery function to the circulation in adult enteric enterocytes (van den 
Berghe and Klomp, 2009). Western blot results generated in this project revealed decreasing Atp7a 
expression levels comparing embryonic and adult tissue specimens. Therefore, a predominant role of 
ATP7A in embryonic development and thus prenatal neurogenesis might be concluded. 
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Taken together, results of expression analyses further supported the selection of ATP7A as 
novel risk factor for HSCR by underscoring its putative regulatory function within the ENS 
microenvironment. 
 
SREBF1 is classified as master regulator of cholesterol and fatty acid homeostasis and is synthesized 
as precursor (~120kDa) in the ER. Under low sterol levels, proteolytic cleavage releases the mature 
protein (~70kDa) that acts as bHLH transcription factor and regulates respective fatty acid and 
cholesterol signalling pathways (Eberle et al., 2004; Horton et al., 2002). Consequently, the observable 
nuclear restricted expression pattern in IF analyses indicated the presence of the mature Srebf1 protein. 
According to its relevance in lipid homeostasis, Srebf1 transcripts have already been identified in liver, 
adipose and adrenal gland tissues (Im et al., 2009; Shimomura et al., 1997). The functional role of 
Srebf1 might as well explain its almost ubiquitous expression in embryonic ENS-relevant tissues. In fact, 
at these early developmental stages, the majority of cells - irrespective of their lineage – might be 
proliferatively active and hence have a high lipid demand. This hypothesis is in line with data in the 
respective literature, where SREBF1 expression was proven in proliferative tissues of the fetal intestinal 
crypt epithelium (Wilentz et al., 2000). IHC staining in human tissues confirmed these results as 
prominent staining signals were observable within epithelial cells. In contrast to this, human enteric 
ganglia displayed only minimal protein expression. In adult murine colon tissue, only a subset of enteric 
neurons also co-expressed Srebf1. Combining results of IF and Western blot analyses, a role for Srebf1 
in general neurogenesis might be suggested, since higher expression levels of Srebf1 were detectable 
in embryonic compared to adult tissues. A brain-specific expression of Srebf1 in rodents has already 
been reported (Ong et al., 2000; Wilentz et al., 2000). Furthermore, a functional relevance in this tissue 
can be suggested as SREBF1 has already been reported in the context of different CNS related 
disorders like Parkinson’s disease and schizophrenia (Chen et al., 2017a; Do et al., 2011).  
In conclusion, generated protein expression data together with the association of SREBF1 to 
CNS disorders, further strengthened the putative relevance of this candidate for the enteric 
neuropathy HSCR.  
ABCD1 encodes for a VLCFA transporter, which regulates substrate uptake and its degradation by ß-
oxidation in peroxisomes (NCBI, Gene ID 215). Dysfunctions of ABCD1 are responsible for the 
accumulation of VLCFAs and can result in X-linked adrenoleukodystrophy (X-ALD) – a 
neurodegenerative disorder (Baker et al., 2015; Kemp et al., 2011). 
According to its function as peroxisomal transporter, IF analyses revealed a vesicular-like staining 
pattern. IF analyses proved an almost ubiquitous expression for Abcd1 in the investigated ENS-relevant 
tissues and therefore suggested a putative relevance for HSCR. Strachan et al. identified an abcd1 
expression in different progenitor cells as oligodendrocytes and motor neurons of early zebrafish 
embryos (Strachan et al., 2017). An oligodendrocyte specific expression of Abcd1 in adult mouse brain 
tissue had already been described earlier. However, Troffer-Charlier et al. had demonstrated respective 
protein expression in a variety of different tissues and cell types (Troffer-Charlier et al., 1998). More 
recent data has validated ABCD1 expression in a broad range of different human tissues including the 
colon. Specifically, an expression in enteric ganglia of the myenteric and submucosal plexus as well as 
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in the intestinal epithelium has been presented (Höftberger et al., 2007; Langmann et al., 2003). The 
IHC analyses carried out in this project confirmed not only ABCD1-specific signals within adult colonic 
enteric ganglia, but also in intestinal epithelial cells. An enteric neuronal specific expression for Abcd1 
was also validated in cryosectioned adult murine colon tissue. In Western blot analyses, GI specimens 
showed an enhanced Abcd1 gene activity compared to CNS-containing tissues. However, deviating to 
mRNA data presented by Morvay et al., Abcd1 protein expression levels were low in adult jejunum/ileum 
but higher in duodenum and colon samples. Abcd1 expression in the duodenum probably reflects its 
role in VLCFA turnover at this site (Morvay et al., 2017; Mutch et al., 2004). Most members of the ABC 
protein family function as dimeric transporters, which could also be illustrated in respective Western blot 
investigations, since two Abcd1-specific signals were detected (Morita and Imanaka, 2012).  
Taken together, results of protein expression analyses as well as its known relevance for the 
neurodegenerative disorder X-ALD suggested a putative relevance of Abcd1 for ENS 
development and therefore the HSCR pathoaetiology.  
PIAS2 acts as a SUMO E3 ligase for proteins of the SIGNAL TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION (STAT) family as well as for various other transcription factors and proteins. 
Posttranslational SUMOylation can affect the target stability, interaction or activity (Kotaja et al., 2002; 
NCBI, Gene ID 9063; Shuai, 2000). Pias2 is also described as transcriptional co-regulator and has 
already been shown to localise to nuclear speckles (Estruch et al., 2016; Kotaja et al., 2002). A definite 
nuclear-specific staining pattern was not observable in any of the IF or IHC investigations of this project. 
An explanation for this phenomenon remains to be found and explored in future studies. Nevertheless, 
there is increasing evidence for SUMOylation occurring outside of the nucleus - especially in the 
neuronal context (Martin et al., 2007). Along the same lines, neuronal specific targets have already been 
described for PIAS2, such as the neurotransmitter nNOS (Shalizi et al., 2007; Watanabe and Itoh, 2011).  
Pias2 revealed an almost ubiquitous expression in the investigated ENS tissues and thus a putative co-
expression with all selected cell type markers. A widespread expression for Pias2 at early embryonic 
stages was in line with published in situ hybridization data (Costa et al., 2011). Moreover, the presence 
of Pias2 in presumptive neuronal tissue has already been investigated in early Xenopus laevis embryos 
(Burn et al., 2011). As demonstrated in this project, Pias2 expression was maintained as well in adult 
murine and human enteric neurons. Nevertheless, Western blot analyses suggested a predominant role 
for Pias2 during embryonic development, since respective specimens showed enhanced expression 
levels compared to the corresponding adult samples. In contrast to this, stable Pias2 mRNA expression 
levels in the mouse cerebellum at different embryonic and postnatal stages have been described (Usui 
et al., 2017). The CNS-specific expression of Pias2 might also indicate the importance of the 
SUMOylation process in the context of neurological disorders. In fact, dysfunctions in this 
posttranslational protein modification pathway were already linked to Parkinson’s, Alzheimer’s or 
Huntington’s disease (Anderson et al., 2009; Rott et al., 2017; Yang et al., 2017). 
In conclusion, the putative relevance of PIAS2 for HSCR could be proven based on its expression 
in the ENS microenvironment and by taking its pivotal role in the SUMOylation process into 
account. 
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4.2 Detailed functional characterization of candidate genes 
 Selection of a suitable cell culture model system – advantages and 
limitations 
As candidates were validated to be expressed at relevant stages and in relevant ENS cell types, their 
putative importance for the HSCR aetiology was further assessed by functional analyses in a neuronal 
cell model. Gene-specific KO cell clones of neuronal origin were generated using the CRISPR/Cas9 
technology, and more specifically by gene disruption via the non-homologous end joining (NHEJ) 
mechanism. KO clones and a mock transfected and control-sorted clone were compared on various 
levels – with a special focus on cell features relevant in the HSCR pathogenesis such as differentiation, 
proliferation, cell survival and migration. In addition to the candidate genes, the major HSCR 
susceptibility locus RET was included as a proof-of-principle control.  
Gene-specific KO cells were generated using the human neuroblastoma cell line SHSY5Y. This cell 
source does not resemble the ENS but allows a detailed gene characterization in a human, neuronal 
setup, which was the main purpose in this project. Furthermore, SHSY5Y cells are well accepted in the 
field as they were used to validating findings on a functional level in a number of HSCR studies (Sharan 
et al., 2015; Shen et al., 2018; Wu et al., 2018). A human ENS-specific, commercially available cell line, 
which would mimic the in vivo situation at its best, is so far not available. The usage of human primary 
ENS cells would be of particular importance for future studies but first requires an intensive 
establishment and validation phase. In addition, applying the CRISPR/Cas9 genome editing technology 
to a primary cell source is much more challenging than in a cell line.  
In summary, this project aimed to establish a pipeline for the functional neuronal in vitro characterization 
of selected HSCR candidate genes. Data might be used in the future as basis for advanced studies in 
a human primary ENS-derived cell culture system. 
SHSY5Y cells were subcloned from the parental neuroblastoma cell line SK-N-SH which has initially 
been derived from a metastatic bone tumour biopsy of a four-year old girl (Biedler et al., 1973). As 
neuroblastomas originate from embryonic cells of the NC, they share the same tissue origin as the ENS 
(Jiang et al., 2011a; Johnsen et al., 2019).  
The SHSY5Y line is a heterogeneous cell population containing neuronal and epithelial-like cells which 
can be classified based on their morphology. Bidirectional interconversion between both cellular 
phenotypes has already been described (Ross et al., 1983). This lineage heterogeneity is one of the 
major disadvantages that goes along in using this cell line for the specific purpose of this project. 
Individual gene-specific KO cell clones were classified on the basis of their neuronal-like morphology, 
while a cell clone classification based on the expression of the lineage marker VIMENTIN, which has 
been presented in different previous studies, was not successful (data not shown) (Bell et al., 2013; 
Ciccarone et al., 1989). Therefore, lineage-specific effects rather than KO-specific effects in individual 
genome edited clones cannot be ruled out. Analysis of further gene-specific KO clones might help to 
investigate and dissect this putative correlation. 
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 Gene-specific KO generation using the CRISPR/Cas9 technology 
All targeted genomic loci were endogenously expressed in the parental cell line SHSY5Y (fig. S4, 
Supplementary).  
The proof-of-principle RET KO clone (c.231_232insC/ p.T78Hfs5*) was validated for the respective 
protein loss in the context of this project (fig. 17 A). So far, no RET-specific KO clone was described, 
but RNAi knockdown analyses for this gene have already been performed in the SHSY5Y cell line 
(Esposito et al., 2008; Meka et al., 2015).  
Three out of four candidate genes were successfully knocked-out in the context of this project. The 
ATP7A KO (c. 500_501insT/500_501insA; p.Q167Hfs*4/p.A168Sfs*3) clone, the SREBF1 KO 
(c.874_875insT/c.874_875insTT; p.K293Efs*70/K293*) clone and the ABCD1 KO (c.1004_1005insG; 
p.K336Efs*65) clone either harboured compound heterozygous or homozygous genome modifications 
at the targeted loci (fig. 17 B-D). The respective protein loss was validated by Western blot analyses. 
However, as in the case of SREBF1, low endogenous expression levels, many annotated protein coding 
isoforms and a low-quality antibody impeded this validation step. Therefore, protein lysates of 
HEK293TN cells transiently transfected with a gene-specific overexpression construct served as internal 
controls in all immunoblot investigations. KO specific clones for ATP7A, SREBF1 and ABCD1 in the 
SHSY5Y cell line have not been described in literature to date. 
CRISPR/Cas9 mediated gene disruption through the introduction of a premature stop codon might 
cause the generation of a truncated protein version of unknown functional relevance (Reber et al., 2018). 
This applies only to edited transcripts that are not targeted by nonsense-mediated decay (NMD), which 
was not studied in the context of this project. However, the presence of truncated protein version is 
unlikely as no additional bands were observable in respective KO clone protein lysates. Nevertheless, 
only mass spectrometry analyses are suitable to rule out their presence (Zhang, 2019).  
KO clones were assessed for off-target effects because high off-target frequencies of about 50% were 
reported in the context of RNA-mediated Cas9 guiding (Zhang et al., 2015). Ideally, off-target detection 
in KO clones should be performed by next-generation sequencing. However, due to its high costs, only 
selected off-targets were assessed by Sanger sequencing in this study. Specifically, all exonic regions 
predicted in the top 20 off-target sites by the CCTop CRISPR/Cas9 target online predictor were included 
into sequence validation (Stemmer et al., 2015). Furthermore, predicted intronic and intergenic regions 
were assessed for their putative functional relevance. In this regard, a high sequence conservation 
across different species and/or the presence of active chromatin marks, annotated expressed sequence 
tags (ESTs) or DNase clusters were valid criteria for a selection for Sanger sequence validation.  
Off-target effects were excluded in all gene-specific KO clones, except for the SREBF1 KO. For this 
clone, a heterozygous one-nucleotide insertion in intron 7 of the EEF1A2 gene was identified (fig. S7, 
Supplementary). However, detailed in silico analyses excluded a putative functional relevance as the 
annotated mRNA EST was located more 3‘ than the introduced nucleotide, and the annotated DNase 
cluster was so far not reported in the SHSY5Y cell line (data not shown). Consequently, the SREBF1 
KO was finally validated for its further usage.  
In general, this data demonstrated the necessity for detailed investigation and evaluation of potential 
off-target effects when applying the CRISPR/Cas9 methodology. 
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Genome editing for the candidate gene PIAS2 was not successful as no gene-specific KO clone could 
be generated. In a first experimental setup, exon 6 of PIAS2 has been targeted and led to the generation 
of an edited clone as demonstrated by genotyping (c.774_775insA) (Master Thesis Mederer, 2015). 
Detailed investigations on transcript level revealed alternative splicing of the edited exon (fig. 18 A). As 
exon 6 consisted of a multiple of 3 bases, alternative splicing did not disrupt the open-reading frame of 
the gene and a novel protein coding isoform might have been generated. This was not followed up in 
this project, but database research revealed that a multitude of protein coding isoforms had already 
been annotated for this gene (tab. S4, Supplementary).  
The phenomenon of alternative splicing in the context of CRISPR/Cas9 mediated genome editing has 
been reported in several recent studies (Chen et al., 2018; Lalonde et al., 2017; Mou et al., 2017; Uddin 
et al., 2015). Nevertheless, precise knowledge of the molecular causes triggering this mechanism is still 
missing (Smith et al., 2018). Based on the PIAS2-specific finding, the general editing strategy of this 
project was revised and all other gene-specific KO clones were validated for no alternative splicing of 
the edited exon (fig. S6, Supplementary). 
In a second editing setup, sgRNAs targeted different sites in exon 2 of PIAS2, which did not consist of 
a multiple of 3 bases (fig. 18 B) (Addgene, 2017; Lalonde et al., 2017). However, still no KO clone could 
be generated. Specifically, the lineage heterogeneity of the parental cell line SHSY5Y caused problems 
as almost exclusively clones of epithelial-like morphology survived the single cell cloning procedure. 
The putatively edited clone of neuronal-like morphology, generated by using sgRNA III, carried most 
probably a larger genomic rearrangement at the Cas9 target site. This would explain the failure of 
generating an amplicon for DNA genotyping and missing transcript expression of the FL PIAS2ß. The 
unintended generation of large deletions and chromosomal rearrangements by CRISPR/Cas9 genome 
editing was just recently explored (Kosicki et al., 2018).  
Gene KO escape when using the CRISPR/Cas9 technology was described for a mitotic spindle 
checkpoint kinase. Here, the authors claimed that this phenomenon might be explained by a near 
essential cellular role of the targeted locus (Meraldi, 2019). CRISPR/Cas9 editing of PIAS2 in another 
cell line might help to elucidate if this hypothesis applies as well for the selected candidate gene. 
However, if a near cell essential or neuronal specific role could be proven experimentally, a functional 
relevance for PIAS2 in HSCR would be very likely. 
 Impairments of KO clones in cell features relevant for ENS development 
Validation of neuronal-like in vitro differentiation of SHSY5Y cells 
The KO clones of RET, ATP7A, SREBF1 and ABCD1 were validated for their suitability for a more 
detailed functional characterization. To assess their neuronal differentiation capacity, a suitable 
differentiation protocol was required, which was established based on the parental cell line SHSY5Y.  
Neuronal cell fate induction in the heterogeneous cell population SHSY5Y causes the generation a more 
homogenous neuronal-like phenotype (Encinas et al., 2000). Two pilot experiments (A, B) were carried 
out, using modified versions of published differentiation protocols (fig. 19 and 20). Specifically, three 
different coatings and two different media compositions were tested as the influence of both for neuronal 
in vitro differentiation has already been characterized (Agholme et al., 2010; Encinas et al., 2000; 
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Raghavan and Bitar, 2014). As neuronal differentiation induction by the Vitamin A derivative RA is a 
well-established method for SHSY5Y cells, this treatment was included in all experimental setups 
(Kovalevich and Langford, 2013). In general, a differentiation protocol should be established for different 
functional in vitro assays in the gene-specific KO clones. The neuronal subtype, that was predominantly 
generated, was not of a specific interest for this project as in the HSCR phenotype all subtypes of enteric 
neurons are completely missing.  
The final selection of differentiation protocol Ib for all further analyses was mostly based on 
morphological evaluations by brightfield microscopy, as mRNA expression profiles displayed only minor 
differences comparing all tested protocols. 
mRNA expression results for WT SHSY5Y cells differentiated with protocol Ib confirmed the suitability 
of the selected protocol. Specifically, relative transcript levels for the neuronal progenitor markers 
P75NTR and NES mostly decreased – especially during early phases of differentiation. A 
downregulation of the intermediate filament protein NES in the context of neuronal differentiation has 
already been reported (Murillo et al., 2017). It needs to be determined in further analyses if upregulated 
relative expression levels of P75NTR after 7+14d of differentiation reflect its role in glial cell commitment 
or its relevance in apoptosis regulation e.g. by expression analyses of additional cell fate markers 
(Meeker and Williams, 2015). As expected, many neuronal cell fate markers, such as SYP, MAP2 and 
GAP43, showed increasing transcript levels during differentiation. These observations were in line with 
literature findings, since an upregulation on protein level has already been analysed for MAP2 and 
GAP43 in differentiating WT SHSY5Y cells (Encinas et al., 2000; Murillo et al., 2017). The pan-neuronal 
markers UCHL1 and TUBB3 were found to be almost stably expressed during differentiation, which also 
partially confirmed previous protein-based investigations (Constantinescu et al., 2007; Murillo et al., 
2017). Interestingly, transcriptional profiling of ASCL1 demonstrated a strong reduction in relative mRNA 
levels comparing undifferentiated and early differentiated SHSY5Y cells. This observation coincided 
with published data from Lopez-Carballo et al.. Authors suggested that a change in the balance between 
differentiation promoting and inhibiting factors might be crucial for general neuronal lineage induction in 
this cell source (Lopez-Carballo et al., 2002). Similar observations were made for NPY, although a high 
standard deviation of the undifferentiated sample needs to be considered. Nevertheless, this neuronal 
subtype specific marker was as well found to be upregulated during later neuronal cell fate induction 
and thereby confirmed previous data (Goldie et al., 2014). In contrast to NPY, the second neuronal 
subtype specific marker TAC1 was found to be almost unexpressed. This applied as well to the 
progenitor marker SOX10 and has already been reported previously (Acosta et al., 2009). Relative 
mRNA expression levels of the microtubule associated protein TAU did not reflect proceeding neuronal 
maturation but mRNA expression levels for this marker have been shown to only poorly correlate with 
respective protein levels and thus neuronal maturation stages (Agholme et al., 2010). This fact might as 
well apply to the results in this project.  
On morphological level, differentiating WT SHSY5Y displayed proceeding neuronal-like network 
formation, since progressive neurite extension and an increase in the number of neuronal-like branches 
were observable. These morphological features are generally regarded as valuable properties indicating 
neuronal-like maturation in SHSY5Y cells (Encinas et al., 2000; Kovalevich and Langford, 2013). 
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In vitro characterization reveals functional defects of variable degrees in the KO clones 
Differentiation of all cell clones using the previously validated protocol, was limited to 7+28d. Although 
transcriptional profiles of the differentiating WT SHSY5Y cell populations suggested that no complete 
neuronal maturation was reached at this time point, this stage was considered to be a suitable 
compromise between time and neuronal-like maturation degrees. 
The set of markers used for mRNA expression profiling in the cell clones was further expanded, as the 
apoptotic marker CASP3, the candidate genes and the major HSCR susceptibility locus RET were 
included. To assess if the marker expression repertoire might be altered in lineage-specific SHSY5Y 
clones, the glial marker GFAP, which has so far not been reported in the context of WT SHSY5Y cell 
differentiation, was also implemented (Kovalevich and Langford, 2013). GFAP expression analyses 
might be also used to classify a putative glial cell specific activity of P75NTR at later stages of 
differentiation (Cragnolini and Friedman, 2008; Meeker and Williams, 2015). In addition to expression 
analyses on mRNA level, markers indicative for proceeding neuronal-like maturation and neuritogenesis 
were selected for IF staining.  
Results for expression analyses on mRNA and protein level as well as brightfield microscopy confirmed 
the suitability of the chosen differentiation protocol for neuronal differentiation of the lineage-specific 
mock control clone (fig. 21 and 26).  
On mRNA level, only minor differences were detectable between the mock control clone and the 
parental cell line. SOX10 and GFAP were also not expressed in the lineage-specific mock control clone. 
Additionally, relative transcript levels for the pan-neuronal markers TUBB3 and UCHL1 in the control 
clone were as well almost stable throughout differentiation. Minor differences comparing both cell 
identities were observable for the two neuronal progenitor markers P75NTR and NES. Specifically, 
expression levels for the neuroepithelial-specific stem and progenitor marker NES did not decline during 
differentiation, and for P75NTR overall higher relative transcript levels were rather observable in the 
mock control clone than in the parental line. These discrepancies might most probably be attributed to 
the difference in cell lineage composition of both entities. It needs to be determined if higher P75NTR 
relative expression levels thereby reflect the presence of more neuronal-like characteristics and an 
enhanced neuronal-like maturation capacity in the clone. 
Proceeding neuronal in vitro maturation of the mock control clone was displayed on various levels. First, 
the relative P75NTR mRNA expression level decreased while relative transcript levels of almost all 
neuronal markers (UCHL1, TUBB3, TAU, MAP2, SYP, NPY) increased under differentiating conditions. 
Second, brightfield microscopy analyses illustrated a gradual increase in the length of neurite-like 
outgrowths and a gain in the number of neuronal-like branches and synaptic-like contacts under 
differentiating conditions. Extensive cellular clustering, which was observable after 7+14d, was in line 
with previous literature findings (Constantinescu et al., 2007). After 7+28d, this clone formed a fragile 
network of clusters connected by long, semi-adherent processes that resembled axons. Third, protein 
expression analyses of selected neuronal markers confirmed mRNA expression data and conclusions 
drawn from brightfield microscopy. Corresponding to their function as cytoskeleton proteins, the 
neuronal markers TUBB3, TAU, MAP2 and GAP43 localised to neurite-like outgrowths. As expected, 
the synaptic marker SYP generated a dotted-like staining pattern along these neurites. Additionally, only 
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a minority of differentiated cells were positive for the proliferative marker Ki67. This suggested that 
neuronal-like clusters rather arose from migrated cells, but were not generated by extensive 
proliferation. 
The expression profile of RET in the mock control clone confirmed previous literature findings, as RA 
treatment has been demonstrated to cause an upregulation in respective gene expression, which might 
be crucial for general neuronal cell fate induction in the SHSY5Y cell line (Bunone et al., 1995; Esposito 
et al., 2008; Korecka et al., 2013). Interestingly, all candidate genes displayed a similar expression 
profile as RET, which might point towards a comparable regulatory role of these genes in neuronal 
maturation.  
All KO clones were differentiated and analysed according to the mock control clone. Comparative 
functional in vitro assays targeting the cell proliferation, survival and migration rate were additionally 
carried out (fig. 32). Results of all these investigations will be jointly discussed for each of the gene-
specific KO clones in the subsequent paragraphs. 
The RET KO represented the proof-of-principle control in this study, since RET is the major HSCR 
susceptibility locus involved in the regulation of all important ENCDC functions (differentiation, 
proliferation, cell survival and migration) during ENS formation (Heanue and Pachnis, 2007).  
Detailed functional characterization of the RET KO clone displayed most striking phenotypic alterations 
for this clone in its neuronal differentiation capacity and its migration capability (fig. 22, 27 and 32). This 
is in line with in vitro data of HSCR patient iPSC-derived ENCDCs (carrying a RET mutation), which 
showed most prominent defects in migration and neuronal lineage commitment (Lai et al., 2017). 
Moreover, neuronal precursors of Ret-deficient mice have shown impairments in migration and neuronal 
differentiation too (Enomoto et al., 2001). 
Neuronal network formation in the RET KO was delayed in comparison to the mock control clone, as 
neuronal-like clusters were not arranged in a highly organized network before 7+21d of differentiation. 
On the expression level, a striking difference comparing the RET with the mock control clone was 
detectable for the neuronal progenitor marker P75NTR. Specifically, RA treatment during the first week 
of in vitro differentiation caused a strong upregulation for this marker in the RET KO clone, which was 
not observable for the mock control clone. A functional interaction for Ret and p75 was already described 
in the context of cell-death regulation in sympathetic neurons and with regard to sensory neuron diversity 
generation (Chen et al., 2017b; Donnelly et al., 2018). If RET deficiency in the KO clone is 
mechanistically and functionally connected to this difference in the P75NTR expression profile, needs 
to be investigated.  
As revealed by descriptive statistical analyses, relative UCHL1 mRNA expression levels were detected 
to be significantly reduced and additionally showed a gradual increase during differentiation in the RET 
KO clone. This observation might reflect the delay in neuronal-like maturation, as described previously. 
Further neuronal markers were as well found to be differentially expressed in comparison to the mock 
control clone. For MAP2 and GAP43 differences were observable at various stages of neuronal 
differentiation. The last-mentioned gene was already shown to be downregulated in the context of a 
transient RET knockdown in SHSY5Y cells, which manifests the failure in neuronal differentiation in 
respective cells (Esposito et al., 2008).  
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As downstream signalling pathways of RET are highly diverse, further investigations are required to 
uncover underlying mechanisms and functional links that underlie the differential marker expression in 
this KO clone (Ibáñez, 2013; Kurokawa et al., 2003). However, qRT PCR data was so far only analysed 
on an exploratory level in order to obtain a first impression about putatively misregulated marker genes. 
Therefore, no confirmatory conclusions can be drawn. Additionally, observations on mRNA level should 
be validated as well on protein level. Although respective IF staining revealed expression and correct 
subcellular localisation of the investigated neuronal markers, these analyses are not suitable for any 
quantitative conclusion. Instead, Western blot analyses might be carried out in the future.  
Interestingly, except for ATP7A in the 7d samples, none of the candidate genes was differentially 
expressed in the RET KO clone compared to the mock control clone. This observation suggested that 
candidate genes are probably no downstream targets of the RET signalling pathway but might either 
act upstream or might be involved in other ENS-relevant signalling cascades. 
Besides the alterations in the neurogenesis behaviour, the RET KO clone showed also a failure in 
migration in its undifferentiated state compared to respective mock control cells. The relevance of RET 
for the migratory capacity in SHSY5Y cells has already been described (Cockburn et al., 2010). 
However, this phenotypic impairment was not reproducible in the differentiated state of the RET KO 
clone. With regard to this, two facts need to be considered. First, RA treatment applied in the context of 
neuronal in vitro differentiation decreases the general migration capacity of neuroblastoma cells (Messi 
et al., 2008). This is in line with results of Boyden Chamber assays, since mean numbers of migrated 
cells/membrane were lower for differentiated than for undifferentiated cell clones. Second, high inter-
experimental variations displayed by large SEMs might mask putative differences between the individual 
clones. This variability was most probably caused by the experimental procedure as an enzymatic 
dissociation of 7d neuronal-like cells was necessary; but these cells were highly sensitive and delicate 
to this procedure due to their advanced maturation state. 
In conclusion, RET KO cells displayed defects in two HSCR-relevant cell features - differentiation 
and migration - thereby partially reflecting the disease-causing pathomechanisms in HSCR 
patients. Based on these findings, the neuronal-like cell culture system was evaluated as 
suitable model to also assess novel HSCR candidate genes for their relevance in the 
pathoaetiology.  
For the ATP7A KO clone most striking alterations were detected in its in vitro differentiation behaviour 
based on microscopic analyses and mRNA expression profiling (fig. 23 and 28). 
On morphological level, at any time of neuronal differentiation, ATP7A KO cells were arranged in a 
neuronal-like network comparable to that of the mock control clone. In fact, cell densities for this clone 
were considerably higher than for any other clone throughout differentiation. Additionally, many cells 
were apoptotic and floating, which caused problems in the cell fixation after 7+28d of differentiation. The 
protocol for IF analyses might be further modified for this clone in the future to prevent cell detachment.  
Induction of neuronal maturation should be associated with a downregulation in proliferation – especially 
when differentiating cells are cultivated without any serum (SHSY5Y DM II). ATP7A expression is 
inversely correlated with neuroblastoma cell proliferation (Telianidis et al., 2013). This functional 
interconnection might account for higher cell densities observable in the respective KO clone. IF 
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analyses after 7+28d validated this hypothesis, since many ATP7A KO cells were immunoreactive for 
the proliferative marker Ki67. However, proliferation rates assessed by BrdU assays did not significantly 
differ from observations of the mock control clone – neither in the undifferentiated nor in the differentiated 
state. Analyses at further differentiation stages should be carried out to investigate if comparable results 
can be generated. Moreover, it needs to be stated that Ki67 expression is highly dynamic during the cell 
cycle (Miller et al., 2018). Higher cell densities might as well be caused by reduced cell death although 
TUNEL assays did not reveal any significant alterations in this clone in comparison to the control. 
However, mRNA expression levels for the apoptotic marker CASP3 in the ATP7A KO clone were almost 
stable throughout differentiation and - as suggested by exploratory data analysis – transcript values 
were significantly lower compared to the mock control clone. Nonetheless, the protease CASP3 is not 
only associated to regulated cell death but might as well play a role in neurogenesis and synaptic activity 
(D'Amelio et al., 2010). To overcome this issue in prospective experiments, expression analyses might 
be performed for members of the pro-apoptotic B-CELL LYMPHOMA 2 (BCL2) gene family, e.g. BCL2-
ASSOCIATED X (BAX) (Westphal et al., 2011). 
Microscopic analyses suggested an impaired neuronal-like maturation capacity of the ATP7A KO clone. 
This in vitro phenotype might mimic the neurodegenerative disorder Menkes disease. Protein deficiency 
in the disease context results in defective cellular copper transport and thus in functional impairments 
of various - as well as neuronal-specific - cuproenzymes (Kaler, 2011; Telianidis et al., 2013). In Atp7a 
mutant mouse lines, impairments in proper axonal outgrowth and synaptogenesis have been described 
(El Meskini et al., 2007). Based on the exploratory mRNA expression data analysis, the ATP7A KO 
clone revealed significant downregulations in the expression of neuronal cell fate markers, such as 
MAP2 and GAP43, at multiple time points of differentiation. Corresponding to murine KO data, these 
differences might also reflect a functional impairment in proper axonal outgrowth for the ATP7A KO 
clone. Moreover, TAU expression levels were higher in the undifferentiated and 7d differentiated 
samples than at later differentiation time points. These findings on mRNA level were confirmed on 
protein level as only weak and disorganized TAU-specific IF signals were detectable in differentiated 
cells. 
Although functional in vitro characterization of the ATP7A KO clone revealed impairments in the 
neuronal-like differentiation behaviour, further investigations are necessary to draw more detailed 
conclusions and to clearly identify the functional relevance of ATP7A for proper neurogenesis. 
Specifically, further mRNA expression analyses applying advanced statistical data evaluations as well 
as additional quantitative protein expression investigations need to be performed.  
For the SREBF1 KO clone most prominent alterations were detectable with regard to the overall 
differentiation behaviour and the cell survival rate after 7+7d of differentiation (fig. 24, 29 and 32). 
Comparable to the proof-of-principle control, neuronal-like network formation was delayed. Additionally, 
the RET KO and the SREBF1 KO clones shared similarities in their mRNA expression profiles, e.g. for 
the neuronal progenitor marker P75NTR and the pan-neuronal marker UCHL1. These findings might 
point towards a functional relevance of SREBF1 during early neuronal maturation and general 
neurogenesis in SHSY5Y cells, as it was previously suggested for RET. 
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As outlined in 4.1.4, SREBF1 has already been associated to different neurological conditions which 
are partially characterized by myelin abnormalities. Its importance for autonomous lipid synthesis within 
the nervous system has already been highlighted in different studies. It has been shown that Srebp1c 
KO mice showed a peripheral neuropathy and that blocking of this factor caused defects in 
oligodendrocyte maturation (Camargo et al., 2009; Cermenati et al., 2015; Monnerie et al., 2017). In 
Drosophila larvae, srebp has been identified as a master regulator for neuronal lipogenesis, reflected 
by its relevance for proper dendrite formation (Ziegler et al., 2017). As these studies point towards a 
pivotal role of Srebf1 in neuronal differentiation and neuronal network formation, the observable 
impairments of the SREBF1 KO clone in neuronal-like in vitro differentiation might be interpreted 
accordingly.  
This clone showed a significantly increased apoptotic rate after 7+7d of differentiation in comparison to 
the mock control clone. In literature, SREBF1 has already been identified to be crucial for general cell 
growth and cell viability in cancer cells (Griffiths et al., 2013; Porstmann et al., 2008).  
Combining both regulatory functions of SREBF1 might explain the decreased cell viability of this clone 
under differentiating conditions. SREBF1 deficiency might result in defective lipid metabolism, which 
prevents neurite elongation and hence results in enhanced apoptosis of 7+7d differentiated cells. 
Interestingly, exploratory mRNA expression data analysis suggested significantly reduced mRNA levels 
of MAP2 and GAP43 – two factors associated with neurite outgrowth - at the same stage in the SREBF1 
KO clone. The proposed hypothesis would be in line with results of brightfield microscopy analyses, 
since SREBF1 KO cells were not connected by extensive long and semi-adherent neurite-like after 
7+14d. 
Further investigations are necessary to determine how the loss of SREBF1 contributes in detail to the 
observable phenotypic alterations. To confirm the identified deregulated cell type markers, a targeted 
experimental setup evaluated with advanced statistical methods should be applied. Additionally, 
expression changes on mRNA level need to be verified on protein level. IF analyses for all investigated 
markers proved respective protein expression and confirmed their expected subcellular localisation but 
no quantitative conclusions can be drawn from these investigations.  
Functional in vitro characterization of the ABCD1 KO clone demonstrated only minor differences in 
neuronal differentiation behaviour in comparison to the mock control clone, while most striking 
phenotypic alterations were detected for the proliferation and cell survival rates (fig. 25, 30, 32). 
Specifically, in the undifferentiated state the proliferative rate was significantly reduced, and the 
apoptotic rate showed a significant increase for this clone.  
As described in 4.1.4, ABCD1 is the major genetic determinant for X-ALD (Kemp et al., 2011). Studies 
in X-ALD zebrafish models have revealed a crucial function of this candidate in myelinating glia, as 
abcd1 mutants showed CNS hypomyelination and decreased numbers of oligodendrocytes due to 
increased apoptotic levels (Strachan et al., 2017). Together, alterations detected for the ABCD1 KO in 
functional in vitro assays might partially correspond to this zebrafish phenotype. To mechanistically 
dissect the ABCD1 relevance for this phenotype, it needs to be determined if VLCFAs accumulate at all 
in the KO clone. Investigations in X-ALD patient-derived iPSCs lacking ABCD1 have shown that 
oligodendrocytes did not display any phenotypic developmental delay suggesting ABC SUBFAMILY 
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MEMBER 2 (ABCD2) as compensatory transporter (Jang et al., 2011). Members of the ABC family are 
half-size transporters, containing one transmembrane and one nucleotide binding domain and therefore 
require dimerization for proper functioning. Although they have been annotated to act predominantly as 
homodimers, an ABCD1-ABCD2 heterodimer has already been described and both family members 
have an overlapping substrate specificity (Geillon et al., 2014; Morita and Imanaka, 2012). These 
findings are in line with in vitro results showing that only a CRISPR/Cas9 double KO of Abcd1 and Abcd2 
resulted in increased VLCFAs levels in a microglial cell line (Raas et al., 2019).  
Taken all these facts into account, the milder phenotypic alterations of the differentiating ABCD1 KO 
clone might be explained as well by a compensatory effect of ABCD2 that is launched during neuronal 
cell fate induction. To validate this hypothesis, further investigations would be required.  
Interestingly, in contrast to all other gene-specific KO clones, explorative qRT PCR data analysis 
displayed for many neuronal markers significantly increased relative mRNA expression levels in the 
ABCD1 KO clone compared to mock control clone. Moreover, the maximal relative expression level in 
the case of MAP2, SYP and GAP43 was already reached after 7+14d of differentiation. Consequently, 
ABCD1 KO cells might either possess a premature neuronal-like maturation capacity or these enhanced 
expression levels might be caused by an overcompensated rescue mechanism of ABCD2 acting as 
complementary transporter. So far, IF analyses validated marker protein expression and confirmed 
respective subcellular localisations in differentiated ABCD1 KO cells. Nevertheless, for detection of 
mislocalised protein accumulations, higher imaging resolution technologies are necessary. Additionally, 
observations on mRNA level first need to be confirmed using a targeted analysis approach and not a 
purely descriptive statistical evaluation. Furthermore, investigations on protein level in a quantitative 
manner and expression profiling of ABCD2 should be included in the future.  
In conclusion, functional in vitro analyses further strengthened a putative relevance of ATP7A, 
SREBF1 and ABCD1 for the development of HSCR, although none of the clones was completely 
disrupted in its neuronal maturation capacity.  
qRT PCR results suggested that impairments in the candidate specific KO clones are not caused by a 
RET dependent mechanism. Remarkably, these analyses showed as well that all edited genes were 
still expressed in respective KO clones. This suggested that edited transcripts were not targeted by 
NMD. However, as outlined earlier, this cellular process was not investigated in the context of the 
presented project and mRNA half-life times must as well be taken into account for data interpretation 
(fig. 31).  
 
Applying the presented experimental pipeline to a primary ENS cell population might help to dissect the 
functional relevance of ATP7A, SREBF1, ABCD1 and PIAS2 for ENS formation in detail and thereby as 
well uncover the underlying molecular pathways. For this purpose, enteric neuronal progenitor cells 
isolated from surgically resected gut specimens might be used (Metzger et al., 2009; Schmitteckert et 
al., 2019). Altered molecular signatures in the major ENS signalling pathways might be identified by 
expression profiling of respective KO clones using microarray or RNA Sequencing technologies. 
Although the presented in vitro approach is proven feasible in the current study to analyse the putative 
functional relevance of a specific molecular player for HSCR, the model system does not reflect the 
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individual genetic background of the respective patient. This can only be achieved by using patient-
derived cells. To finally proof the functional relevance of single HSCR candidate gene in vitro, gene-
specific isogenic control lines would be required. 
 In silico evidence for functional relevance of patient-specific gene variants  
All previously discussed findings add further evidence for the putative HSCR relevance of the selected 
candidates. However, the in vitro study pipeline of this project was based on a candidate specific loss-
of-function approach. In contrast to this, studied HSCR patients carried only hetero- (SREBF1, PIAS2) 
or hemizygous (ATP7A, ABCD1) missense variants with unknown functional impact. To strengthen the 
suitability of the presented in vitro study pipeline, patient-specific variants were characterized on different 
levels (fig. 33).  
In silico analyses demonstrated that - except for the ABCD1 variant - none of the other mutations has 
so far been annotated in the European (non-Finnish) control cohort of the gnomAD dataset. The 
annotated MAF for the ABCD1-specific nucleotide exchange indicated a rare variant. Calculation of the 
CADD scores revealed that each variant can be classified as deleterious (cut off >13), as outlined 
previously.  
On protein level, only the variant in PIAS2 mapped to a functionally annotated protein domain. 
Specifically, the missense variant (R>W) resided in the highly conserved PINIT region shown to be 
important for nuclear localisation and for substrate recognition (Duval et al., 2003; Yunus and Lima, 
2009). In contrast to this, ATP7A, SREBF1 and ABCD1-specific patient mutations did not reside in any 
functionally annotated domain.  
The Arginine (charged) to Glutamine (uncharged) substitution in ATP7A was located C-terminally to the 
phosphorylation (P) domain, close to the second last transmembrane (TM) domain. This P-domain is 
crucial for ATP binding and autophosphorylation and thereby regulates the conformational change of 
the transporter molecule. In general, subcellular trafficking of ATP7A between the trans Golgi network 
and the plasma membrane is highly copper dependent and missense mutations have already been 
shown to affect correct protein localisation. Comparable to the HSCR patient-specific mutation, the 
majority of mutations causative for Menkes disease cluster at the C-terminal end of the protein (Kaler, 
2011; Skjørringe et al., 2017; Telianidis et al., 2013).  
The amino acid substitution in the case of SREBF1 resulted in an exchange of the negatively charged 
Aspartic Acid by the positively charged Histidine. As outlined previously, protein processing of SREBF1 
is reflected by its distinct subcellular localisation either in the ER/the Golgi (precursor) or in the nucleus 
(mature) (Shao and Espenshade, 2014). Although proteolytic cleavage sites reside more to the N-
terminus than the patient-specific amino acid substitution, the carboxy-terminus of SREBF1 has been 
shown to be crucial for proper protein maturation in a cholesterol-dependent manner (Horton et al., 
2002).  
In the case of ABCD1, the patient-specific amino acid substitution (T (uncharged) > R (positively 
charged)) was located at the N-terminal end of the protein. A hydrophobic segment at this terminus has 
been shown to be crucial for correct subcellular localisation of the peroxisomal transporter and thus for 
proper VLCFA metabolism (Kawaguchi and Morita, 2016; Lee et al., 2014a). 
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Protein localisations were investigated by IF analyses of cells, transiently transfected with recombinantly 
expressed WT and MUT candidate proteins. These analyses did not reveal any protein mislocalisation 
– neither in HEK293TN nor in SHSY5Y cells – caused by the specific mutations in any of the candidate 
proteins. Additionally, subcellular localisations of all WT and MUT proteins matched expectations as 
they confirmed previously described data. 
However, several aspects need to be considered. First, recombinantly expressed candidate proteins 
contained specific tag sequences, which might interfere with proper subcellular trafficking and 
localisation in general. Second, analyses were solely carried out under standard cultivation conditions. 
However, in the case of ATP7A and SREBF1 it is well known that copper and sterol levels affect 
respective protein functions and localisations (Horton et al., 2002; Skjørringe et al., 2017). Third, no 
subcellular specific marker was co-stained with the recombinantly expressed candidate proteins. 
Conclusions are based only on observable staining patterns. And finally, variants might not impede 
correct subcellular protein localization, but might interfere with other candidate specific functions as e.g. 
VLCFA transport in the case of ABCD1 or substrate SUMOylation in the case of PIAS2. A putative 
impairment in the SUMOylation capacity of MUT PIAS2 might be assessed by immunoprecipitation and 
mass spectrometry analyses, followed by comparative data analysis. Additionally, the amino acid 
substitutions might be evaluated based on their impact for the respective protein tertiary structure, e.g. 
by in silico protein structure modeling. Altered tertiary structures might be causative for impaired protein 
functions.  
In conclusion, while in silico analyses of all patient-specific candidate gene mutations suggested a 
functional relevance of the respective variants, no further in vitro evidence could be generated in the 
context of this project.  
 Candidate gene confirmation based on risk assessment 
To evaluate and summarize all previously described and discussed findings, a scoring system was 
applied. To allow the most objective and unbiased evaluation of individual candidate genes, this strategy 
was based on a binary system.  
Applying the scoring system to well established HSCR risk loci, validated its suitability for risk evaluation 
of novel HSCR candidate genes. Respective risk scores of RET (14), SOX10 (13), EDNRB (12) and 
GDNF (12) were close to or even reached the maximum value (14) (Tab. 9). However, this system has 
also limitations which are uncovered by the assessment of PHOX2B. Although this gene is well 
characterized for its role in ENS development and for its relevance in HSCR, no rare disease-associated 
mutations could be identified in literature. Hence, no scores for PHOX2B could be attributed in the ‘Gene 
mutation‘ category for all prediction tools (Σ1=Σ2) (Bachelor Thesis Dawid, 2019).  
As outlined in 2.2.1, scores within the ‘Gene expression‘ category were mainly based on evidences 
annotated in different databases. Consequently, missing database entries or incomplete data 
compilation may introduce a bias in the evaluation of specific genes – as illustrated for PHOX2B and 
ABCD1. No protein expression data was available for the candidate gene in the Human Protein Atlas, 
although ABCD1 expression in human colon and brain has already been investigated (Höftberger et al., 
2007; The Human Protein Atlas, ABCD1). Nevertheless, all four selected candidate genes displayed 
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rather high Σ1 and Σ2 scores, which confirmed the initial candidate gene selection procedure in a 
reproducible and robust manner. In the future, this scoring system will be used to facilitate the selection 
of novel and most promising HSCR candidate genes identified by exome sequencing of additional 
patients. 
Evidence implemented in the calculation of Σ2 were combined with functional in vitro data of this project. 
This further strengthened the putative role of ATP7A, SREBF1 and ABCD1 in the HSCR aetiology, as 
respective Σ3 values were highly comparable to the risk score of the major HSCR disease loci RET.  
In conclusion, the complementary research approach presented in this study could be evaluated in an 
objective manner through application of the presented scoring system. Modifications might be applied 
to this system in the future to further improve its validity. To this end, additional categories might be 
introduced or classifications and cut offs might be adjusted based on available data and current 
knowledge.  
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CONCLUSIONS AND OUTLOOK 
This project aimed to establish a complementary research pipeline for the elucidation of novel 
candidate genes in HSCR, taking genetic, bioinformatics, molecular, cellular and functional data 
into account. Application of this strategy in an exemplary way to two sporadic L-HSCR patients 
led to the identification of four novel HSCR risk loci: ATP7A, SREBF1, ABCD1 and PIAS2. This 
classification was confirmed based on the calculation of a single risk score, which summarized 
various evidences generated in this project and thereby underscored the suitability and strength 
of a complementary research approach in the context of a rare and complex disease as HSCR.  
The complex genetics of HSCR in correlation with respective genetic findings of this study suggest that 
ATP7A, SREBF1, ABCD1 and PIAS2 probably contribute to the disease. A variable number of further 
genetic risk variants might be present in both affected individuals.  
Interestingly, on molecular level all selected candidates share one similarity: protein functions of ATP7A, 
SREBF1, ABCD1 and PIAS2 are not highly specific to a particular cell type but are rather of general 
cellular importance. This was as well reflected by the respective expression patterns in various tissues. 
Most likely, these novel risk factors might contribute to the development of the HSCR phenotype at 
various levels rather than affecting only a specific cell type, cell function or signalling pathway. This 
hypothesis was further supported by functional in vitro characterization of gene-specific KO cell clones 
and by in silico evidences based on the IPA knowledge base. Furthermore, so far unknown HSCR risk 
loci in both patients might contribute in the same way thereby shaping the individual’s phenotype. This 
conclusion is in line with knowledge from recent studies, where complex interactions between multiple 
risk loci were suggested to be crucial for the individual’s HSCR risk. 
Generation of more detailed knowledge about the molecular mechanisms of HSCR is pivotal in order to 
understand its postoperative complications and to change the current treatment regime in future. The 
presented study underscored the necessity and strength of a complementary research approach, but 
as well highlighted major challenges and future requirements, which need to be overcome in the field of 
HSCR research.  
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Table S1: Filtered WES data of family I 
CADD scores were calculated using the CADD model GRCh37-v1.4 (https://cadd.gs.washington.edu/snv).  
*For indels, local CADD_PHRED values were calculated by Dr. Nagarajan Paramasivam (Theoretical 
Bioinformatics Division, DKFZ). 
 
Gene name Nucleotide/Amino acid change Mutation type CADD 
ATP7A 
ENST00000350425.4 
exon8:c.G1076A:p.R359Q 
hemizygous 26.9 
DNAH14 
ENST00000439375.2 
exon29:c.4857_4860del:p.1619_1620del 
compound 
heterozygous 
36* 
DNAH14 
ENST00000445597.2 
exon3:c.G356A:p.G119D, 
compound 
heterozygous 
8.636 
DSG1 
ENST00000462981.2 
exon4:c.C192T:p.Y64Y, 
compound 
heterozygous 
23.6 
DSG1 
ENST00000462981.2 
exon4:c.G685A:p.G229S 
compound 
heterozygous 
24 
KIAA1522 
ENST00000401073.2 
exon1:c.G68T:p.R23L, 
de novo 23.2 
PHF16 
ENST00000424392.1 
exon5:c.C409T:p.R137C 
hemizygous 26.9 
PTPRK 
ENST00000368227.3 
exon17:c.G2564A:p.R855H 
compound 
heterozygous 
22.6 
PTPRK 
ENST00000368227.3 
exon12:c.G1929T:p.K643N 
compound 
heterozygous 
25.8 
PVRL2 
ENST00000252485.4 
exon2:c.C227T:p.P76L 
de novo 12.23 
SREBF1 
ENST00000355815.4 
exon19:c.G3262C:p.D1088H, 
compound 
heterozygous 
25.5 
SREBF1 
ENST00000355815.4 
exon14:c.G2525A:p.R842Q, 
compound 
heterozygous 
18.62 
STAG2 
ENST00000455404.1 
exon3:c.A116G:p.K39R 
hemizygous 23.5 
STRC 
ENST00000541030.1 
exon25:c.C2599T:p.L867F 
compound 
heterozygous 
24.7 
STRC 
ENST00000541030.1 
exon23:c.C2242T:p.R748W 
compound 
heterozygous 
23.7 
ZNF275 
ENST00000421401.3 
exon4:c.T877C:p.Y293H 
hemizygous 23.5 
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Gene name Nucleotide/Amino acid change Mutation type CADD 
ABCD1 
ENST00000218104.3 
exon1:c.C41G:p.T14R 
hemizygous 15.38 
CNKSR2 
ENST00000425654.2 
exon19:c.A2588C:p.N863T 
hemizygous 18.93 
EBP 
ENST00000495186.1 
exon5:c.C511T:p.R171C, 
hemizygous 21.6 
FER1L6 
ENST00000522917.1 
exon22:c.G2827T:p.G943W 
compound 
heterozygous 
33 
FER1L6 
ENST00000522917.1 
exon23:c.T2981G:p.V994G 
compound 
heterozygous 
28.4 
MXRA5 
ENST00000217939.6 
exon5:c.G1783A:p.V595M 
hemizygous 15.17 
OR5P2 
ENST00000329434.2 
exon1:c.G56A:p.G19D, 
hemizygous 23.7 
PIAS2 
ENST00000585916.1 
exon7:c.C889T:p.R297W 
de novo 26.9 
RNF213 
ENST00000456466.1 
exon9:c.C1637T:p.T546I 
compound 
heterozygous 
8.843 
RNF213 
ENST00000582970.1 
exon29:c.A6979G:p.N2327D 
compound 
heterozygous 
4.350 
SLC2A4 
ENST00000571308.1 
exon3:c.C236G:p.T79S 
homozygous 14.96 
SPTA1 
ENST00000368147.4 
exon50:c.G6927T:p.M2309I 
compound 
heterozygous 
25.2 
SPTA1 
ENST00000368147.4 
exon32:c.A4564G:p.T1522A 
compound 
heterozygous 
17.61 
SYNE2 
ENST00000394768.2 
exon33:c.T4907C:p.I1636T 
compound 
heterozygous 
16.08 
SYNE2 
ENST00000441438.2 
exon4:c.A488T:p.Q163L 
compound 
heterozygous 
14.60 
TENM4 
ENST00000278550.7 
exon31:c.C5729T:p.A1910V 
de novo 21.3 
TFDP3 
ENST00000310125.4 
exon1:c.G427A:p.A143T 
hemizygous 7.926 
VSIG4 
ENST00000412866.2 
exon7:c.C866T:p.T289I 
hemizygous 13.84 
VSIG4 
ENST00000455586.2 
exon2:c.G274T:p.V92F 
hemizygous 14.96 
Table S2: Filtered WES data of family II 
CADD scores were calculated using the CADD model GRCh37-v1.4 (https://cadd.gs.washington.edu/snv). 
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Summary and overview 
Figure S1: Genotype overview on selected non-coding and coding genetic variants for all individuals of 
family I and II 
A and B: More detailed information about the coding SNVs and CNVs are shown in section 3.1. 
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IPA analysis 
Table S3: ENS and HSCR relevant genes used for IPA analysis and for comparison of rare SNVs 
 (based on (Gui et al., 2017; Lake and Heuckeroth, 2013; Luzón-Toro et al., 2015b)) 
Gene Gene ID Gene Gene ID Gene Gene ID 
ALDH1A2 ENSG00000128918 HOXA4 ENSG00000197576 RBP4 ENSG00000138207 
ARHGEF3 ENSG00000163947 HOXB5 ENSG00000120075 RET ENSG00000165731 
ARTN ENSG00000117407 HOXD4 ENSG00000170166 RMRP ENSG00000277027 
ASCL-1 ENSG00000139352 IFNGR2 ENSG00000159128 SALL4 ENSG00000101115 
BBS1-11 ENSG00000174483 IHH ENSG00000163501 SCG3 ENSG00000104112 
CADM1 ENSG00000182985 IKBKAP ENSG00000070061 SEMA3A ENSG00000075213 
CARTPT ENSG00000164326 IL10RB ENSG00000243646 SEMA3C ENSG00000075223 
CBR1 ENSG00000159228 ITGB1 ENSG00000150093 SEMA3D ENSG00000153993 
CDC42 ENSG00000070831 JAG1 ENSG00000101384 SERPINI1 ENSG00000163536 
CDH2 ENSG00000170558 JAG2 ENSG00000184916 SHH ENSG00000164690 
CRMP1 ENSG00000072832 KIAA1279 ENSG00000198954 SLC6A2 ENSG00000103546 
CSTB ENSG00000160213 KIF26A ENSG00000066735 SMO ENSG00000128602 
CTNNAL1 ENSG00000119326 KLF4 ENSG00000136826 SOD1 ENSG00000142168 
DCC ENSG00000187323 L1CAM ENSG00000198910 SON ENSG00000159140 
DCX ENSG00000077279 LGI4 ENSG00000153902 SOX10 ENSG00000100146 
DHCR7 ENSG00000172893 MAB21L1 ENSG00000180660 SOX2 ENSG00000181449 
DICER1 ENSG00000100697 MAPK10 ENSG00000109339 SOX8 ENSG00000005513 
DLL1 ENSG00000198719 MAPT ENSG00000186868 SPRY2 ENSG00000136158 
DLL3 ENSG00000090932 MLLT11 ENSG00000213190 STMN2 ENSG00000104435 
DLX1 ENSG00000144355 NAV2 ENSG00000166833 STMN3 ENSG00000197457 
DNMT3B ENSG00000088305 NKX2-1 ENSG00000136352 SUFU ENSG00000107882 
DPYSL3 ENSG00000113657 NOG ENSG00000183691 SYT11 ENSG00000132718 
EBF3 ENSG00000108001 NOTCH1 ENSG00000148400 TAGLN3 ENSG00000144834 
ECE1 ENSG00000117298 NOTCH2 ENSG00000134250 TBX3 ENSG00000135111 
EDN3 ENSG00000124205 NOTCH3 ENSG00000074181 TCF4 ENSG00000196628 
EDNRB ENSG00000136160 NRG1 ENSG00000157168 TCF7L2 ENSG00000148737 
ELAVL2 ENSG00000107105 NRG3 ENSG00000185737 TCOF1 ENSG00000070814 
ELAVL4 ENSG00000162374 NRP1 ENSG00000099250 TFAM ENSG00000108064 
ERBB2 ENSG00000141736 NRTN ENSG00000171119  TFF3 ENSG00000160180 
ERBB3 ENSG00000065361 NTF3 ENSG00000185652 TGFB2 ENSG00000092969 
ERBB4 ENSG00000178568 NTRK3 ENSG00000140538 TLX2 ENSG00000115297 
ERCC1 ENSG00000012061 PAX3 ENSG00000135903 TMEFF2 ENSG00000144339 
ETV1 ENSG00000006468 PCDHA1 ENSG00000204970 TPH2 ENSG00000139287 
FGF13 ENSG00000129682 PDS5A ENSG00000121892 TREX1 ENSG00000213689 
GAP43 ENSG00000172020 PDS5B ENSG00000083642 TTC3 ENSG00000182670 
GDNF ENSG00000168621  PFKL ENSG00000141959 TUBB3 ENSG00000258947 
GFRA1 ENSG00000151892 PHACTR4 ENSG00000204138 UCHL1 ENSG00000154277 
GFRA2 ENSG00000168546 PHOX2A ENSG00000165462 VIP ENSG00000146469 
GFRA3 ENSG00000146013 PHOX2b ENSG00000109132 ZEB2 ENSG00000169554 
GFRA4 ENSG00000125861 PLXNA1 ENSG00000114554 ZIC2 ENSG00000043355 
GLI1 ENSG00000111087 PLXNB1 ENSG00000164050   
GLI2 ENSG00000074047 POFUT1 ENSG00000101346   
GLI3 ENSG00000106571 PROK1 ENSG00000143125   
GNG2 ENSG00000186469 PROK2 ENSG00000163421   
GNG3 ENSG00000162188 PROKR1 ENSG00000169618   
GRB10 ENSG00000106070 PROKR2 ENSG00000101292   
HAND2 ENSG00000164107 PRPH ENSG00000135406   
HES1 ENSG00000114315 PSPN ENSG00000125650   
HLX ENSG00000136630 PTCH1 ENSG00000185920   
HMP19 ENSG00000170091 PTEN ENSG00000171862   
HMX3 ENSG00000188620 RAC1 ENSG00000136238   
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Database research of candidate genes 
Table S4: Overview on annotated protein coding isoforms for candidates in different databases 
Transcript identifiers are given. 
 
 
ATP7A SREBF1 ABCD1 PIAS2 
Ensembl 
ENST00000341514.11 
ENST00000343533.9 
ENST00000645454.1 
ENST00000642651.1 
ENST00000355815.8 
ENST00000261646.9 
ENST00000395757.5 
ENST00000423161.3 
ENST00000478616.1 
ENST00000577897.1 
ENST00000486311.5 
ENST00000218104.6 
ENST00000370129.4 
ENST00000585916.6 
ENST00000324794.11 
ENST00000592212.5 
ENST00000545673.5 
ENST00000589917.1 
ENST00000592221.5 
ENST00000586953.1 
ENST00000587810.1 
NCBI NM_000052.7  
NM_001282224.1 
NM_001321096.2 
NM_004176.4 
NM_001005291.2 
NM_000033.4  NM_004671.5  
NM_001354034.1 
NM_001324058.1  
NM_173206.3 
NM_001324046.1 
NM_001324048.1 
NM_001324059.1 
NM_001324051.1 
NM_001324055.1 
NM_001324052.1 
NM_001324054.1 
NM_001324047.1  
NM_001324057.1 
NM_001324053.1 
NM_001324049.1 
NM_001354038.1  
NM_001354039.1  
NM_001354036.1 
NM_001354033.1  
NM_001354035.1 
NM_001354037.1  
NM_001324060.1 
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Negative control staining 
 
 
Figure S2: Negative control staining in murine cryosectioned tissue at E13.5 
A and B: Control staining for different secondary antibody combinations (A’/B’: goat anti mouse AF488 (green), goat 
anti mouse AF568 (red); A’’/B’’: Streptavidin AF488 (green), goat anti rabbit AF568 (red); A’’’/B’’’: goat anti mouse 
AF488 (green), goat anti rabbit AF568 (red), goat anti mouse AF647 (turquoise). B: Tissue was demasked before IF 
staining. Nuclei were counterstained with Hoechst (blue). Scale bar: 50 µm. 
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CRISPR/Cas9 genome editing 
Endogenous candidate gene expression 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4: Endogenous 
gene expression in WT 
SHSY5Y cells 
Results for conventional 
PCR analyses are shown. 
GAPDH served as 
reference.  
 
Figure S3: IHC negative control staining in human FFPE sections 
Control staining for peroxidase conjugated AffiniPure goat anti rabbit antibody 
(brown) in fetal and adult human colon sections were performed by Dr. Cornelia 
Thöni and Jutta Scheuerer (research group of Dr. Felix Lasitschka, Institute of 
Pathology, University Hospital Heidelberg). Images are representatives. Nuclei 
were counterstained with Hematoxylin (blue). Scale bar: 20 µm.   
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sgRNA evaluation 
Table S5: sgRNA evaluation using different design portals 
Ranks are listed. *no longer available  
Gene Exon2 sgRNA sequence (5>3) 
Ranking 
CCTop CHOPCHOP 
Optimized 
CRISPR 
design 
portal* 
RET 
Ex2 TCTACGGCACGTACCGCACA 
TGTGCGGTACGTGCCGTAGA 
1 - 1 
ATP7A  Ex3 
GATCATAGTATGGCTCAAGC 
GCTTGAGCCATACTATGATC 
2 15 - 
SREBF1 Ex5 
GAGACCTGCCGCCTTCACAG 
CTGTGAAGGCGGCAGGTCTC 
1 2 3 
ABCD1  Ex2 
CGCTCCACACATACTTCATG 
CATGAAGTATGTGTGGAGCG 
2 1 11 
PIAS2  
Ex6 
TAATATTCAAGGGGCGTCCA 
TGGACGCCCCTTGAATATTA 
1 2 1 
 
Ex2 
 
CGATATCCACGAACTCTTGA 
TCAAGAGTTCGTGGATATCG 
2 8 3 
CCGAGAATTGTATAGACGCCGAT 
ATCGGCGTCTATACAATTCTCGG 
3 - 2 
CCACGAACTCTTGAAGGACTTTC 
GAAAGTCCTTCAAGAGTTCGTGG 
4 - 7 
 
 
 
sgRNA cloning 
Table S6: Thermal cycler program used for phosphorylation and annealing of sgRNA oligonucleotides 
step temperature time 
1 37°C 30 min 
2 95°C 5 min 
ramp down to 25°C at 5°C/min 
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KO validation by Sanger Sequencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5: Forward and reverse Sanger sequencing of CRISPR/Cas9 engineered KO 
clones 
A-D: CRISPR/Cas9 mediated genome modifications (homozygous or compound 
heterozygous) were verified by forward and reverse Sanger sequencing. Gene-specific sgRNA 
target sites and four coloured chromatograms are shown. NCBI transcript identifiers used for 
annotation of the editing event are displayed. Probable Cas9 cutting sites are highlighted by 
red triangles. PAM sites are underscored.  
XXX  Supplementary 
 
Analysis of alternative splicing in KO clones 
 
 
 
 
 
Figure S6: Analysis of alternative splicing of the genome modified exon in individual KO clones 
A-D: In all genome edited KO clones, alternative splicing of the genetically modified exon (highlighted by an 
asterisk) was excluded by conventional PCR analyses on cDNA level. Primers are illustrated by red arrows. 
GAPDH was used as reference. Expected and observed amplicon sizes are annotated. 
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Off-target analysis 
 
 
 
 
 
 
 
 
 
 
 
 
qRT PCR 
Table S7: Thermal cycler program for qRT PCR 
step temperature time 
1 95° C 2 min 
2  95° C 
60° C 
5 sec 
20 sec 
3                                         Melting curve 
 
 
 
 
 
 
X 40 
Figure S7: Off-target effect in the SREBF1 KO clone 
A: On-target and off-target sequence of the SREBF1 specific sgRNA. PAM site is underscored. 
Mismatching nucleotides are highlighted in red. The core sequence close to the PAM (underscored) 
is marked. B: An unintended heterozygous one nucleotide insertion was detected in the intronic 
region of EEF1A2 in the SREBF1 KO. This indel was located at the respective position of the PAM 
and was not present in the parental SHSY5Y line. PAM sites are underscored. Putative Cas9 cutting 
sites are highlighted by red triangles. Four colored chromatograms from Sanger sequencing are 
shown.  
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Vector maps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8: pSpCas(BB)-2A-GFP vector map 
(from: https://www.addgene.org/48138/) 
Figure S9: pcDNA3.1_2xFLAG_RET vector map 
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Figure S10: pcDNA3.1_2XFLAG_SREBF1B_FL vector map 
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